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Su m m a r y
Oxysterols are oxygenated derivatives of cholesterol or its precursors. One oxysterol, 
24(5'),25-epoxycholesterol (24(S),25-EC), which results from a shunt in the 
cholesterol synthesis pathway has been found at higher than expected levels in 
embryonic murine brain. Interestingly, the receptor that 24(5),25-EC is a ligand for, 
Liver X Receptor (LXR), has been implicated in neurogenesis in the ventral mid brain 
region of embryonic brain; an area with a high density of dopaminergic neurons. The 
mechanism by which LXR induces this effect is unclear. Therefore, proteomic and 
phosphoproteomic studies were performed using a stable isotope labelled in amino 
acid in cell culture (SILAC) approach in order to quantify changes in the proteome 
between different treatment groups in a mouse substantia nigra dopaminergic cell line 
(SN4741)
SN4741 cells were cultured in SILAC media containing differentially isotope labelled 
arginine and lysine. For protein expression studies SN4741 cells were treated in 
serum free media with vehicle, lOpM 24(5),25-EC, or lpM  GW3965, a synthetic 
ligand of LXR, for 24 hours. For analysis of changes in the phosphoproteome SN4741 
cells were treated in serum free media with vehicle, lOpM 24(5),25-EC, or 30pM 25- 
hydroxycholesterol for 6  hours. Cells were lysed and protein combined in a 1:1 ratio 
before trypsin digestion and peptide separation via strong cation exchange 
chromatography. Phosphopeptides were enriched using immobilised metal affinity 
chromatography (IMAC). Resulting fractions were analysed, using a data dependent 
LC-MS/MS method. Data was quantified using MaxQuant software in conjunction 
with Mascot using an IPI mouse database.
In protein expression analysis known oxysterol regulated genes, via SREBP or LXR, 
were differentially expressed. Oxysterol treatment induced global changes in proteins 
involved in lipid (cholesterol, fatty acid, phospholipid, triglyceride) synthesis. LXR(3 
protein expression increased after GW3965 and 24(5),25-EC treatment, though no 
change was seen on LXR0 mRNA, implying that ligand binding protects LXRf3 from 
degradation. 24(5),25-EC induced changes in expression and localisation of the 
membrane protein caveolin-1. Also, phosphoethanolamine cytidylyltransferase and 
collagen type IV alpha-3-binding protein, 2 proteins involved in phospholipid 
synthesis, had an altered expression after 24(5),25-EC treatment suggesting a role for 
oxysterols in membrane homeostasis. A cytokine, macrophage colony stimulating 
factor, which is required for normal neuronal development and macrophage 
differentiation had an LXR independent increased expression after 24(5),25-EC 
treatment. Quantitative RT-PCR data demonstrated that proteomic changes were due 
to both transcriptional and post-transcriptional effects of oxysterol. In addition, 
studies examining changes in the mouse phosphoproteome identified a number of 
novel phosphorylation sites.
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CHAPTER 1: INTRODUCTION
1.1 Oxysterols
1.1.1 Cholesterol
Cholesterol is a molecule that is an essential component of the eukaryotic cell 
membrane, where it plays a key role in the maintenance of permeability and fluidity.. 
Cholesterol orientates itself inside the membrane between phospholipids so that the 
hydroxyl group at position 3 of the ring structure is adjacent to the polar head group 
of phospholipids with the hydrophobic part of the molecule in the hydrophobic core 
of the membrane. The steroid ring structure interacts with the aliphatic chains of the 
phospholipid reducing the mobility of the membrane and its permeability to water 
soluble small molecules. Cholesterol reduces the fluidity of the membrane but this 
also prevents possible phase transitions. Phase transitions occur when lipid 
components of the liquid membrane crystallise at reduced temperatures. Thus, 
cholesterol plays a role in the membrane that allows the bilayer to control entry of 
water soluble small molecules and to maintain the membrane in a liquid, albeit less 
fluid, state (Olsen et al 2012).
In addition, cholesterol is an important precursor for a number of other active bio­
molecules. Cholesterol is the starting material for androgens (e.g. testosterone), 
progestogens (e.g. progesterone), oestrogens (e.g. oestradiol) glucocorticosteroids 
(e.g. hydrocortisone), mineralocorticoids (e.g. aldosterone) and bile acids (e.g. cholic 
acid) (fig. 1.1.). Cholesterol and its derivatives are therefore important molecules that 
play a multifunctional role in cellular function. However, increased levels of 
cholesterol are also associated with artherosclerosis and an increased risk of 
cardiovascular disease. For healthy adults a blood cholesterol level of <5mmol/l is 
considered norm al and concentrations above this considered high 
(http://www.nhs.uk/Conditions/Cholesterol/Pages/Diagnosis.aspx accessed 10-4- 
2013). Therefore, homeostasis is necessary to maintain a balance between cholesterol 
uptake and excretion.
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Figure 1.1. Structure o f cholesterol and bioactive molecules for which cholesterol is 
the starting material. Cholesterol contains 27 carbon atoms and is numbered as shown 
in the figure. Cholesterol is transformed via multistep biochemical reactions to form 
androgens (e.g. testosterone), progestogens (e.g. progesterone), oestrogens (e.g. 
oestradiol), glucocorticosteroids (e.g. hydrocortisone), mineral corticosteroids (e.g. 
aldosterone) and bile acids (e.g. cholic acid). It is apparent that the 4 ring structure of 
cholesterol is the basis of these molecules; changes in the ring structure, side chain or 
oxygenation can lead to profound differences in biological activity.
Cholesterol is obtained from two principal sources -  diet and from de novo synthesis. 
The majority of the daily requirement of cholesterol is achieved from the activity of a 
number o f enzymes involved in a multistep synthesis occurring at the endoplasmic 
reticulum (fig. 1.2.). The starting material for cholesterol synthesis is acetyl CoA that 
is linked to another acetyl CoA to form acetoacetyl CoA. It is converted early in the 
pathway to 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA). HMG-CoA is then 
reduced to yield mevalonate by the action of HMG-CoA reductase; this is the rate
limiting step in cholesterol synthesis and is inhibited by statins, an extensively used 
family of drugs for reducing cholesterol level.
Therefore, the homeostasis of cholesterol is crucial to balance the essential functions 
of the molecule with the negative consequences that high levels induce. Cholesterol 
itself has a role to play by end product negative feedback but, importantly, cholesterol 
can be metabolised to form oxysterols which regulate intercellular cholesterol levels.
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Figure 1.2. The cholesterol synthesis pathway. A shunt in the pathway results in the 
formation of 24(5},25-epoxycholesterol (* = multiple steps). Enzymes responsible for 
the reactions are shown in italics.
1.1.2 Oxvsterols
Oxysterols are biologically active oxidized derivatives of cholesterol. The oxysterols 
are diverse as they can be oxidised in different positions on the molecule either by 
auto-oxidation or by enzymatic means. The oxygen can be introduced onto the 
sidechain (e.g. 22(R )-hydroxycholesterol, 24(5)-hydroxy cholesterol, 25- 
hydroxycholesterol, 24(5),25-epoxycholesterol) or onto the cholesterol ring structure 
(e.g. 7a-hydroxycholesterol, 7-ketocholesterol) (fig 1.3). In vivo oxysterols are 
produced via auto-oxidation, enzymatically via various cytochrome P450 and 
cholesterol hydroxylase enzymes (section 1.1.3.) or by a shunt in the cholesterol 
synthesis pathway that leads to the formation of 24S,25-epoxycholesterol (fig 1.2.). 
The formation of oxysterols is the first step in the synthesis of bile acids from 
cholesterol (fig. 1.4.)
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Figure 1.3. Chemical structure of oxysterols. Oxygen is introduced to the molecule to 
the sidechain or ring structure by auto-oxidation or enzymatic activity. The enzymes 
responsible for the generation of different oxysterols are shown. Biological activity of 
the oxysterols is dependent on the location o f the oxygenation with profound 
differences in efficacy as ligands.
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Figure 1.4. Simplified overview o f bile acid synthesis. The initial step in the 
formation o f bile acids of both the neutral and acidic pathways is the synthesis of 
oxysterols. In the neutral pathway cholesterol is metabolised by CYP7A to form 7a- 
hydroxycholesterol before multiple steps (indicated by *) to form bile acids (cholic 
and chenodeoxycholic acid). In the acidic pathway the initial oxysterol formed is 27- 
hydroxycholesterol by the action of CYP27A1. Multiple steps (indicated by **) 
convert 27-hydroxychoelsterol to bile acids.
The location of the modification is important as although the oxysterols share 
characteristics, such as a reduced hydrophobicity compared with the cholesterol 
parent, the location, and stereochemistry play a role in the biological function of the 
molecules. There are differences between them in terms of activity due to differences 
in protein binding. The activation of Liver X receptor (LXR), for which oxysterols are 
the natural ligand, varies considerably depending on where cholesterol is oxidised 
with E C 5 0  values ranging from 4 or 3p,M for LX Ra/p respectively for 24(S)- 
hydroxycholesterol but below the detection limit for 7-ketocholesterol (Janowski et 
al. 1999). The biological roles of oxysterols will be discussed further in section 1.1.5 
but they have been shown to be important in cholesterol homeostasis and in disease. 
Oxysterols have been associated with artherosclerotic cardiovascular disease (section 
1.1 .6 .1) and, in addition, they have also been implicated in neurodegenerative 
conditions such as Alzheimer’s disease (see section 1.1.6.3; Olkkonen & Lehto 2004, 
Vaya et a l 2007).
1.13 Synthesis of Oxysterols
Oxysterols are synthesised from cholesterol by a number of mechanisms. These 
include auto-oxidation, photo-oxidation and enzymatic formation.
1.13.1. Auto-oxidation and photo-oxidation of cholesterol
When exposed to the atmosphere cholesterol can be auto-oxidised to form oxysterols 
(Weiner et al 1972). The most commonly encountered oxysterols generated in this 
manner are the 7-position modified oxysterols that includes 7a-hydroxycholesterol, 
7 p-hydroxycholesterol and 7-ketocholesterol. In addition, 5 ,6 a -  or 5,613- 
epoxy cholesterol can be produced which is converted to 5 a ,6 P-dihy droxycholesterol. 
All these oxysterols are modified on the ring structure of cholesterol and have poor 
activity with regard to liver X receptor (LXR), the nuclear receptor for which 
oxysterols are the natural ligand (Janowski et al 1999). With the exception of 7a- 
hydroxycholesterol (section 1.1.3.2) they are not produced enzymatically. In addition 
cholesterol is also oxidised by photo-oxidation. This process predominantly yields 
5a-hydroperoxycholesterol which can be transformed to 7-position oxygenated 
oxysterols. Thus, the major products of both forms of non-enzymatic production of 
oxysterols are the same.
It has been shown that some auto-oxidation products are toxic (7(3- 
hydroxycholesterol, 7-ketocholesterol) and therefore their presence may lead to 
harmful biological effects (Hughes et al 1994). In a laboratory context it is important 
to recognise the importance of auto-oxidation with regard to artefacts generated by 
processing of cholesterol in the course of experimental methodology as they could 
potentially lead to false positive conclusions.
1.1.3.2. Enzymatic Formation of Oxysterols
Cholesterol is metabolised to oxysterols enzymatically via a number of different 
enzymes. 24(iS)-hydroxycholesterol, the predominant oxysterol found in the brain, is 
generated by the action of the cytochrome P450 CYP46A1 (Lund et al 1999). 
Unsurprisingly, in both mice and humans it is predominantly expressed in the brain 
with very low expression in other tissues. Human brain was analysed in more depth 
and expression was found across a number of subsections of the brain. Expression 
was stronger however in grey matter compared with white matter. In mouse brain 
cyp46al immunohistochemical staining showed localisation to neurons. The 
expression of CYP46A1 varies with aging. Initially the protein level in the brain, 
measured by Western blotting, of both mouse and human is low in the early stages of 
postpartum development and increases over time until reaching a steady state.
The activity of the cytochrome P450 enzyme cholesterol 7a-hydroxylase (CYP7A) 
results in the formation of 7a-hydroxycholesterol. This oxysterol, which is also a 
product of auto-oxidation, is a precursor in the formation of bile acids. It is 
predominantly expressed in the liver (Jelinek et al 1990) and is the predominant 
location of its activity (Chiang et al 1990).
The enzymatic formation of 25-hydroxycholesterol is due to the activity of cholesterol 
25-hydroxylase (Lund et al 1998). This polytopic membrane protein, unlike CYP7A 
and CYP46A1 which are responsible for the formation of 7a-hydroxycholesterol and 
24(5)-hydroxycholesterol respectively, is not a cytochrome P450. Instead, it belongs 
to a family of enzymes that require di-iron co-factors as a catalyst. Murine cholesterol 
25-hydroxylase was found in lung, heart and kidney. In comparison, human 
cholesterol 25-hydroxylase was found at very low levels in all tissues tested. Recently 
however, it has been reported that the expression of cholesterol 25-hydroxylase
increases dramatically in response to certain stimuli (see section 1.1.7 for a full 
discussion of this effect).
1.1.3.3.24(5'135-epoxvcholesteroI Synthesis
24(5),25-epoxycholesterol is an unique oxysterol as it not a metabolite of cholesterol 
but instead is a final product made by a shunt in the cholesterol synthesis mevalonate 
pathway (fig 1.2.; Nelson et al. 1981). However, the measured level of 24(5),25- 
epoxy cholesterol is much lower than that of cholesterol with levels between 0 .1% and 
1% total cholesterol reported (Spencer et al 1985; Wong et al 2004; Wong et al. 
2007). In the synthesis of cholesterol squalene epoxidase (AKA squalene 
monooxygenase) introduces an epoxide moiety to squalene to produce 2,3(5)- 
monooxidosqualene. This molecule is then cyclised by 2,3-oxidosqualene cyclase to 
form lanosterol and then processed, via a number of steps, to cholesterol. However, it 
is possible for the 2 ,3 (5) -monooxi do squalene to be oxygenated further by squalene 
epoxidase to form 2,3(5);22(5),23-dioxidosqualene. This molecule can then be 
cyclised to oxidolanosterol by 2,3-oxidosqualene cyclase before being processed 
using the same enzymes as those used in the synthesis of cholesterol to form 24(5),25- 
epoxycholesterol as an end product. This implies that any cell that synthesises 
cholesterol has the potential to synthesise 24(5),25-epoxycholesterol. Indeed, in a 
variety of cell types such as macrophages, fibroblasts and astrocytes this has been 
shown to be the case (Wong et al. 2004; Spencer et al. 1985; Wong et al. 2007).
1.1.4. Differential distribution of oxysterols
Just as the expression of oxysterol generating enzymes vary across different tissues 
(section 1.1 .3.2 ) the abundance of the different oxysterols vary depending on the 
tissue or biological fluid examined. A number of studies have been conducted to 
investigate the plasma levels of different oxysterols in humans (summarised in 
Schroepfer 2000). Although the values identified by different research groups had 
variation between them clear trends were also present. The predominant oxysterols 
identified in plasma were 27-hydroxycholesterol (a naturally occurring oxysterol 
derived from the activity of a mitochondrial cytochrome P450 sterol 27-hydroxylase 
(CYP27A1, Andersson et al 1989)), 24(5)-hydroxycholesterol and la -
hydroxycholesterol. In addition, other oxysterols, such as 25-hydroxycholesterol, 
were identified at lower concentrations.
In the central nervous system the predominant oxysterol is 24(5)-hydroxycholesterol 
due to the high expression of CYP46A1 (see section 1.1.3.2; (Lund et al 1999)). 
24(5)-hy droxycholesterol has been identified as a component of cerebrospinal fluid 
(Lutjohann et al 1996). The level of 24(5)-hydroxycholesterol in cerebrospinal fluid 
was -10%  that in plasma. The ratio of 24(5)-hy droxycholesterol to cholesterol was 
measured at 1690±600 ng/mg in children but lower in adults with a ratio of 390±50 
ng/mg. The ratios were 10-fold higher than the ratio of 24(5)-hydroxycholesterol to 
cholesterol in plasma but 50% lower than the ratio found in brain. No other sidechain 
modified oxysterols were reported by the authors. In contradiction a recent paper 
showed that the oxysterol profile of cerebrospinal fluid was a lot more complex with 
numerous oxysterols identified by charge tagging mass spectrometry (Ogundare et al 
2010). O xysterols identified  included 24(5)-hydroxycholesterol, 25- 
hydroxycholesterol, 27-hydroxycholesterol and bile acids. In this study 24(5)- 
hydroxycholesterol was not the highest concentration oxysterol identified.
24(5)-hydroxycholesterol has been identified in the brain of a number of different 
species including rat, cow, horse and human. 24(5)-hydroxycholesterol was measured 
in various tissues but was at a highest concentration in the cerebrum and cerebellum. 
In human adult brain the level analysed post mortem the level of 24(5)- 
hydroxycholesterol (Lutjohann et al 1996) was measured at 0.27-0.58 ng/pg 
cholesterol in cerebrum and 0.68 - 2.19 ng/pg cholesterol in cerebellum. In addition, it 
was reported (thought the data was not presented) that 27-hydroxycholesterol and 25- 
hydroxycholesterol were also found in brain though at lower levels - 5 to 30% and 
<3% respectively.
It is unclear at present whether the distribution of oxysterols to specific tissues, such 
as 24(5)-hydroxycholesterol to the central nervous system, leads to distinct, specific 
effects dependent on the isomer present. However, there has been a large amount of 
work conducted on the biological importance of oxysterols.
1.1.5. Biological Functions of Oxysterols
The major, well studied, biological functions of oxysterols are as important regulatory 
molecules. Due to the presence of oxysterols cholesterol synthesis is inhibited via 
negative feedback by down-regulation of the synthesis of enzymes in the synthetic 
pathway (Gill et al 2008). In addition, they can affect the homeostasis of cholesterol 
by increasing the expression levels of cholesterol exporters (e.g. ATP binding cassette 
Al (ABCA1)) and reducing the low density lipoprotein receptor mediated uptake of 
cholesterol in the form of low density lipoprotein. Oxysterols, generally, exert their 
effects through three methods; regulation of protein transcription through inhibition of 
SREBP (Sterol Response Element Binding Protein) processing, acting as a ligand for 
the nuclear receptor Liver X Receptor (LXR), and by altering the rate of protein 
degradation.
However, the functions of oxysterols are not limited to their classical roles as it has 
recently been shown that oxysterols can affect other diverse processes. Oxysterols can 
alter intracellular cell signalling by altering post-translational protein phosphorylation. 
In addition, it appears that oxysterols are important in the innate immune response, 
embryonic development, and disease progression.
I.I.5.I. Regulation of SREBP
The SREBP family are transcription factors that contain a basic helix loop helix 
leucine zipper motif ((bHLH-Zip). The family of proteins consists of 3 subtypes 
SREBP la, lc  and 2 (Brown and Goldstein 1997). Each subtype consists of a pair of 
membrane spanning domains that allow the N and C terminus domains to project into 
the cytoplasm. However, SREBP 1 and 2 differ in their function. SREBP 1 is 
predominantly expressed in the liver and adrenal gland and is involved in the 
regulation of fatty acid and triglyceride metabolism and de novo lipogenesis whereas 
SREBP2 is ubiquitously expressed and regulates the transcription of the enzymes 
involved in the cholesterol synthesis pathway (Brown and Goldstein 1997). Despite 
the divergence in their role the SREBPs are processed to their active form by a 
common transport and proteolytic mechanism.
SREBP 1/2 in the presence of sterols is retained in the endoplasmic reticulum (Yang et 
al. 2002). As the intracellular cholesterol levels falls SREBP 1/2 is transported, via the 
Golgi apparatus where it is made active due to proteolysis, to the nucleus. Two 
proteolytic cleavages are required to convert SREBP 1/2 to its mature form. The first 
SIP (site-1 protease) splits SREBP 1/2 in two but is unable to release the active 
bHLH-Zip domain (Espenshade et al. 1999). A second protease, S2P (site-2 protease), 
then converts SREBP 1/2 into a transcription factor (Zelenski et al. 1999). Active 
SREBP 1/2 is transferred to the nucleus where it can exert its effect and promote the 
expression of responsive genes.
SREBP 1/2 itself does not contain a sterol binding domain and therefore its regulation 
is reliant on two other proteins -  SCAP (SREBP cleavage activating protein) and 
Insig (Insulin induced gene) (Radhakrishnan et al. 2007). In cholesterol depleted cells 
SCAP transports SREBP 1/2 from the ER to the Golgi apparatus where it is processed 
to its active from as described above. However, SCAP contains a sterol binding 
domain that allows it to bind cholesterol (Radhakrishnan et al. 2004). The presence of 
cholesterol alters SCAPs conformation and results in effects on SREBP 1/2 
processing. SREBP 1/2 is bound to SCAP by an interaction between the c-terminus of 
both proteins that, in the presence of cholesterol, ensures that SREBP 1/2 is tethered to 
the endoplasmic reticulum membrane. Thus, the interaction of cholesterol and SCAP 
results in a down regulation in expression of SREBP 1/2 regulated genes. SCAP is 
only affected by cholesterol; 25-hydroxycholesterol had no effect on its conformation. 
However, a second protein Insig exerts a similar effect mediated by oxysterols. Insig, 
of which there are two closely related proteins Insig-1 and Insig-2, binds oxysterols 
but does not bind cholesterol (Radhakrishnan et al. 2007). In the presence of 
oxysterols Insig binds to SCAP and prevents the SCAP/SREBP1/2 complex from 
being transported to the Golgi for processing. Thus, the action of SREBP 1/2 can be 
modified by cholesterol and oxysterols.
In addition, as another layer of regulation SREBP stimulates the production of Insig 1 
mRNA. Therefore, SREBP promotes the expression of an inhibitor of its processing 
to maturation. Stimulation of Insig expression promotes inhibition of SREBP 
regulated gene transcription (Horton et al. 2003).
1.1.5.2. Activation of Liver X Receptor
The liver X receptor (LXR) is a transcription factor and a nuclear receptor with strong 
similarity to other nuclear receptors such as PPAR, FXR and RXR. LXR was 
classified, initially, as an orphan receptor as its natural ligand was unknown (Apfel et 
al 1994, Song et al 1994). LXR exists as two isoforms a  and p which have a large 
(77%) homology between the two. There are, however, differences in expression with 
L X R a being the predominant isoform in the liver whilst LXRp is ubiquitously 
expressed. Oxysterols have been shown to be the endogenous ligand for both LXRa 
and LXRp (Janowski et al 1998). The potency of different oxysterols vary depending 
on where on the ring or side chain of cholesterol the oxygen is added and the 
stereochemistry of the modification. Structure activity relationships have shown that 
the most potent ligands for LXR are oxysterols with modified side chain (Janowski et 
al 1998). Indeed, the most potent naturally occurring oxysterol ligands for LXR, 
24(5),25-epoxycholesterol and 24(5)-hydroxycholesterol, had an EC50 of <5p,M for 
both LXRa and p. In comparison, 7a-hydroxycholesterol, a naturally occurring 
oxysterol, had an efficacy of ^ 10% at 40pM. In addition to the position the number 
and stereochemistry o f the modifications are also important as cholesterol 
hydroxylated twice were substantially less potent (e.g. Kj 24(5),25- 
dihydroxycholesterol for LXRa = 1200nM) as were enantiomers of active oxysterols 
(e.g. Kj 24(R),25-epoxy cholesterol for LXRa = 1200nM). This can be explained by 
the structure of the oxysterol binding pocket of LXR (Svensson et a l 2003). The 
crystal structure of LXR shows the orientation of the hydrophobic ring structure into a 
hydrophobic cavity. Hydrogen bonding between the hydroxyl at position 3 and 
arginine-305 holds the ring in the correct position. A second hydrogen bond between 
active sidechain oxygenated oxysterols, (e.g. 22(i?)-hydroxycholesterol, 24(5)- 
hydroxycholesterol, 24(5),25-epoxycholesterol) and either histidine-421 or 
tryptophan-443 residues in the binding pocket results in stronger binding of these 
ligands. Inactive oxysterols such as 22(5)-hydroxycholesterol and 24(R)- 
hydroxycholesterol are prevented from binding efficiently in the pocket due to steric 
effects preventing hydrogen bonding to either the histidine-421 or tryptophan-443.
Retinoid x receptor (RXR) is a nuclear receptor that is activated in the presence of 9- 
cis retinoic acid. It can heterodimerise with a number of other nuclear receptors
depending on which activating ligands are present. In the presence of oxysterols 
activated LXR forms heterodimers with RXR. This heterodimer can then activate 
transcription of genes containing a LXR response element in their promoter region. 
The LXR response element is a nucleotide sequence that has the idealised nucleotide 
sequence 5 ’ -AGGTC ANXXXXAGGTCA-3' in the promoter region of LXR activated 
genes. Genes that are regulated by LXR include a number of genes that are associated 
with cholesterol and lipid homeostasis. Examples of genes regulated by LXR include 
ATP binding cassette Al (ABCA1) which is a cholesterol efflux protein, ApoE a 
transporter of cholesterol and other hydrophobic compounds, and SREBP lc which 
controls the synthesis of fatty acid synthesising enzymes (e.g. fatty acid synthase).
I.I.5.3. Regulation of Protein Degradation
In addition to their roles in altering the transcription of genes, either by LXR or 
SREBP, oxysterols can alter the rate of protein degradation. HMG-CoA reductase, a 
membrane bound enzyme and a rate limiting step in the synthesis of cholesterol, is 
transcriptionally regulated by SREBP2. However, it has also been shown that 
oxysterols lead to a increased rate of HMG-CoA degradation (Chin et al. 1985; Gil et 
al. 1985; Nakanishi et al. 1988). This effect is mediated by Insig, the oxysterol 
sensing protein that causes SREBP retention in the endoplasmic reticulum (Sever et 
al. 2003a; Sever et al. 2003b). In the presence of sterols HMG-CoA reductase is 
ubiquitinated which is reliant on Insig; RNAi knockout of Insig 1 and 2 mitigated this 
effect (Sever et al. 2003a; Sever et al. 2003b). Therefore, these synergistic effects 
increase the rapidity of response to changes in cholesterol levels; the rate of synthesis 
of new protein is reduced and the removal of previously synthesised HMG-CoA 
reductase is accelerated.
Another protein that is targeted for degradation by the presence of oxysterols is low 
density lipoprotein receptor (LDLR). Regulation of LDLR expression is by 
modification of SREBP; the LDLR mRNA level is rapidly reduced in the presence of 
oxysterols (Metherall et al. 1989). Similarly to HMG-CoA reductase the protein, due 
to oxysterols, is ubiquitinated and then degraded. However, the mechanism of action 
by which oxysterols achieve this effect differs between the 2 proteins. In the case of 
LDLR stimulation of LXR induces Idol which ubiquitinates LDLR. LDLR is then
degraded (Zelcer et al 2009). Thus like HMG-CoA reductase these effects, at the 
protein and mRNA level, are additive.
In the presence of oxysterols the rate of degradation of LXRa and LXRp is slowed. 
Overexpressed FLAG-tagged LXRa/p in the presence of oxysterols (i.e. in the 
presence of ligand) degraded at a lower rate after protein synthesis was inhibited with 
cycloheximide (Kim et al 2009). It has not been shown whether this effect leads to a 
change in the level of endogenous LXR levels after treatment with oxysterols. Again 
this effect, in the case of LXRa, is potentially additive as the LXRa mRNA 
expression has been shown to be auto regulated in some, but not all, cell types.
Thus, it is potentially possible to affect protein expression levels by treatment with 
oxysterols without altering the level of mRNA expression. Either by inducing 
ubiquitination, as in the examples of HMG-CoA reductase and LDLR, or by 
preventing ubiquitination, in the case of LXR, it is clear that the role of oxysterols in 
protein regulation goes beyond that of transcriptional inhibition/activation via SREBP 
and LXR respectively. Indeed, it has recently been shown that the oxysterols play a 
role in the regulation of post transcriptional cell signalling.
I.I.5.4. Cell signalling
In addition to their regulatory role oxysterols can affect protein phosphorylation in 
particular the phosphorylation of extracellular signal regulated kinase (ERK1/2) 
(Yoon et al 2004, Lemaire-Ewing et a l 2009). Cholesterol stabilises a phosphatase 
complex containing oxysterol binding protein (OSBP) as a scaffold, the 
serine/threonine phosphatase PP2A and the tyrosine phosphatase HePTP that 
decreases the phosphorylation of ERK 1/2 (Wang et al 2003, Wang et a l 2005). By 
competing with cholesterol oxysterols cause the disassembling of the phosphatase 
complex and, therefore, the presence of oxysterol up-regulates ERK 1/2 
phosphorylation at the thr202/tyr204 amino acid residues. ERK 1/2 is an important 
signalling molecule and a known oncogene. It has roles in a number of different 
biological functions including cell growth, differentiation and apoptosis (Avruch 
2007). The up-regulation of ERK 1/2 phosphorylation by disassembly of this 
phosphatase has been shown in a number of different cell lines either by depletion of 
cholesterol with cyclodextrin or with treatment with oxysterols (Furuchi & Anderson
1998, Yoon et al. 2004, Agassandian et al. 2005, Calleros et al. 2006, Kim et al. 
2007, Jin et al. 2008, Lemaire-Ewing et al. 2009). This effect seems to be a feature of 
oxysterols generally as a number of different, dissimilar oxysterols have been shown 
to initiate this effect including 713-hydroxycholesterol, 2 2 -hydroxycholesterol (not 
specified R/S), and 25-hydroxycholesterol.
It is unclear whether treatment with oxysterols only affects ERK 1/2 of the mitogen 
activated protein kinase (MAPK) family as there has been contradictory evidence 
regarding other MAPKs (e.g. JNK) (Ares et al. 2000, Yoon et al. 2004). In addition, it 
is unclear as to what pathways downstream of ERK 1/2 are up/down-regulated due to 
the activation of ERK 1/2.
1.1.6. Role of Oxysterols in Disease
Oxysterols have been hypothesised to play a role in a number of disease states. These 
include cardiovascular disease, eye disease and neurodegenerative diseases.
I.I.6.I. Role of Oxysterols in Cardiovascular Disease
Artherosclerosis is a condition characterised by the hardening and thickening of the 
arterial wall caused by the accumulation of cholesterol, and other substances, in the 
wall of the artery leading to the formation of areas of hardening called plaques. 
Oxysterols have been shown to be cytotoxic to endothelial and arterial smooth muscle 
cells in vitro and have therefore been hypothesised to be artherogenic (Ares et al. 
2000). However, in vivo the situation appears to be equivocal as treatment of animals 
with dietary oxysterols resulted in variable responses. Some articles detailed increased 
levels of artherosclerosis, some reported no change whilst others observed reduced 
levels of disease progression. However, as oxidized low density lipoprotein has high 
levels of non-enzymatically formed oxysterols it is a possibility that these molecules 
have a role to play in the pathology of the disease. Indeed the most cytotoxic 
oxysterol in oxidized low density lipoprotein is 7-hydroperoxycholesterol (Chisholm 
et al. 1994). This oxysterol is rapidly decomposed to other 7-modified oxysterols and 
therefore true concentration of 7-hydroperoxycholesterol is probably under estimated 
but 7-modified oxysterols are found in high concentration in foam cells and 
artheromas. The pathogenic importance may be due to uptake oxidized low density
lipoprotein and accumulation of toxic molecules. However, the dominant oxysterol in 
artheroma is a enzymatically produced one - 27-hydroxycholesterol. It has been 
hypothesised that 27-hydroxycholesterol might act as a defence to large 
concentrations of cholesterol (Bjorkhem et al 1994; Babiker et al 1997). Evidence 
supporting this is found in analysis of the disease cerebrotendinous xanthamatosis 
(CTX). In this disease, which is a genetic autosomal recessive disease that results in 
the absence of cholesterol 27-hydroxylase (the enzyme responsible for the synthesis 
of 27-hydroxycholesterol), there is an early onset of artherosclerosis despite most 
CTX patients having normal cholesterol plasma levels (Fujiyama et al 1991). The 
majority of oxysterols in artherosclerotic plaques are comprised of 4 oxysterols. 
Together, these four oxysterols, 27-hydroxycholesterol, 7-ketocholesterol, 7p- 
hydroxycholesterol and 7a-hydroxycholesterol, account for -80% of the total amount 
of oxysterol in artherosclerotic plaques (Bjorkhem et al 1994; Crisby et al 1997). At 
present there is no direct evidence of the involvement of oxysterols in the disease. 
However, they are cytotoxic and oxysterols have been demonstrated to be pro- 
apotopic. Therefore, it appears that oxysterols have a role to play in the progression of 
this condition.
I.I.6.2. Role of Oxysterols in Eve Disease
Oxysterols have been associated with disease of the eye with implied roles in age 
related macular degeneration and glaucoma. Age-related macular degeneration is a 
disease that, as its name suggests, involves the degradation o f the macula, a 
specialised structure of the retina with a high concentration of cone photoreceptors 
and ganglion cells, and can lead to blindness. The disease is classified as two forms 
wet (or exudative) and dry (or atrophic). The wet form of the disease is due to 
increased choroidal vascularisation. The dry form of the disease is the more common, 
but generally less severe, form of the disease. It is characterised by the formation of 
drusen, extracellular deposits between the retinal pigment epithelium and Bruch’s 
membrane. These deposits can induce retinal pigment epithelial atrophy in the central 
part of the eye. Currently there are no treatments for this form of age-related macular 
dystrophy. It is this form that has been associated with oxysterols as it has recently 
been hypothesised that 7-ketocholesterol is a key player in the development of the 
disease (Rodriguez et al 2004).
In cultured retinal pigment epithelium cells treatment with low density lipoprotein 
caused toxicity after 72 hours. In order to determine if this effect was mediated by 
oxysterols the cells were treated with 50p,M oxysterol and cell viability measured 
after 72 hours (Rodriguez et al 2004) Of the oxysterols tested (25- 
hyd roxycho lestero l, 20 -hydroxychoelste ro l, 7 -k e to ch o lestero l, 70- 
hydroxy cholesterol, 7p-hydroxycholesterol) the most cytotoxic were 20- 
hydroxy cholesterol and 7-ketocholesterol. In addition, 7-ketocholesterol has been 
identified in monkey retina (Moreira et al 2009) and in retina of albino rat 
(Rodriguez and Fliesler 2009) at a level of 0.5-1.5 pmol per nmol cholesterol and 1-4 
pmol per nmol cholesterol respectively. As other sidechain hydroxylated oxysterols 
were below the detection limit (lOOfmol/nmol cholesterol) it is unclear whether these 
concentrations are in the correct range or whether auto-oxidation artefacts have 
artificially elevated them. However, despite no definitive evidence for a role for 
oxysterols in the disease oxysterol binding protein 2 (OSBP2) has been implicated 
(Torrini et al 2007).
Another eye disease with which oxysterols have been associated is glaucoma. 
Glaucoma is a chronic disease that can lead to permanent loss of sight due to optic 
nerve damage and often presents as an increased pressure of the aqueous humour 
inside the eye. A mutation in CYP46A1 was associated with incidence of primary 
open angle glaucoma (Fourgeaux et al 2009). Though there was a genetic link 
between the polymorphism and the disease this was not identified by changes in the 
plasma level of 24(«S)-hydroxycholesterol and therefore cannot be used as a biomarker 
for primary open angle glaucoma.
I.I.6.3. Role of Oxysterols in Neurodegenerative Diseases
Alzheimer’s disease is characterised by neuronal loss and the accumulation of 
amyloid beta (Ap) peptide deposits resulting in plaque formation. Ap peptide is 
formed from cleavage of amyloid precursor protein by a-secretase, P-secretase or y- 
secretase. a-secretase results in the formation of AP40 a soluble form that does not 
result in amyloid plaques. In comparison, p-secretase or y-secretase activity 
synthesises Ap42 which then forms insoluble aggregates. Oxysterols have been
implicated in Alzheimer’s disease as a biomarker of the disease and as 
neuroprotective agents.
In cerebrospinal fluid the level of 24(5)-hydroxycholesterol was increased in 14 
newly diagnosed Alzheimer’s patients compared with 10 healthy controls. In 
Alzheimer’s a level of 2.6±l.lng/ml was recorded in cerebrospinal fluid compared 
with 1.6±0.6ng/ml in healthy controls (Schonknecht et al 2002). This difference was 
considered statistically significant (p<0.05). However, no difference was observed in 
the plasma level of 24(5)-hydroxycholesterol with levels of 60.5±19.3ng/ml and 
53.6±14.3ng/ml measured in Alzheimer’s disease and healthy controls respectively. 
This change in cerebrospinal fluid level of 24(5)-hydroxycholesterol appeared 
independent of plasma cholesterol as both Alzheimer’s disease and control subjects 
had normal plasma cholesterol levels (150-230mg/dl) (Schonknecht et al 2002). In 
another study analysing the plasma level of 24(5)-hydroxycholesterol in a greater 
number of newly diagnosed Alzheimer’s patients (n=30) showed an increase in 
plasma 24(5)-hy droxycholesterol levels as compared to control (Lutjohann et al 
2000). In Alzheimer’s patients the concentration measured was 75±18ng/ml (range 
42-116) compared with 60±21ng/ml (range 24-105) of healthy control (p<0.001, 
ANCOVA). In this study however there was no statistical difference between 
Alzheimer’s and vascular dementia. Vascular dementia patients had a 24(5)- 
hydroxycholesterol plasma level of 78±20 (range 43-114) (Lutjohann et al 2000). In 
a separate study using a larger number of patients (n=40) it was shown that there was 
a significant decrease in the plasma level of 24(5)-hydroxycholesterol in Alzheimer’s 
disease patients who had been diagnosed for at least 4 years (Bretillon et al 2000). 
This decrease was modest (~18%) but statistically significant (p<0.01). Thus, from 
these studies it appears that the level of plasma 24(5)-hydroxycholesterol is an 
indication of disease progression with newly diagnosed patients having increased 
levels of plasma 24(5)-hydroxycholesterol but with a decrease over time.
Analysis of the expression of two oxysterol generating enzymes, cholesterol 24- 
hydroxylase (CYP46A1) and cholesterol 27-hydroxylase (CYP27A1), showed 
differences between Alzheimer’s disease patients’ brain (n=7) and control subjects 
(n=7) (Brown 3rd et al 2004). Both enzymes, in control brain, are expressed in 
neurons and some astrocytes. Cholesterol 27-hydroxylase is also found in
oligodendrocytes. However, in Alzheimer’s disease this pattern of distribution 
changes with expression of cholesterol 24-hydroxylase predominantly in astrocytes 
and around the amyloid plaques. Cholesterol 27-hydroxylase expression decreases in 
neurons but increases in oligodendrocytes. Analysis of the effect of 24(5)- 
hydroxycholesterol and 27-hydroxycholesterol showed that both oxysterols reduced 
the rate of production of Ap peptide in rat primary cortical neurons transfected with 
adenovirus expressed amyloid precursor protein. 24(5)-hydroxycholesterol was the 
more potent of the two oxysterols. After 24 hours treatment with IOjiM 24(5)- 
hydroxycholesterol there was a reduction in A(3(40/42) peptide of -70%  whereas 
15pM 27-hydroxycholesterol reduced the AP(40/42) secretion by -40%.
Interestingly, 24(5)-hydroxycholesterol and 27-hydroxycholesterol have been shown 
to modulate the production of A(3 in human neuroblastoma SH-SY5Y cells (Prasanthi 
et al 2009). 24(5)-hydroxycholesterol did not affect the generation of A(342 while 
treatment with 5pM 27-hydroxycholesterol increased the level of this peptide -2  fold. 
This increase in A|342 level due to 27-hydroxycholesterol treatment was associated 
with increases in both amyloid precursor protein, the source of Ap peptide, and beta- 
secretase the enzyme that generates Ap42. In comparison, 24(5)-hydroxycholesterol 
treatment promoted the alpha secretase pathway that generates non-amyloidogenic 
soluble APP and therefore it appears that 24(5)-hydroxycholesterol plays a 
neuroprotective role to prevent the formation of amyloid plaques. Conversely, it 
appears that 27-hydroxycholesterol promotes the formation of insoluble Ap42.
Questions remain regarding the role of oxysterols in Alzheimer’s disease as it is still 
unclear the biological role that oxysterols play in the disease state. It appears that 
oxysterols, such as 24(5)-hydroxycholesterol, can have a neuroprotective role due to 
changes in Ap processing (Prasanthi et al 2009, Brown 3rd et al 2004). However, it 
has yet to be determined if  changes in oxysterol concentration measured in 
cerebrospinal fluid and plasma of Alzheimer’s patients is a reflection of the cause of 
neuronal loss or merely a by-product of the disease state as a neuroprotective 
homeostatic mechanism.
Table 1.1. Summary of important oxysterols and disease states in which they have 
been implicated.
Oxysterol Formed Enzyme Implicated in disease state
7-ketocholesterol Auto-oxidation n/a Cardiovascular disease.
Glaucoma.
Age related macular 
degeneration
7a-hydroxycholesterol Enzymatically.
Auto-oxidation.
CYP7A Cardiovascular disease.
7(3-hydroxy cholesterol Auto-oxidation n/a Cardiovascular disease.
22R-hydroxycholesterol Enzymatically CYP11A1 n/a
24S-hydroxycholesterol Enzymatically CYP46A1 Alzheimer’s disease.
25-hydroxycholesterol Enzymatically CH25H n/a
27-hydroxycholesterol Enzymatically CYP27A1 Cardiovascular disease 
(proposed protective role).
Alzheimer’s disease.
24(5) ,25-epoxy cholesterol Enzymatically Shunt in 
mevalonate 
pathway
n/a
1.1.7. Role of Oxysterols in Immunity
It has recently emerged that oxysterols have a role to play in the innate immune 
response. In has been shown it that the mRNA encoding cholesterol 25-hydroxylase is 
up-regulated significantly (35x) in mouse macrophages after a short (2  hour) 
incubation with lOng/ml lipopolysaccharide (LPS; Diczfalusy et al 2009). 
Lipopolysaccharide is an important component of Gram-negative bacteria and a 
potent activator of the mammalian immune response. In contrast, lipopolysaccharide 
had no effect on the mRNA level of 2 other oxysterol generating enzymes (CYP27A1 
and CYP7B1). This increase in cholesterol 25-hydroxylase mRNA corresponded with 
a ~6 fold increase in intracellular 25-hydroxycholesterol. In addition, the intravenous
injection of lipopolysaccharide into healthy human volunteers resulted in an increased 
level of 25-hydroxycholesterol in the plasma.
Another study, conducted independently (Bauman et al. 2009), showed a similar 
increase in cholesterol 25-hydroxylase (CH25H) and 25-hydroxycholesterol after 
treatment with Kdo2-Lipid A, a selective toll-like receptor 4 (TLR4) agonist, in 
peritoneal and bone marrow derived murine macrophages. This effect appeared to be 
a general response to toll-like receptor activation as lipopolysaccharide, peptidoglycan 
(a selective agonist for TLR2), polyinosinicipolycy tidy lie acid (poly I:C, a selective 
agonist for TLR3) and lipoteichoic acid (an agonist for TLR2/6) also induced the 
expression of cholesterol 25-hydroxylase and 25-hydroxycholesterol. The Kdo2-Lipid 
A induced changes were inhibited by co-incubation with either MAPK inhibitors or 
NF-kB inhibitors.
This effect of Kdo2-Lipid A was also observed in vivo in wild-type mice after 
interperitoneal injection. Induction of CH25H mRNA was observed in all tissues 
tested with a maximum response (~250fold) in the liver. Protein levels of CH25H 
were also elevated in liver and lung after Kdo2-Lipid A treatment coupled with an 
increase in concentration of 25-hydroxycholesterol in lungs and serum. In CH25H-/- 
knockout mice the level of IgA heavy chain mRNA was increased compared to wild- 
type mice. This was corroborated as the IgA level was increased in serum, lungs and 
intestinal mucosa in CH25H-/- knockout mice. These changes were shown to not be 
due to a increase in the total number of leukocytes in the CH25H-/- knockout mice 
compared with wild type mice. Conversely knockout mice lacking oxysterol 7a- 
hydroxylase (CYP7B1-/-), which in normal circumstances rapidly metabolises 25- 
hydroxycholesterol, showed significant reductions in the IgA level in the lung, serum 
and mucosa. This effect of 25-hydroxycholesterol suppressing IgA release was also 
shown in vitro in splenic B220+ cells with an IC50 of ~50nM. This effect appears to 
be independent of LXR and cellular cholesterol levels as 22(i?)-hydroxycholesterol 
and 24(7?/S)-hydroxycholesterol were inactive and co-incubation of cholesterol with 
25-hydroxycholesterol did not reverse the effect.
The toll-like receptor 3 (TLR3) ligand poly I:C and the toll-like receptor 4 (TLR4) 
ligand LPS increase the mRNA expression of cholesterol 25-hydroxylase (CH25H) in
dendritic cells and macrophages derived from mouse bone marrow (Park and Scott 
2010). It appears that this is primarily a TRIF (TR-domain-containing adapter- 
inducing interferon-P), a TLR3/4 adapter molecule, dependent mechanism as in 
TRIF-/- mice the up-regulation of CH25H after treatment with polyI:C or LPS was 
abolished. In addition, TRIF signaling results in increases in interferon-p (IFNp) 
expression; both polyLC and LPS increased expression of IFNp in bone marrow 
derived dendritic cells and macrophages. Similarly to the effect on CH25H expression 
this effect is abolished in dendritic cells from TRIF-/- mice. In addition, the increase 
in CH25H expression can be induced by direct stimulation with interferons a , p or y. 
Further investigation of the pathway showed that increased expression of CH25H in 
macrophage and dendritic cells is reliant on JAK signalling as JAK inhibitors 
prevented the effects of polyLC, LPS and interferon-p. In addition, JAK inhibition 
reduces TLR3/4 ligand and interferon-p induced STAT1 phosphorylation. The 
absence of STAT1 in knockout models abolishes the increase in CH25H expression 
by polyLC, LPS and interferons a , p, and y in dendritic cells and macrophages.
Recently two groups have reported independently and concurrently the role of 7a,25- 
hydroxycholesterol in inducing the migration of immune cells via Epstein-Barr virus- 
induced gene 2 (EBI2) a G-protein coupled receptor (Hannedouche et al 201 l,Liu et 
al 2011). EBI2, whose natural ligand was previously unknown, is a key regulator of 
the migration of B-cells in lymphoid organs.
7a,25-hydroxycholesterol was identified as the naturally occurring receptor ligand of 
EBI2 (Hannedouche et al 2011). Modification of cholesterol by hydroxylation at both 
positions increased the potency of the oxysterol greatly (~1000-fold) compared with 
the mono-hydroxylated 7a-hydroxycholesterol or 25-hydroxycholesterol. In addition, 
7 a ,25-hydroxycholesterol is a potent chemoattractant of immune cells expressing 
EBI2 including B cells and dendritic cells. Blocking Gai-coupled receptors with 
pertussis toxin blocked the chemoattraction of B-cells induced by 7 a ,2 5 - 
hydroxycholesterol. The synthesis of 7a,25-hydroxycholesterol requires the activity 
of both cholesterol 25-hydroxylase (CH25H) and 25-hydroxycholesterol 7-alpha- 
hydroxylase (CYP7B1); two enzymes shown to be present at high levels in both 
spleen and lymph nodes. Therefore, to further investigate the biological relevance and
function of 7a,25-hydroxycholesterol CH25H-/- knockout mice were used. The 
concentration of 7a,25-hydroxy cholesterol was increased in the spleen of 
lipopolysaccharide treated wild type mice but not in CH25H-/- mice. In addition, 
CH25H-/- mice had attenuated in vivo migration of B-cells in the spleen. The absence 
of CH25H also decreased the level of IgGl response to the presence of antigen by ~3 
fold.
A second, independent, paper (Liu et al. 2011) also identified 7 a ,2 5 -  
hydroxycholesterol as the natural ligand of EBI2 with a EC50 value of 140pM 
measured by 35S-GTP-yS incorporation. 7a,25-hydroxycholesterol was the most 
potent of the oxysterols tested (EC50; 7a,25-hydroxycholesterol = 0.14±0.03nM; 
7a,27-hydroxycholesterol = 1.3±0.28nM; 7|3,25-hydroxycholesterol = 2.1±0.51nM; 
7p,27-hydroxy cholesterol = 51±1.78nM; 7a-hydroxycholesterol = 82±13.3; 7p- 
hydroxycholesterol = 1763±262; 25-hydroxycholesterol = 127±26.6; 27- 
hydroxycholesterol = 3029±571). 7a,25-hydroxycholesterol treatment of CHO cells 
transfected with V5 tagged human EBI2 induced receptor internalisation indicating 
that 7a,25-hydroxycholesterol is the natural ligand of the receptor. The biological 
relevance was demonstrated in vitro as B-cell and CD4+ T-cell migration in response 
to 7a,25-hydroxycholesterol was observed. This response was also observed in vivo 
in LPS activated B-cells, CD4+ T-cells, CD8+ T-cells and dendritic cells. All of these 
cells were characterised as expressing EBI2. However, this effect appears cell type 
specific as there was no response in vitro to natural killer cells, neutrophils and 
macrophages despite all three cell types of the immune system being EBI2 positive. 
7a,25-hydroxycholesterol desensitises EBI2 receptor. The observed effects in cell 
migration in wild-type mice were absent in EBI2-/- mice with no migratory response 
to 7a,25-hydroxycholesterol. Heterozygous EBI2+/- mice had a reduced response 
(-50%) to 7a,25-hydroxycholesterol compared with wild type mice.
It is clear therefore that an emerging, important role for oxysterols in the innate 
immune response is slowly being elucidated. However, it appears that oxysterols, in 
particular those hydroxylated at the 25- position, are key players in this mechanism.
1.1.8. Role in development
A large number of oxysterols are found in the central nervous system (Wang et al 
2009), but the predominant oxysterol produced in adult brain is 245- 
hydroxycholesterol (C5-3|3,245-diol), a CYP46A1 oxidised metabolite of cholesterol 
that is exclusively synthesised in the brain (Lund et al 1999). It has recently been 
shown that in murine embryonic brain 24(5),25-epoxycholesterol (C5-3p-ol-245,25- 
epoxide) is present at relatively high levels compared to other oxysterols (Wang et a l 
2009). As previously described (section 1.1.3.3), unlike other oxysterols 24(5),25- 
epoxycholesterol is not a metabolite of cholesterol but a final product in a shunt of the 
mevalonate pathway of cholesterol synthesis.
24(5),25-epoxycholesterol has a potential role in the development of the embryonic 
brain as it has been shown that the level of 24(5),25-epoxycholesterol is present at 
relatively high levels in comparison to other oxysterols in the cortex and spinal cord 
of embryonic mice (Wang et al 2009). The predominant oxysterol in adult mouse 
brain is 24(S)-hydroxycholesterol with level o f 2.53±0.05ng/pg 24(5)- 
hydroxycholesterol to cholesterol (Lutjohann et al 2002). In the embryonic murine 
brain this level is greatly reduced; at embryonic day 11 there was an observed level of 
0.026pg/g (wet weight) in the cerebral cortex and 0.013pg/g (wet weight) in the 
spinal cord. In comparison, the concentration of 24(5),25-epoxycholesterol was 
0.165pg/g (wet weight) in the cerebral cortex and 0.091 pg/g (wet weight) in the 
spinal cord. In comparison in human primary neurons, derived from 14-18 week old 
foetuses, 24(5),25-epoxycholesterol synthesis has been detected (Wong et al 2007). 
The overall level of 24(5),25-epoxycholesterol was not measured though the rate of 
synthesis of the oxysterol was 0.001-0.05% of the rate of synthesis of cholesterol 
(Wong et al 2007). It is unclear the role this increased concentration plays in murine 
embryonic neural development. However, LXRa/p is present in embryonic brain 
(Sacchetti et al 2009) and as 24(5),25-epoxycholesterol is a potent ligand for this 
nuclear receptor (Janowski et al 1999) it might play a role in neural development. 
Indeed, there is evidence to suggest that the presence of LXR is essential to 
dopaminergic neurogenesis in the ventral midbrain (Sacchetti et al 2009).
LXR is expressed in embryonic mice (Annicotte et al 2004). LXRa was observed to 
be abundant in the liver, intestines and adipose tissue whereas LXRp was more 
ubiquitously expressed with strong expression in neuronal and endocrine tissue. LXR 
is expressed in ventral midbrain progenitor cells (Sacchetti et al 2009). In addition to 
this these cells also express oxysterol generating enzymes (e.g. CYP46A1, 
oxidosqualene lanosterol cyclase) and ABCA1, whose expression is reliant on LXR 
activation. LXRa/p knockout mice showed down regulation of two genes that control 
dopaminergic neuron development Lmxlb and Wntl. These reduced expressions, 
consequently, caused the down-regulation of Pitx3 a gene regulated by Lmxlb and 
W ntl. The effect of LXRa/p knockout cased a reduced number of cells in the 
marginal zone where dopaminergic neurons are present. These effects result in 
impaired dopaminergic neuron development in LXRa/p knockout mice.
The reduction in dopaminergic neurogenesis was reliant on LXRa/p as there was no 
increase in apoptosis and oxysterols did not have a direct effect on neurogenesis in 
LXRa/p knockout mice. However, at embryonic day 11.5 dopaminergic neurogenesis 
was impaired in the floor plate midbrain, the area of the brain where dopaminergic 
neurons are derived. In LXRa/p knockout mice there were less tyrosine hydroxylase 
positive (TH+) neurons. Tyrosine hydroxylase is the rate-limiting enzyme for 
dopamine synthesis. In ventral midbrain primary cultures 22{R)-hydroxycholesterol 
and GW3965, a synthetic LXR ligand, increased the number of TH+ cells in wild type 
but not in LXRa/p knockout cells.
In addition, the efficiency of the differentiation of mouse embryonic stem cells to 
dopaminergic neurons treated with 2 2 (/?)-hydroxycholesterol was increased. 
Overexpressing LXRp had a similar effect and interestingly the combination of 
22(i?)-hydroxycholesterol treatment and LXRp was additive. The balance between, 
and organisation of, different cell types was disrupted by LXRa/p knockout as the 
number RC2+ glia increased whilst there was disorganisation of GFAP+ astrocytes. 
However the primary defect caused by LXRa/p knockout is on ventral midbrain 
dopaminergic neurogenesis.
LXRa/p knockout also disrupted the cell cycle (Sacchetti et al 2009) as there was an 
increase in cells entering the active stages of mitosis, measured by Ki67+ staining, but
no subsequent increase in Brdu incorporation and cell cycle exit was decreased. In 
LXRa/p knockout cells were held at G2/M with an increased percentage of 
progenitor cells and reduced neurogenesis.
In human embryonic stem cells LX Ra/p are expressed and increases during 
differentiation. The number of Tujl+ neurons was increased by 70% and TH+ 
neurons increased by 300% after treatment with 22(i?)-hydroxy cholesterol during 
differentiation (Sacchetti et al. 2009). The number of Tujl+ that also stained positive 
for TH cells was also increased. This effect was at its maximum at a concentration of 
0.1-0.5pM 22(R)-hydroxycholesterol. There were no signs of toxicity at these 
concentrations and TH+ oxysterol treated cells expressed midbrain dopaminergic 
markers (LMXla, ENGRAILED 1, NURR1, PITX3, GIRK2, DAT). In contrast, very 
few GABA+, serotonin+, and dopamine beta-hydroxylase (DBH)+ neurons were 
detected indicating that treatment with 2 2 (R)-hydroxycholesterol gave a specific 
enhancement of dopaminergic neuron development. In addition there was reduced 
progenitor proliferation and in the number o f astrocytes whilst increasing the 
generation of midbrain dopaminergic neurons.
More recently it has been shown that 24(«S),25-epoxycholesterol is a potent ligand of 
LXR during ventral midbrain neurogenesis and specifically promotes dopaminergic 
neurogenesis (Theofilopoulos et al. 2013). In embryonic mouse midbrain neurons 
organotypic cultures treatment with 24(5),25-epoxycholesterol increased the number 
of tyrosine hydroxylase positive neurons by 88% c .f  vehicle. Similarly 24(5),25- 
epoxycholesterol treatment increased the number of tyrosine hydroxylase positive 
neurons in mouse primary progenitor cultures. In addition, 24(5),25-epoxycholesterol 
promoted the differentiation of mouse embryonic stem cells into dopaminergic 
neurons. Thus, it appears that 24(5),25-epoxycholesterol is a critical ligand for normal 
dopaminergic neurogenesis.
However, the mechanism(s) by which 24(5),25-epoxycholesterol/LXR acts to result 
in this effect on neuron proliferation is unclear. Increased concentrations of 24(5),25- 
epoxycholesterol could alter protein expression directly through transcriptional 
modification of known or unknown LXR. In addition, 24(5),25-epoxycholesterol 
could have indirect effects by inhibiting SREBP2 and decreasing biosynthesis of
cholesterol and other members of the mevalonate pathway or inducing downstream 
effects of differentially expressed proteins.
In addition, oxysterols have been shown to affect Hedgehog signalling, a pathway that 
is involved in embryonic development. Cholesterol and oxysterols have been shown 
to increase proliferation of medulloblastoma cells through Hedgehog signalling with 
20(5)-hydroxycholesterol and 22(5)-hydroxycholesterol having the greatest effect 
(Corcoran and Scott 2006). It has also been demonstrated independently that 20(5)- 
hydroxycholesterol and 22(5)-hydroxycholesterol activate the Hedgehog pathway and 
induce an osteoinductive effect (Dwyer et al 2007). In addition, it has been 
demonstrated that 20(5)-hydroxycholesterol inhibits the differentiation of bone 
marrow stromal cells into adipocytes through a Hedgehog dependent mechanism and 
that 20(5)-hydroxy cholesterol can induce expression of Notch target genes (Kim et al 
2007; Kim et al 2010). The mechanism by which 20(5)-hydroxycholesterol effects 
Hedgehog signalling is by activating the protein Smoothened; Smoothened mediates 
the signal induced by Hedgehog ligands (Nachtergaele et al 2012). Thus, there is 
evidence for a role for oxysterols in the regulation of embryonic development.
1.2. Proteomics
Proteomics is the study of global protein expression (Wilkins et al 1996). As proteins 
are the macromolecules that implement cellular biological processes the analysis of 
changes in their expression can identify gross changes in cell function. The proteins 
expressed, including any post-translational modifications, at any given point is called 
the cell’s proteome. The proteome is more complex than the genome. The genome 
can be considered as a stable constant whereas the proteome is highly variable. The 
proteome varies with cell type, with time and as a response to stresses or stimuli (Dix 
et al 2008). In addition, mRNA splice variants of genes add further complexity as do 
post-translational modifications of proteins such as phosphorylation (Uhlen & Ponten
2005). Indeed, some proteins are able to have multiple different post-translational 
modifications illustrating the complexity of a proteomic sample at any given point.
The analysis of the proteome can be analysed as whole proteins or more commonly as 
peptides. It is common to digest protein enzymatically by using, for example, the 
enzyme trypsin. Trypsin hydrolyses the peptide bond on the carboxylic side of the
amino acids lysine and arginine. Thus, peptides are fragments of the protein backbone 
that have been generated from intact proteins. Peptides are analysed by mass 
spectrometry and their sequence identified using bioinformatic software. From this 
information the proteins present can be deduced.
A strength of proteomics is the direct analysis of protein expression rather than 
extrapolating from mRNA data e.g. microarray; it has been shown that changes in 
mRNA expression need not correlate with a change in protein expression (Rogers et 
al. 2008). It has the advantage over immunoblotting (Western blotting) as the 
expression of a large number of proteins can be analysed in one run. In addition, post- 
translational modifications of the proteome can be analysed giving information 
regarding signalling pathways or the response to a given stimulus (Olsen et al. 2006). 
Proteins can be modified after translation to alter their function, localization or 
interactions with other proteins. These alterations are termed post-translational 
modifications. Post-translational modifications significantly increase the diversity of 
the proteome as they can be initiated in response to a given stimulus to regulate 
cellular processes. A large number of diverse modifications have been identified 
including phosphorylation, glycosylation and ubiquitination. Proteomics allows the 
analysis of changes in post-translation modifications that would not be possible using 
immunoblotting due to no commercially available specific antibody (Jensen 2004).
1.2.1. Phosphoproteomics
Phosphoproteomics is a specialized branch of proteomics examining phosphorylated 
proteins. In the case of phosphorylation, an extensively studied post-translational 
modification, it has been demonstrated to be involved in the regulation of diverse 
cellular processes (e.g. apoptosis, cell cycle).
Phosphorylation, is a reversible post translational modification and plays a role in a 
variety of cellular processes and it is a common mechanism for cell signalling and 
protein regulation. In eukaryotic cells phosphorylation of protein occurs on the side 
chains of serine, threonine and tyrosine residues. These amino acids have in common 
a nucleophilic hydroxyl group that reacts with adenosine triphosphate (ATP) resulting 
in the covalent attachment of a phosphate to the amino acid side chain. 
Phosphorylation is often associated with protein activity as the addition of the
phosphate can result in conformational changes in the newly phosphorylated protein 
and can regulate the activation or inactivation of an enzyme. In addition, 
phosphorylation can induce proteins to associate and is important in signal 
transduction as it can allow an enzyme to bind its substrate. The phosphorylation and 
dephosphorylation of protein(s) is regulated by kinases and phosphatases respectively. 
The balance between the activities of these two enzyme families influences the 
dynamic phosphorylation state of a cell. At any given point the phosphorylation state 
of a cell’s proteins is called its phosphoproteome.
Phosphoproteomics is the analysis of the phosphorylation state of the entire proteome. 
This can be done in order to identify novel post-translational modification sites or to 
identify activation or deactivation of signalling pathways (Olsen et al 2006). The 
technical challenge of phosphoproteomics is high. Phosphopeptides are present in low 
abundance compared to their non-phosphorylated counterparts. In addition they are 
poorly ionized. These two factors mean that phosphoenrichment is required in order 
to examine these molecules.
1.2.2. Mass Spectrometry
Mass spectrometry measures an ion’s mass to charge ratio (m/z). Mass spectrometers 
generally consist of an ionisation source (e.g. electrospray), a mass analyzer and an 
ion detector. In combination these components allow the detection ions of different 
mass to charge ratios.
I.2.2.I. Electrosprav Ionization
The ability to investigate global protein expression has blossomed since the invention 
of 2 soft ionising techniques -  matrix assisted laser desorption ionisation (MALDI; 
Tanaka et al. 1989) and electrospray ionisation (ESI). These techniques have the 
advantage of ionizing macromolecules without inducing fragmentation. Therefore, 
these techniques have become essential for proteomic analysis as they allow the 
ionization of amino acid chains without disrupting the peptide bonds and thus 
conserving sequence information.
Electrospray ionization was developed to ionise macromolecules without inducing 
fragmentation (Fenn et al 1989). The analyte, e.g. a peptide mixture, dissolved in a
solvent is subjected to an electrical voltage that induces generation of a Taylor cone 
and the formation of a fine aerosol spray. Volatile organic solvents such as acetonitile 
or methanol are commonly used as they evaporate easily facilitating ion formation of 
the analyte. In addition, the ionisation of large flow electrospray can be improved by 
using an inert gas in order to help remove solvent. However, electrospray ionisation is 
more efficient at low flow rates due to the lower size of initial droplets. A flow rate of 
300-800nl/min resulted in an increased performance of HPLC-MS analyses (Emmett 
and Caprioli 1994). The flow rate can even be reduced even further to a nanoflow of 
~25nl/min and still generate efficient electrospray (Wilm and Mann 1996).
Mass spectrometer design also promotes ionisation e.g. a heated capillary that ions 
follow into the mass spectrometer helps evaporation. Evaporation continues until the 
droplet becomes unstable upon reaching its Rayleigh limit and emits charged jets in 
Coulomb fission. Two theories have been proposed to explain the production of gas 
phase ions. The first, the ion evaporation model theorises that that as the radius of the 
droplet decreases the surface of the droplet increases to assist in the field desorption 
of solvated ions. The second model is the charge residue model suggests that 
electrospray droplets as the solvent evaporates and splits until the droplets contain one 
analyte ion. The solvent evaporates leaving the analyte carrying the charge. 
Whichever theory is correct the end result of this ionisation technique is the formation 
of gas phase ions.
The ions produced by electrospray ionization can either be due to the addition of a 
proton [M+H] or the removal of a proton [M-H]. These modes are termed positive 
and negative modes respectively. In order to promote protonation or deprotonation, in 
positive and negative modes respectively, an acid (e.g. formic acid) or base (e.g. 
ammonia solution) can be added to the solvent. Positive mode is generally used for 
the analysis of proteins and peptides in proteomic experiments. In the case of peptides 
multiply charged ions are commonly seen. This is because both the N-terminus and 
arginine and lysine residue sidechains can act as proton acceptors thus creating ions 
carrying a +2  charge.
1.2.2.2. Mass Analyzer
A large number of different mass analyzer technologies exist including quadrupole, 
time of flight (TOF), Fourier transform ion cyclotron resonance (FTICR) and Orbitrap 
instruments. Hybrid instruments also exist that consist of a number of analyzers 
combined e.g. triple quadrupole, Q-TOF. These mass analyzers vary in how they 
measure ion m/z and technical specifications. In addition, the choice of mass analyzer 
is often determined by the application.
In proteomic studies high resolution LTQ-Orbitrap instruments are commonly used. 
The Orbitrap consists of 2 electrodes - a central electrode kept at a high voltage when 
ions are being trapped and a second electrode surrounding the first at ground potential 
(Hu et al 2005, Scigelova et al 2011). The frequencies of the oscillating ions can be 
detected and following a Fourier transform can be displayed as a mass spectrum. An 
Orbitrap instrument has a high resolution (>100,000) and a high mass accuracy 
(<5ppm) making it suitable for proteomic studies. The use of an Orbitrap mass 
analyzer for high mass accuracy MS spectra is in commercial instruments coupled 
with a linear ion trap (Hu et al 2005). The ion trap acts as an accumulation device 
that stores ions before introduction to the Orbitrap and therefore allows the use of 
continuous electrospray ionisation. In addition, the ion trap allows MS“ that fragments 
the precursor ion and therefore allows elucidation of structural information.
1.2.23. Precursor Ion
The initial mass spectrometry scan identifies all ionisable components of a sample. 
These ions identified in the MS scan give an indication of the molecular weight of 
analyte. Importantly, a precursor ion can be selected for fragmentation by selecting an 
ion at a given m/z. Fragmentation of an ion yields structural information about it. 
Peptides have a distinctive isotope envelope due to the fact that peptides can accept 
multiple protons inducing charge states of +2, +3 or more. Thus, in the example of a 
doubly charged peptide each isotopic peak that is IDa apart will be 0.5m/z apart. 
Therefore an analyte can be deduced to be a peptide by examining its precursor ion. 
However, an MS/MS scan is required for sequence information.
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I.2.2.4. Tandem Mass Spectrometry (MS/MS)
Tandem mass spectrometry allows further analysis of an ion identified in the initial 
MS spectra. A precursor ion of interest is selected, based on its m/z and is fragmented 
e.g. collision induced dissociation (CID) yield structural information about the 
analyte. In the case of peptides by colliding the precursor ion with an inert gas, e.g. 
nitrogen, the peptide bonds break leading to information regarding the amino acid 
sequence (Mann & Wilm 1994). Thus, the fragmentation pattern o f a peptide’s amino 
acid backbone allows database searching (e.g. Mascot) to identify the peptide 
sequence and the protein from which it was derived by comparing it to predicted 
peptide sequence. Depending on the distribution of charge post-fragmentation (i.e. to 
the N- or C-terminus) b- and y- ions are predominantly generated (though a, c, x and z 
ions can also be formed; fig. 1.5; Roepstorff & Fohlman 1984) that allow 
identification of the sequence due to specific m/z changes that correspond to each 
amino acid. A subscript number indicates which peptide bond is broken. Thus, the 
mass differences between the b and y fragmentation ions (e.g. bi and b: fig 1.5) 
generated indicate which amino acid residue is lost. From the generated y- and b- ions 
a peptide's sequence from a given MS can be deduced.
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Fig 1.5. Peptide fragmentation notation. The dominant ions in MS/MS spectra are b 
and y ions.
1.2.2.5. Multistage activation
The analysis of phosphopeptides is dependent on detecting the phosphorylation 
modification of the peptide and fragmentation of the amino acid backbone of the 
peptide to deduce its sequence. The phosphate group of a phosphopeptide is relatively 
weak and they are liable to break instead of peptide bonds. Thus, phosphopeptides in 
a CID MS/MS spectrum are likely to exhibit a large neutral loss peak 98Da (H3PO4) 
or 80Da (HPO3) less than the precursor peak. This leads to inability to deduce 
sequence information from the MS/MS spectra. Therefore a second step of activation 
is required in order to obtain this information required for identification. This can be 
achieved by using MS when a dominant neutral loss peak is identified in the MS/MS 
spectra and is subsequently selected for fragmentation yielding a spectra displaying 
sequence information.
A second method that can be used to identify and sequence phosphopeptides is 
multistage activation and has the advantage of having a shorter time for analysis than 
MS3. In this method a pseudo-MS3 spectrum is generated. A precursor ion is selected 
for fragmentation at both its observed m/z and, critically, at the m/z where the neutral 
loss ion is theoretically present. This yields a spectrum with no neutral loss ion peak. 
The spectrum contains b and y ions allowing identification of the peptide sequence. In 
addition b-98 and y-98 ions are present derived from fragmentation of the neutral loss
■j
peak. Therefore, multistage activation generates a hybrid pseudo-MS spectrum 
showing both MS and MS fragmentation on the same spectrum that can be analysed 
for both peptide sequence and phosphorylation.
1.2.3. Quantitative Proteomics
After protein identification the next step is quantification to give an indication for the 
level of protein expression and how it differs in cells with different treatments. To this 
end a number of different approaches have been developed including isotope labelled 
and label free methodologies. In label free methods each sample is run individually 
and then subsequently compared. However, in the case of isotope labelling each group 
is labelled with a different isotope marker and thus they are distinguishable by mass 
spectrometry. Due to this ability to distinguish different groups it is possible to 
combine samples and compare them in a single mass spectrometry analysis.
1.2.3.1. Stable Isotope Labelling with Amino Acids in Cell Culture (SILAC)
SILAC is a quantitative proteomic technique that allows the identification of relative 
changes in protein expression using non-radioactive isotope labelling (Ong & Mann
2006). SILAC can be used in many applications and can be used in order to monitor 
changes in gene expression, post-translational modification and protein-protein 
interactions. In this technique cells are grown in cell culture and are split into 2 or 3 
populations (fig. 1.6 .). The first population is cultured in growth media that contains 
normal, non-isotope labelled amino acids. However, the second population is grown 
in the presence of amino acids, commonly arginine and lysine, labelled with stable, 
non-radioactive isotopes. Commonly used are 13C6 and 13C6 15N4 arginine (R^/Rio) 
together with D4 and i3C6 l5N2 lysine (KVKg). These are termed light (unlabelled R  
and K), medium (K4/R6) and heavy (Kg/Rio). Due to the mechanism of action of 
trypsin that cleaves peptide bonds to the C-terminus side of arginine and lysine. Thus, 
each peptide generated, except the C-terminus, theoretically results in only having a 
single label.
As the cell population increases, and is passaged, the heavier amino acids are 
incorporated into the proteome. Eventually all proteins contain the isotope labelled 
amino acids and are heavier than their normal counterparts. Thus, they are 
distinguishable by mass spectrometry but otherwise chemically and biologically 
identical. It is therefore possible to combine the protein derived from different SILAC 
states and analyse it simultaneously as pairs or triplets of peptides that co-elute from 
HPLC columns. Therefore this methodology allows 3 treatment groups to be 
simultaneously analysed. The ratio of the peak intensities of the peptides can then be 
analysed and their relative abundance determined. Peptide ratios can then be 
extrapolated to protein expression ratios.
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Figure 1.6. Schematic of SILAC experimental design. In this study SN4741 cells were 
cultured in isotope labelled amino acid containing media. This approach can be 
extended to any cells grown in culture. Cells are then treated, in this case with vehicle 
(control), 24(5'),25-epoxycholesterol (24(S'),25-EC) and GW3965, before cells are 
lysed and protein harvested. The protein lysates are then mixed on a 1:1 ratio before 
trypsin digestion and strong cation exchange (SCX) fractionation. Fractions are then 
analysed using LC-MS/MS. Due to the isotope labelling it is possible to distinguish 
between the Might’, ‘medium’ and ‘heavy’ peptides. Mass spectra of SILAC peptides 
result in a characteristic triplet envelope and the intensity of the signal from each 
SILAC state can be used for relative quantification.
1.2.3.2. Isobaric Tagging
Isobaric tagging (e.g. iTraq) is a relative quantitative proteomic technique that allows 
identification of chemically tagged peptides from different treatment groups (Ross et 
al. 2004). In iTraq a N-succinimide ester group on the tag that reacts with primary 
amines. The workflow of the experimental approach means that the labelling occurs 
after trypsin digestion but before mixing and assumes that the labelling between 
different treatment groups is equal. The total molecular weight of tag remains 
constant but is split into a reporter moiety and a balance moiety. Thus, tagged
peptides have the same molecular weight and all identical sequence peptides co-elute 
during liquid chromatography. In addition, the precursor ion is the same molecular 
weight in all groups. Upon fragmentation low molecular weight reporter ions 
distinguish between the different groups and allow relative quantification. An 
advantage of iTraq over SILAC is that more treatment groups, up to 8 , can be 
analysed at the same time.
1.2.3.3. Label Free Quantification
Label-free quantification of proteins does not rely on an isotope label. These 
approaches are suitable for identifying large changes (> 2  orders of magnitude) but 
less reliable for identifying smaller, subtle changes. Due to the lack of an isotope label 
samples can’t be run simultaneously and require the detection of the corresponding 
peptide across different LC-MS or LC-MS/MS runs for quantification. Thus, care is 
required to account for experimental variation. Two methods used for label free 
quantification are ion peak intensity and spectral counting (Bantscheff et al. 2007).
Ion peak intensity relies on precursor signal intensity in order to quantify peptides and 
therefore relies on LC-MS only. Thus, high mass precision spectrometers are required 
for this approach as high resolution power is required for identifying peptide signals 
at the MS level. Peptides are differentiated from noise due to their isotopic pattern. 
The peptide precursor ion is tracked over time gives a chromatographic profile of the 
monoisotopic peak which is integrated to estimate original peptide concentration. No 
MS/MS spectra are generated and thus peptides with a similar m/z and coincidentally 
eluting at the same point or overlapping may be confused. The second method, 
spectral counting, compares the total number of MS/MS spectra for a given peptide 
between samples. The number of spectra is correlated with the abundance of the 
protein. Both techniques require significant normalization.
1.2.4. Peptide Mixture Complexity Reduction
Peptide mixtures generated from the protein digestion are complex and techniques to 
simplify these mixtures are commonly used. In the case of both proteomics and 
phosphoproteomics the peptide mixtures derived from proteome digestion are 
inherently complex. In order to reduce this complexity prior to mass spectrometric
analysis a number of techniques can be used. These include polyacrylamide gel 
electrophoresis, 2D-gel electrophoresis, affinity chromatography, ion exchange 
chromatography and reverse phase liquid chromatography. These steps help to 
maximize the number of peptides observed by mass spectrometry and thus increase 
the number of proteins identified. Low abundance peptides (and therefore low 
abundance proteins) are more likely to be identified in less complex mixtures. The 
techniques utilized in this work (strong cation exchange chromatography, reverse 
phase high performance liquid chromatography, phosphoenrichment) are discussed in 
more detail below.
1.2.4.1. Reverse Phase High Performance Liquid Chromatography
High performance liquid chromatography (HPLC) is a chromatography technique to 
separate analytes in complex mixtures. HPLC utilizes a stationary phase in column 
and a mobile phase that is pumped through the column carrying analytes. The 
retention time of an analyte is dependent on its interaction with the stationary phase 
and the mobile phase. Commonly C18H37 modified stationary phases are used and the 
technique is known, for historical reasons, as reverse phase HPLC. In reverse phase 
chromatography the retention of hydrophobic compounds is increased. Conversely, 
more polar analytes are eluted quicker. The retention of a given analyte can be 
adjusted by adding increased levels o f organic solvent, such as acetonitrile or 
methanol, and is commonly manipulated using a solvent gradient on a HPLC 
instrument. Importantly, liquid chromatography can be coupled to a mass 
spectrometer so that analytes eluting from the column and transferred directly to the 
spectrometer for ionization and subsequent analysis.
1.2.4.2. Strong Cation Exchange
Strong cation exchange chromatography is a form of ion exchange chromatography. 
This form of chromatography separates of molecules on the basis of their charge. The 
stationary phase of the column has anionic functional groups (e.g. polysulphoethyl 
aspartamide (PolyLC Inc.)) that interact with cationic analytes. A chromatography 
gradient increases the salt concentration (e.g. N H 4 C I )  in the solvent and results in the 
cationic molecules in the solvent competing for the anionic sites on the strong cation 
exchange column. Thus, cationic molecules are displaced and elute from the column.
Therefore, during strong cation exchange chromatography anionic analytes are eluted 
first off the column whereas strongly cationic analytes take longer. Strong cation 
exchange can be used for sample fractionation to reduce complexity prior to further 
analysis.
I.2.4.3. Phosphoenrichment
Phosphorylated peptides require enrichment prior to mass spectrometry analysis due 
to their low abundance and poor ionization (Zhou et al 2000). Strategies to extract 
phosphorylated peptides from a peptide mixture include immobilised metal ion 
affinity chromatography (IMAC) and metal oxide affinity chromatography (MOAC). 
Both techniques use metal ligands to interact with phosphate groups in order to retain 
phosphopeptides whilst allowing non-phosphorylated peptides to elute.
Immobilised metal ion affinity chromatography (IMAC) relies on the phosphate 
group’s oxygen interacting with an immobilized metal ion. A high affinity for 
phosphate groups has been shown with chelated iron(III) and gallium(III) ions (Zhou 
et ah 2000). During chromatography this results in the retention o f the 
phosphopeptides on the column and washing of the non-phosphorylated peptide 
mixture through. The phosphopeptides can then be washed off the column by 
changing the pH of the mobile phase or adding a competitor. Thus, IMAC increases 
the concentration of phosphopeptides.
Titanium dioxide is used for metal oxide affinity chromatography (MOAC) 
phosphoenrichment (Larsen et al. 2005). Similarly to IMAC titanium dioxide chelated 
resins are used to form complexes with phosphate groups. MOAC can be combined 
with IMAC in order to increase the number of phosphopeptides in the sample. In 
addition both IMAC and MOAC can be used after fractionation (e.g. strong cation 
exchange) to improve the phosphoenrichment by reducing sample complexity.
1.2.5. Proteomic Bioinformatics
The identification of peptides and therefore proteins by using the mass spectrometric 
data is reliant on bio-informatic software. It is possible to analyse spectra manually 
although this is prohibitively time consuming when considering the many thousands 
of spectra typically generated in one experiment. Therefore, database searching has
become an integral part of proteomics experiments. This search is conducted using 
software such as Mascot that identifies peptides from the raw mass spectrometry data. 
The data is analysed bio-informatically to identify peptides by comparing sequence 
information derived from MS/MS spectra to a sequence database containing all 
theoretical peptide sequences. The peptidase, such as trypsin, can be defined before 
searching so that the generated experimental peptides match the theoretical. The 
database search can be constructed so that any modifications, such as phosphorylation 
and SILAC, are taken into account. Peptides are identified and can be assigned a score 
that indicates the probability of a correct identification.
The database used for the Mascot search is not limited to one and a number of 
databases are available for various species from different sources. International 
protein index (IPI) is a database from the European Bioinformatics Institute founded 
to catalogue the disparate databases and act as a link between them. Since its 
inception a concerted effort has led to a significant synchronization of data. In light of 
this, the IPI database has recently been retired and IPI numbers are currently being 
superseded by Uniprot numbers. Uniprot is comprehensive database managed by a 
consortium of the European Bioinformatics Institute, the Swiss Institute of 
Bioinformatics and the Protein Information Resource (Uniprot Consortium 2011). 
These consortium members each individually maintained a database but joined forces 
to produce a curated protein database Uniprot knowledgebase (UniprotKB). 
UniProtKB comprises 2 sections Uniport/Swissprot that is reviewed and manually 
annotated and Uniprot/Trembl that is unreviewed and annotated automatically. 
UniprotKB/Swissprot gives indication of a large range of factors and has the ultimate 
aim of providing all known, relevant information in a single place. Therefore, Uniprot 
is currently the canonical reference set of proteins for a number of organisms.
In our study the quantification of peptides was performed using MaxQuant software. 
MaxQuant is specialised software designed for the analysis of SILAC MS spectra 
(Cox et al. 2009). MaxQuant identifies the characteristic doublet/triplet isotope 
envelopes of SILAC labelled peptides. The software tracks these precursor ions over 
time that allows the merger of the separate signal intensity peaks into a 3D 
representation. The volumes of the 3D peaks are then compared allowing the 
generation of ratios between the different SILAC states (e.g. medium:light,
heavy:light). To identify peptides MS/MS data is analysed. The data is then combined 
to give an identified and quantified peptide. In the case of phosphopeptides this means 
that they can be identified and when coupled with SILAC labelling can give an 
indication of the relative levels of phosphorylation at a specific site between control 
and treatment groups. In addition to quantifying each individual peptide the quantified 
peptide is combined with others derived from the same protein and extrapolated in 
order to generate the ratio between the SILAC states of the protein. Thus, the relative 
quantification of proteins between different SILAC states is identified and further 
analysed to identify changes in protein expression.
1.2.6. Experimental Considerations of Proteomic Studies
1.2.6.1 SN4741 Cell Line.
Due to the limited amount of primary dopaminergic neurons from mouse embryonic 
brain available for large-scale proteome wide screening in the experimental work 
presented here the differentiated neuronal cell line SN4741 was used. SN4741 cells 
are dopaminergic neurons derived form the substantia nigra of embryonic mice (Son 
et al 1999). It has previously been shown that SN4741 cells are tyrosine hydroxylase 
positive and express other neuronal markers (Son et al 1999). Dopaminergic neuronal 
markers, such as tyrosine hydroxylase, can be searched for in the proteomic data set to 
validate the model.
In order to achieve large-scale accurate protein quantification stable isotope labelling 
approaches such as SILAC or iTraq are the preferred choices. The use of a SILAC 
approach allows the harvesting of a large amount of protein (mg scale) for use in the 
proteomic experiments easily. Thus, by having a large amount of starting material the 
probability of identifying low abundance proteins is improved and therefore SILAC is 
the most appropriate choice.
1.2.6.2. Proteomic Profiling Validation of Existing Knowledge
One of the strengths of proteomic studies is the ability to analyse the proteome as a 
whole. This provides the opportunity for the experimental data to validate previously 
identified changes in protein expression as a response to a given treatment. Oxysterols 
have known regulatory roles for SREBP2 and LXR controlled genes. However, no 
previous work has been conducted analysing the effect of oxysterols in SN4741 cells. 
Indeed, it can be anticipated that 24(5),25-epoxycholesterol will induce changes in the 
cholesterol synthesis pathway in SN4741 cells through inhibition of SREBP2 and 
induction of LXR regulated genes such as ABCA1.
1.2.6.3. Identification of Novel 24(5h25-epoxvcholesterol Regulated Genes
It is difficult, if not impossible, to predict novel 24(5),25-epoxycholesterol regulated 
genes in the context of proteomic studies. The basic hypothesis of the experiments is 
broad; 24(5),25-epoxycholesterol induces protein expression changes in SN4741 cells 
via SREBP, LXR or other unknown oxysterol receptors. Early studies suggest that 
oxysterols promote dopaminergic neurogenesis through LXR (Sacchetti et al. 2009;
Theofilopoulos et al. 2013). However, which LXR regulated proteins induce this 
effect is not clear. The aim of the work is to pinpoint the protein pathways which are 
affected by 24(5),25-epoxycholesterol by employing a quantitative proteomics 
approach. This is essential to fully understand the mechanism(s) of 24(5),25- 
epoxycholesterol in promoting dopaminergic neurogenesis. The data generated from 
the proteomic studies will also be analysed for the presence of neurotrophins, proteins 
that have an important regulatory role in neuron development, survival and function 
(Hempstead 2006), and any changes in their expression. In addition, neuronal markers 
from different stages of neuronal development will be analysed to determine if 
24(5),25-epoxycholesterol has an effect on the maturation of neurons.
1.2.6.4. Identification of Novel 24(5),25-epoxvcholesterol Regulated Protein 
Phosphorylation
Oxysterols have been shown to induce changes in ERK phosphorylation (section 
1.1.5.4) a pathway associated with dopaminergic neurogenesis (Kim et al. 2006; Kim 
et al. 2008; Yoon et al. 2011; Jaeger et al. 2011). We speculate that 24(5),25- 
epoxy cholesterol could promote dopaminergic neurogenesis at multiple levels i.e. via 
activation of LXR and also, possibly, by activation of the ERK signalling pathway 
Thus, a phosphoproteomic approach will be used to identify novel 24(5),25- 
epoxy cholesterol regulated protein phosphorylation either downstream of ERK or any 
other kinase pathways. These data will provide further insight into the mechanism of 
oxysterol activity in addition to the quantitative proteomics study. Again, the basic 
hypothesis of the experiments is broad; 24(5),25-epoxycholesterol induces protein 
phosphorylation changes in SN4741 cells. Therefore, the data generated from the 
phosphoproteomic studies will be analysed to identify changes, if  any, in cell 
signalling pathways.
1.3. Aims and Objectives
The work presented here is founded on the previously reported requirement of LXR in 
normal neuronal development (Sacchetti et al. 2009) and the above expected level of 
24(5),25-epoxycholesterol in embryonic mouse brain (Wang et al. 2009b). Therefore, 
three main hypotheses form the basis of this work:
• 24(5),25-epoxycholesterol is an important molecule in normal murine 
neuronal development.
• 24(5),25-epoxycholesterol exerts an influence on neuronal development by 
inducing LXR dependent and independent changes in protein expression.
• 24(5),25-epoxycholesterol induces changes in the phosphoproteome and exerts 
an influence on neuronal development by affecting cell signalling.
In order to examine these hypotheses a SILAC experimental model was followed in 
order to examine the proteome and phosphoproteome as a whole. A differentiated 
dopaminergic neuronal cell line was chosen, SN4741, for in vitro experiments due to 
the fact they are derived from the ventral midbrain region of embryonic mice (Son et 
al. 1999) -  the same area of the brain where LXR was observed to be important in 
normal development (Sacchetti et al. 2009),
C h a pter  2: M aterials  and  M eth ods
2.1. Cell Culture
Mammalian cell culture was performed aseptically in a cell culture flow hood. All 
single use cell culture apparatus used were sterile (Greinier BioOne). Items 
transferred into the cell culture hood were sprayed with 70% ethanol.
2.1.1. SN4741 Cell Culture
SN4741 murine dopaminergic neuronal cells were cultured on 90mm tissue culture 
dishes (Greinier) in full media (see table 2.1) with incubation at 5% CO2/ 37°C. For 
routine SN4741 cell culture media was removed before the cells were washed once 
with pre-warmed phosphate buffered saline (37°C, PBS, Lonza). Trypsin/EDTA 
(approx. 2.5ml, Invitrogen) was incubated with the cells for 30s at room temperature 
before removal of the majority of the trypsin/EDTA and a further incubation of the 
cells for 4 min at 37°C/5% CO2. Detachment of the cells was observed using an 
inverted light microscope. Detached cells were re-suspended in 10ml of pre-warmed 
(37°C) full media and mixed thoroughly to ensure a homogenous cell suspension. 
Cells were then counted using a Neubauer haemocytometer (Fisher) with lOp.1 of cell 
suspension in each chamber. Cells were seeded to new 90mm tissue culture plates 
containing 15ml of full media. Plates were incubated at 37°C/5% CO2 until ready.
Table 2.1. SN4741 full media. Dulbecco’s modified Eagle medium (DMEM) with L- 
glutamine and glucose, and without sodium pyruvate was modified by adding the 
reagents shown below. Serum free media is as below with the exception that foetal 
bovine serum is omitted.
Component Manufacturer Volume
DMEM + glucose, L-glutamine w/o sodium pyruvate Invitrogen 500ml
Foetal bovine serum Invitrogen 50ml
Penicillin/streptomycin/L-glutamine Sigma 5ml
2 0 % glucose solution Sigma 15ml
2.1.2 Hela Cell Culture
Hela human cervical cancer cells were cultured on 90mm tissue culture dishes 
(Greinier) in full media (see table 2.2) with incubation at 5% CO2/ 37°C. For routine 
Hela cell culture media was removed before the cells were washed once with pre- 
warmed phosphate buffered saline (37°C, PBS, Lonza). Trypsin/EDTA (approx. 
2.5ml, Invitrogen) was incubated with the cells for 30s at room temperature before 
removal of the majority of the trypsin/EDTA and a further incubation of the cells for 
4 min at 37°C/5% CO2. Detachment of the cells was observed using an inverted light 
microscope (Zeiss). Detached cells were resuspended in 10ml of pre-warmed (37°C) 
full media and mixed thoroughly to ensure a homogenous cell suspension. Cells were 
then counted using a haemocytometer with 10pl of cell suspension in each chamber. 
Cells were then seeded to new 90mm tissue culture plates containing 15ml of full 
media. Plates were incubated at 37°C/5% CO2 until ready for use or further culture.
Table 2.2. Hela full media. Dulbecco’s modified Eagle medium (DMEM) with L- 
glutamine and glucose, and without sodium pyruvate was modified by adding the 
reagents shown below. Serum free media is as below with the exception that foetal 
bovine serum is omitted.
Component Manufacturer Volume
DMEM Invitrogen 500ml
Foetal bovine serum Invitrogen 50ml
Penicillin/streptomycin/L-glutamine Sigma 5ml
2.1.3. THP1 Cell Culture
THP1 human monocytes were cultured in 25cm2 tissue culture flasks (Coming) in full 
media (see table 2.3) with incubation at 5% CO2/ 37°C. THP1 cells grow in 
suspension. For routine culture, the cell suspension was transferred to a 15ml 
centrifuge tube and centrifuged at 700g for 5min. The media was discarded without
disruption of the cell pellet before resuspension in 10ml of full media. A 0.5ml aliquot 
of the cell suspension was taken and diluted 20x with full media. This diluted cell 
suspension was then counted using a Scepter automated hand held cell counter 
(Millipore) using 60pm sensor tips. Cells were then transferred to a new 25cm or 
75cm tissue culture flask for a final concentration of 200,000 cells/ml and a final 
volume of 10ml or 25ml respectively. Cells were incubated at 37°C/5% CO2 until 
ready for use or further culture.
Table 2.3. THP1 full media. RPMI-1640 media w/o L-Glutamine was modified by 
adding the reagents shown below. Serum free media is as below with the exception 
that no foetal bovine serum is added.
Component Manufacturer Volume
RPMI-1640 W/O L-Glutamine Invitrogen 500ml
Foetal bovine serum Invitrogen 50ml
Penicillin/streptomycin/L-glutamine Sigma 5 ml
50mM 2-mercaptoethanol in PBS Sigma 500pl
2.1.4. Freezing Cells
For long term storage cells were stored in liquid nitrogen. To freeze cells the protocol 
for culturing was followed with the following exceptions. The cells were resuspended 
after treatment with trypsin (after centrifugation in the case of THP1 cells) in 1ml of 
freezing media (10% dimethyl sulfoxide (DMSO; Sigma) in foetal bovine serum) per 
90mm tissue culture plate (25cm flask for THP1 cells). The cell suspension was 
transferred to a freezing vial and stored at -80°C overnight in a bicell biofreezing 
vessel (Nihon) before transfer to liquid nitrogen.
2.1.5. SILAC Cell Culture
SN4741 murine dopaminergic neuronal cells grown for stable isotope labelling in cell 
culture (SILAC) experiments were cultured as previously described for 5 passages in 
SILAC DMEM (Pierce) supplemented with dialysed foetal bovine serum (Invitrogen), 
Penicillin/Streptomycin/L-glutamine (Sigma), and glucose (Sigma, table 4). SILAC 
DMEM was also supplemented with isotopically labelled arginine and lysine to a 
concentration of 0.398mM and 0.44mM respectively (Tight’, 12C6 Ko,12C6 Ro (Sigma);
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‘medium’, H4  K4 , C6 K6 (Cambridge Isotope Laboratories Inc.); ‘heavy’, C6 R6, 
13C6 15N2 Kg, I3C6 15N4 Rio (Cambridge Isotope Laboratories Inc.)). Amino acid 
solutions were made to a 1000X stock solution of 0.398M and 0.44M for arginine and 
lysine respectively in PBS.
Table 2.4. SN4741 SILAC media. SILAC Dulbecco’s modified Eagle medium 
(DMEM) was modified by adding the reagents shown below. Serum free media is as 
below with the exception that no dialyzed foetal bovine serum is added.
Component Manufacturer Volume
SILAC DMEM Invitrogen 45ml
Dialyzed foetal bovine serum (dFBS), Invitrogen 4.5ml
Penicillin/streptomycin/L-glutamine (PSG) Sigma 0.45ml
2 0% glucose solution Sigma 1.35ml
L-arginine (0.398M) in PBS Sigma/Cambridge Isotope 
Laboratories Inc.
45 pi
L-lysine (0.44M) in PBS Sigma/Cambridge Isotope 
Laboratories Inc.
45 pi
2.2. Cell Culture Treatments.
In all cases appropriate volumes of vehicle (EtOH, 45% hydroxypropyl-p- 
cyclodextrin in 0.9% NaCl or both) were also added to media to act as controls 
between treatments.
2.2.1. Oxvsterol Treatment
2.2.1.1. Adherent cells - SN4741
Oxysterols (24(5),25-epoxycholesterol (Enzo Life Sciences), 7a-hydroxycholesterol 
(Steraloids), 7(3-hydroxycholesterol (Sigma), 19-hydroxycholesterol (Steraloids), 245- 
hydroxycholesterol (Avanti Polar Lipids), 25-hydroxycholesterol (Sigma), 27- 
hydroxy cholesterol (Avanti Polar Lipids)) were prepared at a lOmM concentration in 
45% hydroxypropy 1-p~cyclodextrin/0.9% saline (both Sigma) before dilution to lOpM 
in serum free media. Solutions were vortexed to ensure thorough mixing before sterile 
filtration.
SN4741 cells were washed twice with PBS before addition of 10ml of treatment per 
90mm tissue culture plate and incubated for 24 hours at 37°C/5% CO2.
2.2.1.2. Suspension cells - THP1
O xysterols (2 4 (5 ) ,25 -ep o x y ch o leste ro l, 7a-hydroxy  cholestero l, 7p-
hydroxycholesterol, 245-hydroxycholesterol, 25-hydroxycholesterol) was prepared at 
a lOmM concentration in 45% hydroxypropyl-p-cyclodextrin/0.9% saline (both 
Sigma) before dilution of 11.1 pi in 10ml serum free media. These solutions were 
vortexed to ensure thorough mixing before sterile filtration. 9ml of sterile treatment 
was added per 25cm flask as appropriate.
THP1 cells were transferred to a centrifuge tube before being spun at 700g for 5min. 
The media supernatant was discarded and cells resuspended in 10ml PBS. Cells were 
then spun at 700g for 5min. The PBS was discarded and the wash step repeated. The 
cells were then resuspended in 10ml serum free media. An aliquot of the cell 
suspension was diluted 1:40 with serum free media and then counted using a Scepter 
automated hand held cell counter (Millipore) using 60pm sensor tips. Cells were then 
diluted to 6x l06 with serum free media before addition of 1ml per flask as appropriate
for a final concentration of 6xl05 cells/ml and incubated for 24 hours at 37°C/5% 
C 02.
2.2.2. GW3965 Treatment
2.2.2.1. Adherent cells - SN4741
GW3965 (Sigma) prepared as a lOmM solution in ethanol before dilution to 1_M 
with serum free media. This 1 pM solution was vortexed to ensure thorough mixing 
before sterile filtration. SN4741 cells were then washed twice with PBS before 
addition of 10ml of appropriate treatment was added per 90mm plate and incubated 
for 24 hours at 37°C/5% C 02.
2.2.2.2. Suspension cells - THP1
GW3965 (Sigma) prepared as a lOmM solution in ethanol before dilution of 1.1 pi in 
10ml serum free media. This solution was vortexed to ensure thorough mixing before 
sterile filtration. 9ml of sterile treatment was added per 25cm2 flask as appropriate.
THP1 cells were transferred to a centrifuge tube before being spun at 700g for 5min. 
The media supernatant was discarded and cells resuspended in 10ml PBS. Cells were 
then spun at 700g for 5min. The PBS was discarded and the wash step repeated. The 
cells were then resuspended in 10ml serum free media. An aliquot of the cell 
suspension was diluted 1:40 with serum free media and then counted using a Scepter 
automated hand held cell counter (Millipore) using 60pm sensor tips. Cells were then 
diluted to 6x l06 with serum free media before addition of 1ml per flask as appropriate 
for a final concentration of 6x105 cells/ml and incubated for 24 hours at 37°C/5% 
C 02.
2.3. SN4741 viability assays
SN4741 cells were seeded at 200pl/well, 50,000 cells/ml in 96 well plates and 
incubated for 24 hours at 37°C/5% C 02. After incubation the cells were washed twice 
with PBS before addition of lOOpl of treatment (vehicle, lpM  GW3965, lOpM 
24(5),25-epoxycholesterol or lOpM 245-hydroxycholesterol) in charcoal stripped 
serum containing media and incubated at 37°C for the desired time.
2.3.1. Cell Viability Assay: XTT
Cell viability was measured using XTT Cell proliferation Assay Kit (ATCC) 
following the manufacturer’s instructions. XTT, in the presence of viable cells, is 
reduced to an orange colour formazan derivative that can be read by absorbance on a 
plate reader. Briefly, to 5ml of XTT solution 100 pi of activating solution was added 
and mixed. To lOOpl media (per well on a 96 well plate) 50pl of activated XTT 
reagent was added and incubated for 2-4 hours at 37°C. The plate was then read at 
475nm (test) and 660nm (control) using a POLARstar Omega plate reader (BMG 
Labtech). Wells containing media only (i.e. no cells) served as a blank control and the 
average from these wells were deducted from test wells. The reading measured at 
660nm was then deducted from the 475nm reading.
2.3.2. Cell Viability Assay: CellTiter Blue
Cell viability was then measured using CellTiter Blue assay (Promega) following the 
manufacturer’s instructions. CellTiter blue is a resazurin based assay; in the presence 
of viable cells resazurin can be reduced to resorufin, a fluorescent compound. Briefly, 
to lOOpl media (per well on a 96 well plate) 20pl of CellTiter Blue reagent was added 
and incubated for 2-4 hours at 37°C. If the treatment was in a larger volume then the 
volume of CellTiter Blue reagent was scaled up accordingly. Fluorescence was then 
measured using a POLARstar Omega plate reader (excitation 544nm; emission 
590nm). Wells containing media only (i.e. no cells) served as a blank control and the 
average from these wells were deducted from test wells.
2.4. Cell Lvsis -  Protein Extraction
Cells were washed twice with ice cold PBS before lysis was performed with 200pl ice 
cold lysis buffer (200mM ammonium bicarbonate, 0.1% sodium dodecyl sulphate 
(SDS, Invitrogen), 1% phosphatase inhibitor cocktail 1 (Sigma), 1% phosphatase 
inhibitor cocktail 2 (Sigma)) per plate. A cell scraper (Greinier) was used in order to 
ensure thorough lysis before transfer to a 1.5ml microcentrifuge tube. The lysate was 
then centrifuged at 4°C, 14000 rpm for 30min. The supernatant was transferred to a 
new microcentrifuge tube for further analysis/storage and the cell pellet was 
discarded. Samples intended for Western blotting were supplemented with Complete
protease EDTA-free inhibitors (Roche) at a 1:25 dilution from a stock 25x solution. 
Lysates were stored at -20°C for short term or -80°C for longterm.
2.5. Protein Estimation
Protein lysate concentration was estimated using Bradford assay. A bovine serum 
albumin (BSA) linear standard curve of known concentrations (table 2.5) is measured 
in order to allow regression of the absorbance of the unknown samples. To achieve 
this 60pl of 2mg/ml BSA (Bio-Rad) is mixed with 60pl of water in a 1.5ml 
microcentrifuge tube. This lpg/pl solution is then used to create the standards to test. 
The standards were prepared in duplicate.
Table 2.5. Dilutions of BSA for Bradford Assay standard curve
BSA concentration (pg/pl) Volume lpg/pl BSA (pi) Volume H20  (pi)
1 20 0
0.75 15 5
0.5 10 10
0.25 5 15
0.125 2.5 17.5
0 0 20
The lysate sample of unknown concentration were vortexed and centrifuged briefly 
before 2pi was taken and diluted 1:10 with water. These dilutions were prepared in 
duplicate for each sample. The Bradford dye reagent (Bio-Rad) was then diluted from 
a 5x stock to a lx  working solution with distilled water. 1ml of lx Bradford reagent 
was then added to each standard and sample, vortexed, and are left to incubate for 
5min. Once the incubation is complete 250pl of each standard or sample were 
transferred in duplicate to a 96-well flat-bottomed tissue culture plate (Greinier) and 
the absorbance measured at 595nm on an iMark plate reader (Bio-Rad). A linear 
standard curve was generated and the concentration of the 1:10  diluted sample
solutions were calculated from their observed absorbance. These concentrations are 
then multiplied by 10 to take into account the dilution of the sample and the volume 
required for a given weight of protein (e.g. 2 0 pg) can be calculated.
2.6. Stable Isotope Labelling in Cell Culture (SILAC)
Changes in protein expression were examined using SILAC. SN4741 cells were 
cultured for SILAC as described earlier (section 2.1.5.).
2.6.1. SILAC Treatment(s) - SN4741
Treatments (24(5),25-epoxycholesterol lOpM, GW3965 lpM ) intended for SILAC 
cells were prepared as described previously (sections 2 .2 .1, 2 .2 .2 ) in the appropriate 
serum free SILAC media (Tight’, ‘medium’, ‘heavy’). To ensure that the isotope 
labelling itself led to no change in protein expression the treatments assigned to each 
SILAC state were rotated with each biological replicate (i.e. if  24(5),25- 
epoxycholesterol used to treat Tight’ SILAC cells in first experiment then for next 
experiment 24(5),25-epoxycholesterol used to treat ‘medium’ SILAC cells.
2.6.2. SILAC Sample Reduction and Methvlation
Protein from the different SILAC states were mixed at a 1:1:1 ratio for 2mg total 
protein before incubation for lhour at 60°C with an appropriate volume of 50mM 
tris(2-carboxyethyl)phosphine hydrochloride (TCEP, Sigma) in HPLC grade H20  to 
give a final concentration of 5mM. To block the thio groups of cysteine amino acid 
residue the sample was then incubated for 15min at room temp with an appropriate 
volume of 200mM 5'-Methyl methanethiosulfonate (MMTS, Sigma) in HPLC grade 
isopropanol to give a final concentration of lOmM. Protein was digested using 200pg 
sequencing grade trypsin (Promega) with incubation overnight at 37°C.
2.6.3. Strong Cation Exchange (SCX) Chromatography
Strong cation exchange chromatography was performed on a Dionex Ultimate 3000 
H P L C  system using a Polysulfoethyl A column (200mmx4.6mm, 5pm, 200A, Poly 
L C  Inc; solvent A = 2% H P L C  grade acetonitrile (Fisher), 0.1% formic acid; solvent 
B = 0.6M N H 4 C I ,  2% H P L C  grade acetonitrile, 0.2% formic acid). 50pg of trypsin
digested BSA was used to validate SCX performance before sample was loaded onto 
the column. Samples were diluted lOx using solvent A and then, if required, adjusted 
to pH 2.5-3 with formic acid prior to loading. Loading of the sample was performed 
by injecting 2ml sample at 5 min intervals with a flow rate of 800pl/min of solvent B. 
Once the sample was fully loaded LC gradient was run over 70 min (0-10min 2% B, 
10-15min 2-15% B, 15-45min 15-30% B, 45-55min 30-50% B, 55-60min, 50-100% 
B, 60-65min 100% B, 65-66min 100-2% B, 66-70min 2% B) at a flow rate of 
800pl/min with fraction collection performed from 15 to 70min. Fraction collection 
was more frequent (90s per fraction) at the beginning of the run (see fig. 3.6). A UV 
trace was recorded in order to visualise the fractionation of the loaded peptide 
mixture.
2.6.4. Desalting
Sep-Pak Vac 3cc C18 cartridges (Waters) were activated with 1ml 80% 
acetonitrile/0.1% formic acid before equilibration with 4ml H2O/0.1% formic acid. 
SCX fractions were diluted 1:1 with H2O/0.1% formic acid before loading onto the 
Sep-Pak C l8 cartridge and washed with 4ml H2O/0.1% formic acid. Peptides were 
eluted from C l8 with 1ml 80% acetonitrile/0.1% formic acid before drying overnight 
under vacuum. Dry samples were resuspended in 45 pi H2O/0.1% formic acid.
2.6.5. LTO-Orbitrap Calibration Electrosprav Positive Ion Mode
The LTQ-Orbitrap (Thermo) instrument was calibrated prior to use by using the 
electrospray source in positive ion mode. Calmix (Caffeine, MRFA, Ultramark) was 
injected to the source at 3pl/min and the instrument was tuned on the 524.3m/z peak. 
The tune file was then saved. The ion trap settings calibrated initially were multipole 
RF frequency, main RF frequency, electron multiplier gain. After successful 
calibration of these parameters the following were calibrated:- mass calibration- 
normal scan rate types; mass calibration -  enhanced scan rate types; Mass and 
resolution calibration- normal scan rate type; Isolation wave form; Activation wave 
form. Following successful calibration the following Fourier transform (FT, i.e. 
Orbitrap) parameters were checked only:- transfer multipole RF frequency; storage 
multipole RF frequency; positive ion mode- storage transmission; positive ion mode -  
FT transmission. The only FT parameter calibrated was Positive ion mode -  mass
calibration. The calibration was then backed up. The ion trap was calibrated as least 
once a month and the Orbitrap calibrated at least twice a week. After calibration 
spectra were recorded of the calmix in the FT and ion trap modes to allow an audit 
trail of performance.
2.6.6. LTO-Orbitrap Nanosprav
After calibration the electrospray source was removed and replaced with the 
nanospray source. A solution of [Glu^-fibrinopeptide B human (Glufib, Sigma) 
lOOfmole/pl was required for tuning and was prepared by diluting 1 Ojul of a 
lpmole/pl stock with 90pl 40% acetonitrile/0.1% formic acid. The glufib was injected 
at a rate of 0.3pl/min. The ion trap was then tuned on 785.8m/z. Spectra were then 
acquired in the FT and ion trap (MS and MS2) modes to allow an audit trail of 
performance.
2.6.7. Liquid Chromatography
Liquid chromatography was performed in nanoflow mode on a Dionex Ultimate 3000 
HPLC system using as solvent A1 2% acetonitrile/0.1% formic acid and as solvent B1 
90%acetonitrile/0.1% formic acid. For loading H2O/0 .1% formic acid was used as the 
solvent. Lines were purged prior to LC flow commencing for 300 seconds at a flow 
rate of 2000pl/min. The LC system was attached to the mass spectrometer and the 
flow started; 4%B 0.3pl/min for micropump 1 and 15pl/min for micropump 2
2.6.8. Liquid Chromatography Validation - Bovine Serum Albumin
To evaluate liquid chromatography (LC) performance 5p,l o f 20fmol/pl trypsin 
digested BSA was injected to test the instrument. The method for the LTQ-Orbitrap 
was an nth order double play method analysing the top 6 peaks. The method consisted 
of 2 scan events. Scan event 1 was a MS scan in the FT mode with the following 
settings -  acquire time = 35min, lock mass = 445.1200, scan range =400-2000m/z, 
data format = profile, resolution = 60,000. Scan event 2 was a MS scan performed in 
the ion trap with the following settings -  centroid; activation - type = CID, default 
charge state = 2, isolation width m/z = 3, normalised collision energy = 35, activation 
Q = 0.25, activation time = 30, minimum signal required = 500, top n peaks = 6 ;
enable charge state screening, enable monoisotopic precursor selection, reject charge 
state = 1; enable dynamic exclusion, repeat = 1, repeat duration = 30s, exclusion list 
size = 500, exclusion duration = 30s, exclusion mass width = ±7ppm, early expiration 
enabled. Contact closure was used to synchronise the LC to the mass spectrometer.
2.6.9. LTO-Orbitrap LC-MS/MS
10|xl of each fraction was analysed by LC-MS/MS over a 120min gradient (0-3min 
4% B, 3-99min 4-50% B, 99-100min 50-90% B, 100-105min 90% B, 105min 90-4% 
B, 105-120min 4% B). For the first 3min of the gradient samples were loaded at 
15p,l/min onto a Symmetry300 C l8 trap column (Waters) before separation on a 
RSLCnano column C l8 column (75p,m i.d. x 15cm, Dionex) at a ~250nl/min flow 
rate. Separated peptides were analysed on a LTQ-Orbitrap over 4 mass ranges (400- 
610 m/z, 590-800 m/z, 780-1010 m/z and 990-2000 m/z) using an Orbitrap resolution 
of 60,000 and an nth order double play ‘top 6 ’ method to select ions for CID MS/MS 
(singly charged precursors ions or those with signal <500 not selected).
The method consisted of 2 scan events. Scan event 1 was a MS scan in the FT mode 
with the following settings -  acquire time = 118 min, lock mass = 445.12, scan range 
= 4 mass ranges (400-610 m/z, 590-800 m/z, 780-1010 m/z and 990-2000 m/z), data 
format = profile, resolution = 60,000. Scan event 2 was a MS2 scan performed in the 
ion trap with the following settings -  data format = centroid; activation - type = CID, 
default charge state = 2, isolation width m/z = 3, normalised collision energy = 35, 
activation Q = 0.25, activation time = 30, minimum signal required = 500, top n peaks 
= 6; enable charge state screening, enable monoisotopic precursor selection, reject 
charge state = 1; enable dynamic exclusion, repeat = 1, repeat duration = 20, 
exclusion list size = 500, exclusion duration = 90s, exclusion mass width = ±5ppm, 
early expiration enabled. Contact closure was used to synchronise the LC to the mass 
spectrometer.
2.6.10. Orbitrap Velos LC-MS/MS
Dry samples were resuspended in 100fxl H2O/0.1% formic acid. lOjxl of each fraction 
was analysed by LC-MS/MS over a 120min gradient (solvent A H2O/0.1% formic 
acid, solvent B acetonitrile/0.1% formic acid; 0-5min 2% B, 5-85min 2-40% B, 85-
lOOmin 40-80% B, 100-104min 80% B, 104-105min 80-2% B, 105-120min 2% B). 
For the first 5min of the gradient samples were loaded at lOpl/min onto a trap column 
(CapTrap, Michrom Bioresources) before separation on a Reprosil C l8 column 
(100pm i.d. x 15cm, Nikkyo Technos Co. Ltd) at a ~200nl/min flow rate. Separated 
peptides analysed on a LTQ-Orbitrap Velos over a mass range of 400-2000 m/z using 
an Orbitrap resolution of 60,000 and a data dependent (singly charged precursors ions 
or those with signal <500 not selected) ‘top 20’ method to select ions for CID 
MS/MS.
2.6.11. Analysis of SILAC LC-MS/MS data
SILAC data was analysed using MaxQuant software (v. 1.0.13.8 downloaded from 
www.maxquant.org). Thermo-Finnigan RAW files transformed to msm files using 
MaxQuant Quantify (v. 1.0.13.8) software using appropriate triplet SILAC states. 
Parameters used were Orbitrap; Triplet (Arg6 , Lys4, ArglO, Lys 8 ); maximum of 3 
labelled amino acids; variable modifications = oxidation (M), acetyl (protein n-term), 
methylthio (C); trypsin/P; MS/MS tolerance = 0.5Da; maximum msm file size = 
350Mb; maximum missed cleavages = 2; top ms/ms peaks per lOODa = 6 .
Database used was IPI mouse v3.52 modified using Maxquant SequenceReverser 
(v. 1.0.13.8). Database searching was performed using Mascot (Matrix Science 
v.2.2.2) using parameters generated by MaxQuant. MaxQuant Identify (v. 1.0.13.8) 
was used to generate data tables for further analysis. Parameters used were peptide 
false discovery rate (FDR) = 0.01; site FDR = 0.01; protein FDR = 0.01; apply site 
FDR separately; maximum peptide PEP = 1; minimum peptides = 1; minimum unique 
peptides = 1; minimum peptide length = 6 ; reverse string =REV_; contaminant string 
= CON_; use only unmodified peptides and oxidation (M), acetyl (protein N-term), 
methylthio (C); use razor and unique peptides; discard unmodified counterpart 
peptides; minimum ratio count = 1; use least modified peptides; number of threads = 
1; re-quantify; filter labelled amino acids; low scoring version of identified peptides 
not kept.
MaxQuant generated protein ratios were analysed by following the method reported 
by Graumann et al.. Low and high z-values of >2 (the equivalent of 2 standard
deviations away from the median) were treated as up- or down-regulated. Three 
biological replicates were performed.
2.7. PhosphoSILAC
Changes in protein phosphorylation after treatment with oxysterols were examined 
using a quantitative proteomic approach (SILAC). The following experimental 
protocols were used to examine changes in the phosphoproteome. SN4741 cells were 
cultured for SILAC as described earlier (section 2.1.5.).
2.7.1. PhosphoSILAC Treatments - SN4741
Treatments (24(5'),25-epoxycholesterol 10p,M, 25-hydroxycholesterol 30pM) 
intended for phosphoSILAC studies were prepared as described previously (sections
2.2.1. 2.2.2) in the appropriate serum free SILAC media (Tight5, ‘medium5, ‘heavy5) 
with the following exceptions - oxysterols were dissolved in ethanol; 25- 
hydroxycholesterol was used at a higher concentration and therefore prepared as a 
30mM stock solution before dilution to 30pM; cells incubated with treatment for 6 
hours. To ensure that the isotope labelling itself led to no change in protein expression 
the treatments assigned to each SILAC state were rotated with each biological 
replicate.
2.7.2. phosphoSILAC Sample Reduction and Methvlation
As section 2.6.1.
2.7.3. Strong Cation Exchange Chromatography
As section 2.6.2. With the exception that fraction collection was more frequent 
(1 minute per fraction) at the beginning of the run (see figures. 4.2 and 4.3)
2.7.4. Desalting
As section 2.6.3.
2.7.5. Peptide Methvlation
In one phosphoSILAC experiment methanolic HC1 (hydrochloric acid in methanol; 
Sigma) was used to methylate acidic moieties. 3N methanolic HC1 was diluted to 2N 
with HPLC grade methanol. 900pi 2N methanolic acid was added to each desalted 
dried fraction and incubated for 2 hours at room temperature with sonication every 15 
minutes before being dried under vacuum.
2.7.6. Immobilised Metal Affinity Chromatography (IMAC) Phosphoenrichment
IMAC was performed using Phos-Select Iron Affinity gel (Sigma). 150pl of gel slurry 
(-75 pi gel; suitable for ~150pg phosphopeptide) was added to a Mobicol spin column 
(Mobitec) with a 10pm pore filter inserted (Mobitec).To the slurry 500pi 30% 
acetonitrile, 250mM acetic acid was added, vortexed and centrifuged at 8200g for 1 
minute. The flow through was discarded and this step repeated twice. Dry 
phosphoSILAC samples were resuspended in 500pl 30% acetonitrile, 250mM acetic 
acid, and vortexed. The resuspended samples were added to the spin columns and 
then shaken with end over end rotation (30rpm) for 2 hours at room temperature. The 
columns were then centrifuged at 8200g for 1 minute. The gel was then washed by 
adding 500pl 30% acetonitrile, 250mM acetic acid, vortexing and then centrifuging at 
8200g for 1 minute. A second wash was the performed by adding 500pl HPLC grade 
H20 , vortexing and then centrifuging at 8200g for 1 minute. For elution 500pl 
400mM ammonium hydroxide (pH =11) was added to the gel, vortexed and shaken 
with end over end rotation (30rpm) for 5 minutes at room temperature. This was then 
eluted by centrifuging at 8200g for 1 minute to a 2ml microcentrifuge tube. A second 
elution was performed by adding 200pi 400mM ammonium hydroxide (pH = 11) to 
the gel, vortexed and shaken with end over end rotation (30rpm) for 5 minutes at 
room temperature. This was then eluted by centrifuging at 8200g for 1 minute to a 
1.5ml Protein Lo-Bind microcentrifuge tube (Eppendorf). The two sequential elutions 
were combined in a 1.5ml Protein Lo-Bind microcentrifuge tube and 5pi of formic 
acid was added to neutralise the ammonium hydroxide. The samples were then dried 
overnight under vacuum. Samples were re-suspended in 60pl H2O/0.1% formic acid.
2.7.7. LTO-Orbitrap Calibration Electrosprav Positive Ion Mode
As section 2.6.4.
2 .7 .8 . LTO-Orbitrap Nanosprav
As section 2.6.5.
2 .7 .9 . Liquid Chromatography
As section 2.6.6.
2 .7 .1 0 . Liquid Chromatography Validation - Bovine Serum Albumin
As section 2.6.7.
2 .7 .1 1 . LTO-Orbitrap LC-MS/MS
20pl of each fraction was analysed by LC-MS/MS over a 120min gradient (0-3min 
4% B, 3-99min 4-50% B, 99-100min 50-90% B, 100-105min 90% B, 105min 90-4% 
B, 105-120min 4% B). For the first 3min of the gradient samples were loaded at 
15pl/min onto a Symmetry300 C l8 trap column (Waters) before separation on a 
RSLCnano column C18 column (75 pm i.d. x 15cm, Dionex) at a ~250nl/min flow 
rate. Each phosphopeptide fraction was analysed twice (i.e. two 20pl injections) on a 
LTQ-Orbitrap over 2 mass ranges (400-760 m/z, 740-2000 m/z) using an Orbitrap 
resolution of 60,000 and a data dependent ‘top 6 ’ MS/MS method to select ions for 
CID MS/MS(singly charged precursors ions or those with signal <500 not selected). 
Multistage activation was used for fragmentation (neutral loss within top 10 of 32.70 
m/z, 49.00 m/z, 65.30 m/z, 98.00 m /z).
The method consisted of 7 scan events. Scan event 1 was a MS scan in the FT mode 
with the following settings -  acquire time =118 min, lock mass = 445.12, scan range 
= 2 mass ranges (400-760 m/z, 740-2000 m/z), data format = profile, resolution = 
60,000. Scan event 2 was a MS scan performed in the ion trap with the following 
settings -  data format = centroid; activation - type = CID, default charge state = 2, 
isolation width m/z = 3, normalised collision energy = 35, activation Q = 0.25,
• t hactivation time = 30, current scan event = 500, n most intense ion = 1; enable
multistage activation; product mass range = 400; neutral loss within top 10 of 32.70 
m/z, 49.00 m/z, 65.30 m/z, 98.00 m/z; enable charge state screening, enable 
monoisotopic precursor selection, reject charge state = 1; enable dynamic exclusion, 
repeat = 1, repeat duration = 30, exclusion list size = 500, exclusion duration = 45s, 
exclusion mass width = ±5ppm; early expiration enabled. Subsequent scans (3-7)
threpeated scan 2 with the next 5 most intense ions (i.e. in scan 3 n most intense ion =
aL
2, scan 4 n most intense ion = 3 etc.). Contact closure was used to synchronise the 
LC to the mass spectrometer.
2.7.12. Analysis of phosphoSILAC LC-MS/MS data
SILAC data was analysed using MaxQuant software (v. 1.0.13.8 downloaded from 
www.maxquant.org). Thermo-Finnigan RAW files transformed to msm files using 
Maxquant Quantify (v. 1.0.13.8) software using appropriate triplet SILAC states. 
Settings used were Orbitrap; Triplet (Arg6 , Lys4, ArglO, Lys 8 ); maximum of 3 
labelled amino acids; variable modifications = oxidation (M), acetyl (protein n-term), 
methylthio (C), phosphorylation (ST), phosphorylation (Y); trypsin/P; MS/MS 
tolerance = 0.5Da; maximum msm file size = 350Mb; maximum missed cleavages = 
2; top ms/ms peaks per lOODa = 6 .
Database used was IPI mouse v3.52 modified using Maxquant SequenceReverser 
(v. 1.0.13.8). Database searching was performed using Mascot (Matrix Science 
v.2.2.2) using parameters generated by MaxQuant. MaxQuant Identify (v. 1.0.13.8) 
was used to generate data tables for further analysis. Parameters used were peptide 
FDR = 0.01; site FDR = 0.01; protein FDR = 0.01; apply site FDR separately; 
maximum peptide PEP = 1; minimum peptides = 1; minimum unique peptides = 1; 
minimum peptide length = 6 ; reverse string =REV ; contaminant string = CON_; use 
only unmodified peptides and oxidation (M), acetyl (protein N-term), methylthio (C), 
Phospho (ST), Phospho (Y); use razor and unique peptides; discard unmodified 
counterpart peptides; minimum ratio count = 1; use least modified peptides; number of 
threads = 1; re-quantify; filter labelled amino acids; low scoring version of identified 
peptides not kept.
2.8. Western Blotting
2.8.1. Polyacrylamide Gel Casting
The electrophoresis apparatus was assembled and the resolving gel prepared (see table 
2 .6  for the required reagents for one 10cm2 plate, 1mm spacers, and a final 
concentration of 10% acrylamide). The 10% acrylamide solution was then transferred 
to the glass plates avoiding the generation of air bubbles and 1ml of water-saturated n- 
butanol was gently added to the top of the gel. The resolving gel was then left to 
polymerise.
# y
Table 2.6. Reagents used m preparation of resolving gel. Volumes are for one 10cm 
glass plate, 1mm spacers, and a final concentration of 10% acrylamide. 4X Resolving 
Gel Tris consists of 1.5M Tris HC1 pH 8 .8 , 0.4% SDS adjusted to pH 8.8  with 1M 
HC1. TEMED = N,N,N’,N’-tetramethylethylenediamine (Sigma).
Reagent Volume
Distilled water 3.15ml
Acrylamide 30% solution (Sigma) 2.5ml
4x Resolving Tris solution 1.875ml
10% w/v ammonium persulphate (APS; for electrophoresis >98%; 
Sigma)
75|xl
TEMED (for electrophoresis approx. 99%) (Sigma) 7.5pl
Once the resolving gel had polymerised the water saturated n-butanol was removed 
and the gel washed using distilled water. The stacking gel was then prepared (see 
table 2.7 for the required reagents for one 10cm2 plate, 1mm spacers, and a final 
concentration of 3% acrylamide). The solution was then transferred to the glass plates 
avoiding the generation of air bubbles. The comb was added and the stacking gel was 
then left to polymerise.
Table 2.7. Reagents used in preparation of the stacking gel. Volumes are for one 
10cm2 glass plate, 1mm spacers, and a final concentration of 3% acrylamide. 4X 
Stacking Gel Tris solution consists of 0.5M Tris HC1 pH 6 .8 , 0.4% SDS adjusted to 
pH 6.8 with 1M HC1. TEMED = N,N,N’,N’ -  tetramethylethylenediamine.
Reagent Volume
MilliQ distilled water 2 .1ml
Acrylamide 30% solution (Sigma) 0.325ml
4x Stacking gel Tris solution 0 .8ml
10% w/v ammonium persulphate (APS; for electrophoresis >98%; 
Sigma)
34pl
TEMED (for electrophoresis approx. 99%) (Sigma) 3.4pl
2.8.2. Polyacrylamide Gel Electrophoresis Sample Loading
From the concentration given by the protein estimation the volume required for 20pg 
of protein was calculated. The sample was combined with 4x sample buffer 
(Invitrogen), lOOmM dithiothreitol (DTT, Sigma), and distilled H20  in a 
microcentrifuge tube. For a 20pl reaction - x pi sample, 5 pi 4x sample buffer, 2pi 
lOOmM DTT, H20  to 20pl are combined, vortexed to ensure thorough mixing and 
then spun briefly in a microcentrifuge. The samples were then heated to 70°C for 5 
min, vortexed and then spun briefly in a microcentrifuge to collect the sample at the 
bottom of the tube prior to loading.
The wells were washed before loading by gently pipetting 1ml of running buffer (IX 
Tris-glycine tank buffer -  SDS = 200ml 4x tris-glycine tank buffer-SDS (36g Tris 
base, 172.8g glycine, distilled H20  to 31), 8ml 10% SDS, distilled H20  to 800ml) into 
the wells removing any loose polyacrylamide. The inner chamber was then filled with 
running buffer and 2 0 pl sample added to the appropriate lanes using gel-loading tips.
7pi of Novex sharp stain molecular weight ladder (Invitrogen) was added to one lane. 
Any surplus lanes were loaded with lOpl of 4x sample buffer (Invitrogen). Once 
loading is complete the outer tank is filled with running buffer and electrophoresis is 
performed at 125V for 130min at room temperature noting the current initially and on 
completion.
2.8.3. Protein Transfer to Nitrocellulose Membrane
Protein transfer was performed using XCell II™ Blot Module (Invitrogen) Western 
blotting apparatus using XCell SureLock Mini-Cell (Invitrogen). Fibre blotting pads 
and the nitrocellulose membrane were soaked in transfer buffer (1.456g Tris base, 
7.2g glycine, 200ml methanol, distilled water to 1000ml) prior to use. Filter paper was 
soaked briefly in transfer buffer prior to placing in the cassette. Care was taken 
throughout to ensure that there are no air bubbles between the components that could 
affect protein transfer. Working from the cathode core of the blotting module the 
transfer cassette was assembled by placing two fibre blotting pads, filter paper and the 
gel were assembled in order. A small amount of transfer buffer was then used to wet 
the gel before addition of the nitrocellulose membrane. A second piece of filter paper 
was then added on top of the nitrocellulose and finally, two fibre blotting pads were 
added. The anode core is then placed onto the assembly ensuring that the components 
are held firmly and with a complete connection. The whole assembly is then slid into 
the transfer tank and braced into position. Transfer buffer is added to the transfer 
chamber until the gel/membrane assembly is covered. The outer chamber is filled 
with H20 . Electrophoresis is then performed at 16V overnight at room temperature 
noting the current (in mA) initially and on completion.
2.8.4. Blocking Non-Specific Binding
After protein transfer the nitrocellulose membrane is removed from the transfer 
cassette and washed with H20  to remove any polyacrylamide residue. The membrane 
is stained with lx  Ponceau S solution (1% Ponceau S (Sigma) in 5% acetic acid) to 
ensure successful transfer has occurred. The membrane was washed with PBS-Tween 
and then blocked to prevent non-specific binding by using 2 % blocking reagent 
(Amersham) in PBS-Tween. at room temperature for lhr with gentle shaking.
2.8.5. Primary Antibody Incubation
Primary antibodies were incubated with the membrane overnight at 4°C or at room 
temperature for 3 hours with gentle shaking (Caveolin-1, 1:5000, Cell Signalling 
Technologies; ATP binding cassette A1 (ABCA1), 1:500, Novus; Actin, 1:200, 
Sigma; phosphoethanolamine cytidylyltransferase (PCyt2), 0.5pg/ml, Abeam; 
Macrophage colony stimulating factor, 0.2pg/ml, Abeam; p44/p42 MAP kinase, 
1:1000, Cell Signalling Technologies; phospho-p44/p42 MAP kinase 
(Thr202/Tyr204), 1:1000, Cell Signalling Technologies). Sodium azide was added to 
the primary antibody solution to give a final w/v concentration of 0.05% to prevent 
bacterial growth and allow the reuse of the antibody solution after storage at 4°C.
2.8.6. Secondary Antibody Incubation
After primary antibody incubation the membrane was then washed three times for 10 
minutes each with 2% Amersham blocking reagent in PBS-Tween before incubation 
with appropriate horseradish peroxidase (HRP)-linked secondary antibody (donkey 
anti-rabbit HRP-linked (Amersham) unless otherwise noted); Caveolin-1, 1:5000; 
ABCA1, 1:10,000; Actin, 1:50,000; phosphoethanolamine cytidylyltransferase 
(PCyt2), 1:20,000; Macrophage colony stimulating factor, 1:2000 donkey anti-goat 
HRP-linked (Santa Cruz) p44/p42 MAP kinase 1:2000; phospho-p44/p42 MAP 
kinase (Thr202/Tyr204) 1:1000) for 1 hour at room temperature. The nitrocellulose 
was then washed three times for 15min with PBS Tween at room temperature with 
gentle shaking. Before detection the nitrocellulose membrane was then washed with 
20ml PBS for at least 5min.
2.8.7. Detection
Enhanced chemiluminescence (ECL) is used for detection using ECL Advance kit 
(GE Amersham). An equal volume of reagent 1 and 2 are mixed (typically 1000pi of 
each for 1 blot) and are then added to the nitrocellulose. The detection reagent is 
incubated with the nitrocellulose for 5min at room temp before visualisation using a 
Biorad ChemiDoc XRS and Quantity One software (Bio-Rad). Tracker tape 
(Amersham) is used to visualise the position of the Novex sharp stain molecular 
weight ladder on the Chemidoc system.
2.9. Fixed Cell Confocal Microscopy
Glass cover slips (Fisher) were placed in each well of a 24 well tissue culture plate 
(Greinier) before incubation for 10 min with 250pl poly-L-lysine (0.01% BioReagent, 
mol wt 150,000 -  300,000 sterile filtered suitable for cell culture; Sigma). The poly- 
L-lysine was then removed and the cover slips left to dry for 20min at room 
temperature. SN4741 cells were trypsinised and counted, as previously described, 
before being seeded at a density of 50,000 cells per well in 1ml full media and 
incubated for 24 hours prior to treatment.
Oxysterols (24(5),25-epoxycholesterol (Enzo Life Sciences), 7a-hydroxycholesterol 
(Steraloids), 19-hydroxycholesterol (Steraloids), 24(5)-hydroxycholesterol (Avanti 
Polar Lipids), 25-hydroxycholesterol (Sigma), 27-hydroxycholesterol (Avanti Polar 
Lipids)) were prepared at a lOmM concentration in 45% hydroxypropyl- - 
cyclodextrin/0.9% saline (both Sigma) before dilution to lOpM in serum free media. 
GW3965 (Sigma) prepared as a lOmM solution in ethanol before dilution to lpM  
with serum free media. These solutions were vortexed to ensure thorough mixing 
before sterile filtration.
SN47471 cells were then treated with vehicle, 0.5ml GW3965 lpM  (Sigma), or 0.5ml 
lO pM  oxysterol (24(5),25-epoxycholesterol, 7a-hydroxycholesterol, 19- 
hydroxycholesterol, 24(5)-hydroxycholesterol, 25-hydroxycholesterol or 27- 
hydroxycholesterol) in the presence or absence of 250pM cholesterol (Sigma) for 24 
hours at 37°C/5% C02. After incubation cells were washed twice with 1ml PBS prior 
to fixing by incubating with 250pl 4% paraformaldehyde (Sigma) in PBS for 15 
minutes.
Fixed cells were washed three times with 1ml of Hank’s Balanced Salt Solution 
(HBSS; Invitrogen) and then stained with 250pl of lpg/ml Alexa-555 labelled wheat 
germ agglutinin (Invitrogen) per well for 5min at room temperature. After incubation 
the cells were washed twice for 5minutes with 1ml HBSS then permeabilised by 
incubating with 250p,l PBS Triton-XlOO 0.2% (Sigma) in for lOmin at room 
temperature. Non-specific binding was blocked with incubation for 30min with 250pl 
blocking buffer (0.5% essentially fat free BSA (Sigma) in PBS Triton-XlOO 0.1%)
per well before treatment with anti-caveolin-1 antibody ( 1:200  in blocking buffer, 
Cell Signalling Technologies) for lhour at room temperature. The primary antibody 
was removed and the cells washed three times with 1ml PBS Triton-XlOO 0.1% for 
5min. Alexa 488 linked anti-Rabbit secondary antibody (1:2000 in blocking buffer; 
Invitrogen) was incubated with the cells for 1 hour at room temperature before 
washing three times with 1ml PBS Triton-XlOO 0.1%. The cover slips were then 
mounted onto glass slides (Fisher) using Mowiol 4-88 mounting medium and left to 
dry overnight. Slides were imaged on a Zeiss LSM 510 Meta microscope.
2.10. Real Time Reverse Transcription PCR
2.10.1. RNA Extraction -  Adherent cells
RNA extraction was performed using RNeasy Mini Kit (Qiagen) following the 
manufacturer’s instructions. Treatments were removed from cells and stored for 
future ELISA assays. Cells (on 90mm tissues culture dishes (Greinier)) were washed 
twice with ~10ml ice cold PBS (Lonza) before addition of 600pl RLT lysis buffer 
(Qiagen). Cells were scraped using a cell scraper (Greinier) before transfer of the 
lysate to a certified RNase/DNase free 2ml microcentrifuge tube (Eppendorf). The 
lysate was then homogenised using a 1ml syringe with a BD Microfine 23G, 1_” 
needle by drawing the lysate up then expelling 10 times.
After homogenisation 600pi of 70% ethanol was added to the lysate and mixed by 
pipetting (no centrifugation). The lysate was then loaded to a RNeasy spin column 
(Qiagen) placed in a 2ml collection tube. 600pl of sample was loaded and then spun 
in a microcentrifuge for 15s at 13,000 rpm. The flow through was discarded and the 
loading was repeated until all lysate was transferred to column. 700pl of RW1 buffer 
was added to the column and spun for 15s at 13,000 rpm to wash the sample and the 
flow through was discarded. A second wash was performed; 500pl of RPE buffer was 
added to the column, spun for 15s at 13,000 rpm and the flow through was discarded. 
For the final wash 500pl of RPE buffer was added to the column, spun for 2min at 
13,000 rpm and the flow through was discarded. The column was transferred to a 
clean 2 ml collection tube and then spun again for lmin at 13,000 rpm to ensure 
removal of all wash buffers.
RNA was eluted from the column with 40pl RNase free water to a clean 1.5ml 
centrifuge tube. The water was added directly to the membrane of the column and 
then spun for lmin at 13,000 rpm. To ensure a good yield of RNA the flow through 
was reloaded onto the column and then spun again for lmin at 13,000 rpm. RNA was 
stored at -80°C.
2.10.2. RNA Extraction -  Suspension Cells
RNA extraction was performed using RNeasy Mini Kit (Qiagen) following the 
manufacturer’s instructions. The cell suspension was transferred from the tissue
culture flask to 15ml centrifuge tube and then centrifuged at 700g for 5min. The 
supernatant, i.e. the treatment media, was stored for future ELISA assays at -80°C. 
The cell pellet was washed by resuspending cells in 10ml ice cold PBS (Lonza) before 
centrifugation for 5min at 700g. This was repeated once before addition of 600pl 
RLT lysis buffer (Qiagen). The lysate was then transferred to a certified 
RNase/DNase free 2ml microcentrifuge tube (Eppendorf) and homogenised using a 
lml syringe (BD) with a BD Microfine 23 G, 1_” needle (BD) by drawing the lysate 
up then expelling 10 times.
The remainder of the extraction follows same method as adherent cells (2.9.1).
2.10.3. RNA Concentration Estimation
RNA concentration was estimated using a Nanodrop ND-1000 spectrophotometer 
(Labtech). The capillary was cleaned before use using water. The option to measure 
nucleic acid was chosen and lp l of water was loaded and used to initialise the 
instrument. The setting was switched to ‘RNA’ and lp l of water was loaded and 
measured as a blank. 1 pi of sample(s) were then loaded sequentially and measured. 
The RNA concentration was recorded (ng/pl) and the 260nm/280nm and 260/230 
ratios that indicates the quality of the RNA.
2.10.4. Reverse transcription
Reverse transcription was performed using a Quantitect Reverse Transcription kit 
(Qiagen) following the manufacturer’s instructions. All components were kept on ice 
until used. Before the reverse transcription a step to remove genomic DNA was 
undertaken; for each sample 900ng of RNA was taken and diluted to 12pl with RNase 
free water and 2pl of genomic DNA wipeout buffer added (Qiagen) for a total volume 
of 14pl. This mixture was mixed and centrifuged briefly before incubation at 42°C for 
2min (iCycler, Bio-Rad). A master mix for the reverse transcription reaction was then 
prepared consisting of 4pl 5x Quantiscript RT buffer, lp l Quantiscript reverse 
transcriptase and 1 pi of primers (all Qiagen) per sample. After incubation the sample 
was centrifuged briefly 6 pi of reverse transcription master mix was added per sample 
to give a final volume of 20pl. The samples were mixed, centrifuged briefly and then 
incubated at 42°C for 15min followed by 95°C for 3min (iCycler, Bio-Rad) to
generate cDNA. No reverse transcriptase control reactions were performed as above 
but with the Quantitect reverse transcriptase enzyme in the reaction mixture replaced 
with water.
2.10.5. Primers
Each primer set (table 2.8., Sigma (unless otherwise noted)) was evaluated to ensure 
that they amplified the target while avoiding the generation of primer dimers and that 
a linear standard curve was generated across a broad range by dilution with water 
(cDNA neat, 1:10 , 1:100, 1:1000). Primers were reconstituted from lyophilised 
powder to a lOOpM concentration with H20 .
Table 2.8 .Primers used for reverse transcription qPCR. The primers for LXRa and 
LXR|3 were obtained from the Nuclear Receptor Signalling Atlas website 
(www.nursa.org/10.1621/datasets.02001 - accessed 13-12-2010). Primers for StarD4 
se lf  designed using NCBI P rim er-B last prim er designing tool 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast). The primers for FADS2 were taken 
f r o m  t h e  R T p r i m e r D B  w e b s i t e
(http://medgen.ugent.be/rtprimerdb/assay_report.php?assay_id=8122 -  accessed 17-1- 
2011). Primers for CERT were obtained from Qiagen. No sequence information was 
provided. * Mismatch in primer sequence in referenced manuscript. Possible 
typographical error therefore primer sequence used 100% complementary.
Primer Name Species Sequence (5’-3’) Reference
LXRa forward Mouse AGG AGT GTC GAC TTC GCA AA See table legend
LXRa reverse Mouse CTC TTC TTG CCG TTC AGT TT See table legend
LXRP forward Mouse AAG CAG GTG CCA GGG TTC T See table legend
LXRp reverse Mouse TGC ATT CTG TCT CGT GGT TGT See table legend
SREBPlc forward Mouse ATC GGC GCG GAA GCT GTC GGG 
GTA GCG TC
Shimomura et al. 
1997
SREBPlc reverse Mouse ACT GTC TTG GTT GTT GAT GAG CTG 
GAG CAT
Shimomura et al. 
1997
Cav-1 forward Mouse AAC GAC GAC GTG GTC AAG A Bailey & Liu 2008
Cav-1 reverse Mouse CAC AGT GAA GGT GGT GAA GC Bailey & Liu 2008
LDLR forward Mouse CAT GCA GCA GGA ACG AGT TC* Masson et al. 2004
LDLR reverse Mouse GGA GTC AGG AAT GCA TCG GC Masson et al. 2004
StarD4 forward Mouse ATG CGT TAC ACC ACT GCT GGG C See table legend
StarD4 reverse Mouse TCT GGT CTC GTC TCA CTC CAC TCA See table legend
MCSF forward Mouse GAA CAC TGT AGC CAC ATG ATT GG Wang et al. 2009
MCSF reverse Mouse TGG CAT GAA GTC TCC ATT TGA C Wang et al. 2009
Col4a3bp forward Mouse Unknown See table legend
Col4a3bp reverse Mouse Unknown See table legend
P-actin forward Mouse GGT CGT ACC ACA GGC ATT GTG 
ATG
Shimomura et al. 
1997
P-actin reverse Mouse GGA GAG CAT AGC CCT CGT AGA 
TGG
Shimomura et al. 
1997
IDOL forward Mouse AGG AGA TCA ACT CCA CCT TCT G Zelcer et al. 2009
IDOL reverse Mouse ATC TGC AGA CCG GAC AGG Zelcer et al. 2009
MCSF forward Human TGC AGC GGC TGA TTG ACA Razzaque et al. 2002
MCSF reverse Human TTC AAC TGT TCC TGG TCT ACA AAC 
TC
Razzaque et al. 2002
P-actin forward Human GAT GGC CAC GGC TGC TTC Cronin et al. 2011
P-actin reverse Human TGC CTC AGG GCA GCG GAA Cronin et al. 2011
2.10.6. Real Time Polymerase Chain Reaction
Primers (table 2.8) were diluted from a lOOpM stock solution to lOpM with water, 
vortexed and centrifuged. A master mix was then prepared for each gene. For each 
well 12.5pl of QuantiFast SYBR green PCR master mix 2x (Qiagen), 2.5pi forward 
primer (i.e. lpM  final concentration), 2.5pi reverse primer (i.e. lpM  final 
concentration), 5.5pi RNase free water was required and therefore these values were 
multiplied by the number of wells to be used (plus an overage). The master mix was 
then mixed and centrifuged briefly.
cDNA was taken from each sample and pooled in order to be used to generate a 
standard curve. The pooled cDNA used for the standard curve was diluted 1:10, 1:100 
and 1:1000 using serial dilutions. Samples to be analysed for gene expression (and 
noRT controls) were diluted 1:4 with water so that they fell within the limits of the 
standard curve. At each stage the cDNA was mixed and centrifuged to give a 
homogenous mixture. Each sample was analysed in triplicate. The master mix was 
then transferred into the PCR plate with 23 pi per well as appropriate. 2pl of cDNA 
(or water for no template controls (NTC)) was added to each well as appropriate (see 
figure 2.1 for example of plate set up).
1 2 3 4 5 6 7 8 9 10 11 12
A 1:1000, Pooled, 
Target
1:4, sample A, 
Target
1:4, sample E, 
Target
1:4, sample D, 
Target noRT
B 1:100, Pooled, 
Target
1:4, sample A, 
P-actin
1:4, sample E, 
P-actin
1:4, sample D, 
P-actin noRT
C 1:10, Pooled, 
Target
1:4, sample B, 
Target
1:4, sample A, 
Target noRT
1:4, sample E, 
Target, noRT
D Undiluted, Pooled, 
Target
1:4, sample B, 
P-actin
1:4, sample A, 
P-actin noRt
1:4, sample E, 
P-actin, noRT
E 1:1000, Pooled, 
P-actin
1:4, sample C, 
Target
1:4, sample B, 
Target noRt
F 1:100, Pooled, P- 
actin
1:4, sample C, 
P-actin
1:4, sample B, 
P-actin noRT
G 1:10, Pooled, P- 
actin
1:4, sample D, 
Target
1:4, sample C, 
Target noRT
NTC target
H Undiluted, Pooled, 
P-actin
1:4, sample D, 
p-actin
1:4, sample C, 
P-actin noRT
NTC P-actin
Figure 2.1. Typical plate set up for real time RT-PCR. All samples were run in 
triplicate. A standard curve derived form pooled cDNA from the samples was 
generated using 4 serial dilutions. Samples for analysis of expression were diluted 1:4 
with DNase/RNase free water. NoRt = No reverse transcriptase added to sample in the 
RT step. NTC = No template control
The plate was then centrifuged briefly to ensure that samples were collected at the 
bottom of the well and then checked to ensure that no air bubbles were present. The 
plate was then transferred to an iQ5 real time PCR detection system (Bio-Rad) to be 
analysed using the conditions shown in table 2.9.
Table 2.9. Conditions for real time PCR
Cycle Cycle
Repeated
Temperature (°C) Dwell Time (s) Additional
information
1 lx 95°C 300
2.1 45x 95°C 10
2.2 60°C 30 Real time analysis
3 lx 95°C 60
4 lx 55°C 60
5 81x Start at 55°C with a 0.5°C 
increase per cycle
10 Melt curve analysis
2.10.7. Data Analysis
The standard curve derived from the pooled cDNA was used to monitor primer 
efficiency. Primer efficiency expressed as a percentage was generated using the Bio- 
Rad iQ5 software. Primer efficiencies summarised in table 2.10.
Table 2.10. Summary of RT-PCR primer efficiencies. Efficiency shown as mean with 
standard deviation.
Gene Species Primer efficiency
LXRa Mouse 93.5±5.2
LXRp Mouse 109.7±6.8
SREBPlc Mouse 93.1 ±4.0
Cav-1 Mouse 88.2±0.64
LDLR Mouse 100 .8±8.2
StarD4 Mouse 100.0±2.3
MCSF Mouse 98.4±7.6
Col4a3bp Mouse 102.9±2.0
IDOL Mouse 94.1 ±1.3
p-actin Mouse 97.4±6.7
MCSF Human 102.8±4.3
p-actin Human 102.0±1.3
Analysis of the data was performed using AACt method. The cycle threshold value 
(Ct) of the gene of the interest was subtracted from the Ct value of the reference gene 
(p-actin) from the same sample giving the ACt value.
A C t  — Ct(sample) — Ct^reference)
This was repeated for each experimental condition. The ACt values for the treatment 
were then subtracted from the control value giving a AACt value.
A A C t  — ACt(treatment) — ACt(control)
The AACt value was then converted into fold induction; as the amount of product 
amplified theoretically doubles with each PCR cycle this can be written as:-
Fold induction c.f. control = 2'MCt
2.11. Mouse MCSF Enzyme Linked Immunosorbant Assay
A mouse MCSF Quantikine kit assay (R&D Systems) was performed following the 
manufacturer’s instructions. Briefly, a mouse MCSF standard was reconstituted with 
2ml of calibrator diluent RD5-16 (R&D Systems) giving a stock solution of 
2000pg/ml. This solution was incubated at room temperature for 5min with gentle 
shaking before being used to create samples for a standard curve by using serial 
dilution. Calibrator diluent RD5-16 was used as a diluent. The concentrations for the 
standard curve were 2000pg/ml (stock solution), lOOOpg/ml, 500pg/ml, 250pg/ml, 
125pg/ml, 62.5pg/ml, 31.25pg/ml, Opg/ml (Calibrator diluent RD5-16). The kit’s 
supplied mouse MCSF internal control was reconstituted in 1ml ddFLO. This internal 
control should yield a reading of 175-29 lpg/ml. For unknown concentration samples, 
0.5ml of cell culture supernatant was vortexed then centrifuged at 14,000 rpm for 
2min at 4°C.
50pl of assay diluent RD1N (R&D systems) was added to each well of the MCSF 
antibody pre-coated microplate supplied with the kit. 50(xl of standard, control or 
sample was then added to each well as appropriate. To ensure thorough mixing the 
plate was tapped gently for one minute. The plate was then covered with an adhesive 
strip and incubated for 2 hours at room temperature. After incubation each well was 
aspirated and washed (~400pl) with lx  wash buffer (supplied as a 25x concentrated 
solution, R&D Systems). This wash step was repeated four times (i.e. 5 washes in 
total). The plate was then gently blotted against a clean paper towel to ensure removal 
of remaining wash buffer. 100pi of mouse MCSF conjugate (R&D Systems) was then 
added to each well and the plate covered with a new adhesive strip. The plate was 
then incubated at room temperature for 2 hours. After incubation the wells were 
washed as described previously.
Substrate solution was prepared by mixing equal volumes of colour reagent A and B 
(both R&D systems). 100pi of substrate solution was then added to each well and 
incubated for 30 min at room temperature protecting the plate from light. lOOpl of 
stop solution was added to each well. The plate was gently tapped in order to ensure 
thorough mixing and the development of a uniform colour. The optical density of 
each well was then read on an iMark microplate reader (Bio-Rad) set at a wavelength
of 450nm. The plate was then read at 595nm to correct for optical imperfections of the 
plate.
2.12. Human MCSF Enzyme Linked Immunosorbant Assay
A human MCSF Quantikine kit assay (R&D Systems) was performed following the 
manufacturer’s instructions. Precautionary measures were taken to prevent 
contamination from MCSF found in human saliva -  a facemask and gloves were 
worn. Briefly, a human MCSF standard was reconstituted with 1ml of calibrator 
diluent RD5-18 (R&D Systems) giving a stock solution of 50,000pg/ml. This solution 
was incubated at room temperature for 15min with gentle shaking before being used 
to create samples for a standard curve by using serial dilution. Calibrator diluent RD5- 
18 was used as a diluent. The concentrations for the standard curve were 5000pg/ml 
(stock solution), 2500pg/ml, 1250pg/ml, 625pg/ml, 312.5pg/ml, 156.25pg/ml, 
78.125pg/ml, Opg/ml (Calibrator diluent RD5-18). For unknown concentration 
samples, 0.5ml of cell culture supernatant was vortexed then centrifuged at 14,000 
rpm for 2min at 4°C.
lOOpl of assay diluent RD1-56 (R&D systems) was added to each well of the MCSF 
antibody pre-coated microplate supplied with the kit. lOOp.1 of standard or sample was 
then added to each well as appropriate. To ensure thorough mixing the plate was 
tapped gently for one minute. The plate was then covered with an adhesive strip and 
incubated for 2 hours at room temperature. After incubation each well was aspirated 
and washed (-400pi) with lx  wash buffer (supplied as a 25x concentrated solution, 
R&D Systems). This wash step was repeated three times (i.e. 4 washes in total). The 
plate was then gently blotted against a clean paper towel to ensure removal of 
remaining wash buffer. 200pi of human MCSF conjugate (R&D Systems) was then 
added to each well and the plate covered with a new adhesive strip. The plate was 
then incubated at room temperature for 2 hours. After incubation the wells were 
washed as described previously.
Substrate solution was prepared by mixing equal volumes of colour reagent A and B 
(both R&D systems). 200pl of substrate solution was then added to each well and 
incubated for 30 min at room temperature protecting the plate from light. 50pl of stop 
solution was added to each well. The plate was gently tapped in order to ensure
thorough mixing and the development of a uniform colour. The optical density of 
each well was then read on an iMark microplate reader (Bio-Rad) set at a wavelength 
of 450nm. The plate was then read at 595nm to correct for optical imperfections of the 
plate.
2.13 Statistical Analysis
Statistical analysis was performed on the data using Microsoft Excel 2007 software 
using Student’s two-tailed t-test. p values below 0.05 were considered a significant 
change.
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3.1. Introduction
24(5),25-epoxycholesterol is an unusual oxysterol. It is unusual as it is not an 
oxygenated metabolite of cholesterol but a product of a shunt in the mevalonate 
biosynthetic pathway. An epoxide group is introduced to squalene by squalene 
epoxidase during synthesis of cholesterol. The product of this reaction, 2,3- 
oxidosqualene (AKA 2,3-monoepoxysqualene), is then processed by a number of 
downstream enzymes to synthesise cholesterol. However, 2,3-oxidosqualene can be 
processed further in order to create 2,3:22,23-dioxidosqualene. This can then be 
cyclised by lanosterol synthase and further processed along the same enzymatic 
pathway in order to create 24(5),25-epoxycholesterol. 24(5),25-epoxycholesterol is a 
potent endogenous ligand of Insig and LXR (see sections 1.1.5.1. and 1.1.5.2. 
respectively). Therefore, an increase in the concentration o f 24(5),25- 
epoxycholesterol results in up-regulation of genes with a LXR response element in 
their promoter and down-regulation of SREBP2 regulated genes.
24(5),25-epoxycholesterol appears to have a role in the development of the embryonic 
brain as 24(5),25-epoxycholesterol is present at relatively high levels in comparison to 
other oxysterols in the cortex and spinal cord of embryonic mice (Wang et al. 2009). 
The major oxysterol in adult mouse brain is 24(5)-hydroxycholesterol with a 
concentration of 2.53±0.05ng/pg 24(5)-hydroxycholesterol to cholesterol (Lutjohann 
et al. 2002). In the embryonic murine brain 24(5)-hydroxycholesterol is not the most 
abundant; at embryonic day 11 there was an observed level of 24(5)- 
hydroxycholesterol of 0.026pg/g wet weight in the cerebral cortex and 0.013pg/g wet 
weight in the spinal cord. In comparison, the concentration of 24(5),25- 
epoxycholesterol was 0.165pg/g wet weight in the cerebral cortex and 0.091 pg/g wet 
weight in the spinal cord. It is unclear the role 24(5),25-epoxycholesterol, the most 
abundant oxysterol in foetal brain, plays in murine embryonic neural development 
though as LXR is present in embryonic brain (Annicotte et al. 2004) and that 
24(5),25-epoxycholesterol is a potent ligand for this nuclear receptor (Janowski et al. 
1999) it might play a role in neural development. Indeed, there is evidence to suggest
that the presence of LXR is essential to ventral midbrain neurogenesis (Sacchetti et al 
2009)
The mechanism by which LXR induces neurogenesis is unclear. Therefore, in order to 
investigate the role of 24(5),25-epoxycholesterol and LXR in neurogenesis a 
quantitative proteomic approach was employed. The proteomic technique stable 
isotope labelling in cell culture (SILAC) was used in order to identify changes in the 
proteome after treatment with 24(5),25-epoxycholesterol and GW3965. To this end, 
as a model for embryonic mouse brain, the murine neuronal cell line SN4741 was 
used. SN4741 cells are dopaminergic neurons derived from the substantia nigra of 
embryonic mouse (Son et a l 1999). The substantia nigra is located in the ventral 
midbrain. Therefore, SN4741 cells are a relevant model to the increased neurogenesis 
seen after LXR activation in vivo. Treatment of SILAC labelled SN4741 cells with 
either 24(5),25-epoxycholesterol or the synthetic LXR ligand lpM  GW3965 (which 
only activates LXR and has no effect on SREBP2) allows differentiation of effects as 
LXR dependent or independent. Thus, the aim of this work is to identify protein 
expression changes in SN4741 cells after 24(5),25-epoxy cholesterol treatment and 
identify if  these effects are LXR dependent or independent.
3.2. Results
3.2.1. Analysis of 24(5h25-epoxvcholesterol Treatment on SN4741 Growth
To determine if 24(5),25-epoxycholesterol is toxic to SN4741 cells grown in culture 
cells were incubated with either lOpM 24(5),25-epoxycholesterol or with vehicle and 
the total cell number counted. In order to ensure that the cells survived in culture for a 
prolonged period but without introducing lipid small molecules that could affect the 
activity of 24(5),25-epoxycholesterol the media used contained charcoal stripped 
foetal bovine serum (FBS). After 76 hours there was no difference in cell number 
between 24(5),25-epoxychoelsterol and control (fig 3.1). However, incubation with 
charcoal stripped serum reduced the rate of growth and the vehicle and 24(5),25- 
epoxycholesterol treated cells in this media grew slower than control cells incubated 
in full media. Five days after seeding SN4741 cells at 2.5x104cells/well in 24 well 
plates in full media they reached confluency and the plateau of the stationary phase of 
the curve. However, the 24(5),25-epoxycholesterol and control cells in stripped serum 
media did not reach confluency. However, as there were no statistical differences 
between control and 24(5),25-epoxycholesterol treatment (p>0.05 Student’s t-test) it 
appears that 24(5),25-epoxy cholesterol is non-toxic to SN4741 cells when measured 
by total cell number.
O J
4 0 0 0 0 0
3 5 0 0 0 0
3 0 0 0 0 0
j  2 5 0 0 0 0  c| 200000  
?  1 5 00 00  
1 0 00 0 0  
5 0 0 0 0  
0
rn
10
n
i
±
PI
i
20 30 4 0  50
Time (hours)
60
r  i.
¥
mj j i_
70 80
♦ Full Media
■  Control
A 24(S),25- 
epoxycholesterol
Figure 3.1. Effect of 24(5),25-epoxycholesterol on the rate of growth of SN4741 cells. 
24 well plates were seeded at 2.5x104 cells/well in media containg charcoal stripped 
media with either lOpM 24(5),25-epoxy cholesterol or vehicle as control. Full media 
media was used to determine the effect of the charcoal stripped serum media on rate 
of cell growth. No difference in cell growth was observed with 24(5),25- 
epoxycholsterol and vehicle in charcoal stripped serum media. Cells grown in full 
media had a higher rate of cell growth compared with those grown in charcoal 
stripped serum media.
3.2.2. Analysis of 24(53.25-epoxvcholesteroi Treatment on SN4741 Viability
In addition the toxicity of 24(5),25-epoxycholesterol was measured using two other 
techniques -  XTT (sodium 2,3,-bis(2-m ethoxy-4-nitro-5-sulfophenyl)-5- 
[(phenylamino)-carbonyl]-2H-tetrazolium inner salt) assay and Cell Titer Blue assay 
(a resazurin based assay marketed by Promega). Both techniques measure the ability 
of the cell to metabolise XTT or resoruzin respectively and induce a colour change 
that is proportional to the healthy cell number. XTT is not believed to enter the cell 
due to the net negative charge of the molecule and is believed to be reduced at the 
plasma membrane. Treatment with 24(5),25-epoxycholesterol led to no toxicity as 
shown by XTT assay (fig 3.2). After 24 or 48 hours of incubation with vehicle, lpM  
GW3965, IOjiM 24(5),25-epoxycholesterol, lOpM 24(5)-hydroxycholesterol no 
differences were observed. In the case of Cell Titer Blue again no toxicity was
observed (fig 3.3) after treatm ent with ljaM GW 3965, lOpM 24(5),25- 
epoxycholesterol or lOpM 24(5)-hydroxycholesterol for 24 or 48 hours.
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Figure 3.2. 24(5),25-epoxycholesterol is not toxic in SN4741 cells as measured by 
XTT assay (n= l). Measurements were conducted at the specific absorbance 
wavelength of reduced XTT (475nm) and at 660nm as a measure of non-specific 
absorbance. No differences were observed between control, lpM  GW3965, lOpM 
24(5),25-epoxycholesterol, 10pM 24(5)-hydroxycholesterol after 24 or 48 hours.
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Figure 3.3. 24(5),25-epoxycholesterol is not toxic in SN4741 cells as measured by 
Cell Titer Blue assay (n=2). Measurements were conducted at fluorescent excitation 
wavlength (544nm) and emission wavelength (590nm) of resorufin (the metabolite 
generated by the reduction of resoruzin). No differences were observed between 
control, lpM  GW 3965, lOgM 24(5),25-epoxycholesterol or IOjiM 24(5)- 
hydroxycholesterol after 24 or 48 hours.
3.2.3. LXR Expression in SN4741 cells.
The aim of this study was to investigate LXR dependent and independent changes in 
protein expression. Therefore, the expression of LXRa and LXR|3 was evaluated in 
SN4741 cells to ensure the appropriateness of the cell line as a model. The expression 
of both isoforms was evaluated by RT-qPCR to identify the presence of mRNA. In 
SN4741 cells both isoforms were present with LXR(3 the predominant isoform with 
levels -1 0  higher than LXRawhich correlates with previously published data for the 
central nervous system (Whitney et al. 2002; table 3.1.).
Table 3.1. Threshold cycle for LXRa and LXR|3 after RT-qPCR. Threshold cycle is 
inversely proportional to the abundance of mRNA. Therefore, more LXRf3 mRNA is 
present than LXRa mRNA; LXR(3 has a higher expression level.
Gene Threshold Cycle
LXRa 21.1±0.9
LXR(3 17.8±1.1
In addition, after SN4741 cells were treated with either 10pM 24(5),25- 
epoxycholesterol or lpM  GW3965 the protein o f the LXR responsive gene ABCA1 
was increased (fig 3.4). The expression of ABCA1 is low in untreated cells. However, 
after 24 hours treatment with either lOpM 24(5),25-epoxycholesterol or lpM  
GW3965 the protein level is increased markedly indicating activation o f LXR. At the 
mRNA level RT-qPCR experiments showed that the LXRa regulated gene SREBPlc 
was up-regulated after treatment with both 24(5),25-epoxycholesterol and GW3965 
indicating the expression of LXRa and the expected response (fig 3.12). GW3965 had 
a greater effect on SREBPlc expression with a ~7-fold increase over control whereas 
24(5),25-epoxycholesterol only induced a ~3-fold increase.
Figure 3.4. The protein level of ABCA1 is increased after 24 hours treatment with 
either 10pM 24(5),25-epoxycholesterol or lpM  GW3965 indicating that SN4741 
cells express LXRa/(3.
3.2.4. Strong Cation Exchange Fractionation of SILAC peptides
Treatment of SN4741 cells with 10pM 24(5),25-epoxycholesterol or lpM  GW3965 
showed no toxic effects of these small molecules and SN4741 cells expressed 
LXRa/p. Thus, SN4741 cells were deemed suitable as a model for proteomic studies 
and grown in SILAC media for 5 passages. 5 passages is enough time to ensure full 
incorporation of the labelled amino acids to occur based on previous experience in our 
laboratory. SILAC SN4741 cells were treated with either vehicle, lpM  GW3965 or 
lOpM 24(5),25-epoxycholesterol for 24 hours in serum free SILAC media, before 
lysis and protein estimation. An equal amount of protein from each SILAC state was 
combined on a 1:1 basis and digested with trypsin to form a SILAC peptide mixture. 
This peptide mixture was then subjected to further analysis to elucidate proteomic 
changes.
Before the mass spectrometric analysis of the SILAC peptides 2-dimensional LC- 
MS/MS was performed. The first dimension of separation was performed using strong 
cation exchange chromatography. Strong cation exchange separates molecules by 
charge; anionic molecules elute first. Thus, the technique can be used as a 
fractionation step to reduce sample complexity prior to the second dimension of 
separation that is reverse phase C l8 LC-MS/MS. In order to validate the strong cation 
exchange chromatography that was to be used on the SILAC samples the system was 
tested. A blank injection of solvent showed no detection of peptides eluting from the 
column (fig 3.5A) and therefore indicated lack of contamination of the system. In 
addition, to validate the ability of the column to separate peptides trypsin digested 
bovine serum albumin (BSA) was used. 50pg of peptide mixture was separated on the 
column and detected by UV (fig 3.5B).
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Figure 3.5. Strong Cation Exchange chromatography validation. Example UV 
(X=214nm) chromatogram are shown highlighting expected instrument performance. 
A) A blank was run to ensure no carry over was present from previous experiments B) 
50pg of BSA trypsin digested peptides loaded onto the column were separated by 
SCX.
Before fractionating the SILAC samples by SCX an additional blank run was to 
ensure that the column was free from BSA digest contamination. These procedures 
ensure no carry over from previous experiments and sufficient column performance. 
Once column performance was evaluated SILAC peptides were injected onto the 
column. From the UV chromatogram (fig. 3.6) it can be seen that there is a large 
amount of material present (c.f. blank and 50jj.g BSA chromatograms fig. 3.5) and 
that the material present has been separated. The majority of the peptides were eluted 
early in the run and therefore the time interval for fraction collection was shorter 
before increasing towards the end of the run where less material is present. The total 
number of peptides, compared to the number of unique peptides per fraction, can be 
seen in figure (fig. 3.6.). Therefore, the use of strong cation exchange chromatography 
was successful in reducing the complexity of the initial peptide mixture for 
subsequent LC-MS/MS steps. However, the number o f peptides present in the 
fractions results in a complex mixture for reverse phase chromatography despite the 
fractionation.
Figure 3.6. Strong Cation Exchange chromatography trace o f SILAC peptides. 
Example o f strong cation exchange chromatography fractionation from one 
experiment presented. A) The UV (?^=214nm) chromatogram highlights the large 
number of peptides present on the column. The time interval for fraction collection is 
indicated B) In this example a total 38458 peptides were identified. O f these 15526 
were unique peptides. Strong cation exchange chromatography reduced the total 
number of peptides and number o f unique peptides per fraction with ^10% of the 
experiment total per fraction. Thus, each fraction is simplified compared to the initial 
mixture yet remains a complex peptide mixture in its own right.
3.2.5. C18 Reverse Phase LC-MS/MS of SILAC peptides
The peptide mixture fractions derived from strong cation exchange chromatography 
were desalted using Seppak C18 columns, dried under vacuum and resuspended in 
H2O/0.1%formic acid to be analysed by LC-MS/MS. In order to test the performance 
of the reverse phase C l8 column performance prior to running the SN4741 derived 
SILAC samples trypsin digested bovine serum albumin (BSA) was used. This allowed 
validation of both chromatography and mass spectrometry performance. The use of 
5pi of a 20fmol/pl BSA trypsin digest gave a good signal in the mass spectra with 
sharp chromatographical peaks that indicate that the column performance is 
acceptable (a typical chromatogram is shown in fig. 3.7). In order to ensure the 
complete removal of the BSA peptides prior to running the SILAC SN4741 samples a 
blank run was performed injecting 80% acetonitrile.
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Figure 3.7. Reverse Phase LC-MS/MS validation. Example of column performance 
showing separation of peptides from a BSA trypsin digest. In order to ensure reverse 
phase column is clean a blank is run before initiating SILAC proteomic samples.
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Figure 3.8. Reverse Phase LC-MS/MS SILAC peptide separation. An example 
chromatogram is shown that exemplifies the fact that peptides co-eluting from the 
strong cation exchange chromatography step can be separated by C 18 reverse phase 
chromatography.
SILAC peptides were injected on to the HPLC system and separated over a 2 hour 
gradient. It can be seen from the example in figure 3.8 that a fraction obtained from 
strong cation exchange chromatography is still a very complex sample but the 
peptides present can be separated on the C l8 column. Peptides eluting from the 
column are then analysed by mass spectrometry. Peaks with characteristic features of 
peptides were identified by the initial mass spectrometry scan and, if they conformed 
to the pre-selected criteria, were chosen for fragmentation (see Materials and Methods 
section 2.6.8.). The mass spectrometric scan of the fragments leads to the analysis of 
the backbone sequence and identification. However, the initial MS scan is critical to 
SILAC success as this scan is used for quantification. The SILAC envelope patterns 
have a triplet motif which are used for quantification. Indeed, the SILAC envelope 
patterns are indicative of labelled peptides (fig 3.9.). The use of differentially labelled 
arginine and lysine made it possible to distinguish between peptides terminating in 
different amino acids which contributes to the ease with which the bio-informatic 
software can identify peptides. It is possible to determine if a peptide contains 
arginine or lysine merely by examining the initial MS scan (fig 3.9) without any 
further information of sequence. For each technical replicate all raw spectrometric
data files were analysed simultaneously using MaxQuant software. This allowed the 
software to generate protein ratios derived from all the available spectra.
A
B
3w
<
652 70
5
665 70
663 0
J  L
'Light'
 1-----
'M edium '
1
'Heavy'
:
*  60-J
2 4
rot
802% 
an?*»
-------- a n *   l_______
* 7  42
605%
1
ar»»
00 11 306 r  j 3*90
'Light'
1
'Medium '
i
'Heavy'
Figure 3.9. Example SILAC spectra for lysine and arginine containing peptides. The 
lysine containing spectra (A) is a triply charged peptide which, for the light peptide 
has a MW of 1953.057. It can be identified as containing lysine due to the mass shift 
between the SILAC states (medium +1.33m/z i.e. + 4Da; heavy = +2.66m/z i.e. 
+8Da). This peptide was identified by ms/ms fragmentation as having the sequence 
VAPDEHPILLTEAPLNPK from -actin. The arginine containing spectra (B) is a 
doubly charged peptide which, for the light peptide, has a MW of 1601.889. It can be 
identified as containing lysine due to the mass shift between the SILAC states 
(medium +3m/z i.e. + 6Da; heavy = +5m/z i.e. + 10Da). This peptide was identified by 
ms/ms fragmentation as having the sequence AAAAGALAPGPLPDLAAR from 
UDP-N-acetylhexosamine pyrophosphorylase-like protein 1.
3.2.6. Peptide and Protein Identifications
A large number of peptides were identified in each biological replicate and on each 
instrument though in these SILAC experiments the Orbitrap Velos instrument 
performed better than the LTQ-Orbitrap with regard to total number of peptide 
identifications. The LTQ Orbitrap identified in total 22,395 (10,495 unique), 38,458 
(10,495 unique) and 75,322 (18,755 unique) peptides and the Orbitrap Velos 39,160 
(18,671 unique), 52,249 (23,292 unique) and 105,952 (34,650 unique) peptides from 
each biological replicate respectively. This corresponds to an increase in the number 
of unique peptides identified on the Orbitrap Velos compared to the LTQ-Orbitrap of 
77.9%, 121.9% and 84.8% for each biological replicate. This increase in number of 
peptides identified corresponded to an increased number of proteins identified on the 
Orbitrap Velos instrument compared with the LTQ-Orbitrap (table 3.2). A large 
number of proteins were identified from the 3 biological replicates on both the LTQ- 
Orbitrap and the Orbitrap Velos instruments and, in each case, the majority of 
proteins were identified with ^2 peptides (table 3.2). The Orbitrap Velos identified 
1117, 971 and 1540 more proteins than the LTQ Orbitrap with ^2 peptides in each of 
the 3 biological replicates respectively.
Table 3.2. Comparison of proteins identified between LTQ-Orbitrap and Orbitrap 
Velos instruments. The majority of proteins were identified with ^2 peptides. A large 
proportion of proteins were identified with more peptides.
Replicate 1 2 3
Instrument LTQ-
Orbitrap
Orbitrap
Velos
LTQ-
Orbitrap
Orbitrap
Velos
LTQ-
Orbitrap
Orbitrap
Velos
Proteins
identified
with:-
> 1 peptide 2941 4211 3654 4672 3662 5219
> 2 peptide 2039 3156 2739 3710 2879 4419
> 3 peptide 1382 2334 2009 2844 2223 3622
> 4 peptide 983 1763 1489 2223 1753 2985
> 5 peptide 720 1392 1143 1755 1417 2501
There was a large overlap between the same lysates run on the two different 
instruments with the majority of leading proteins identified on both instruments. The 
number of proteins identified with s>l peptide from 3 biological replicates on both 
instruments was 2612 (59.0% of the 4425 proteins identified in total from both 
instruments), 3252 (64.7% of the 5025 proteins identified in total from both 
instruments) and 3098 (54.1% of the 5722 proteins identified in total from both 
instruments) respectively. The number of proteins identified with >2 peptides from 
the 3 biological replicates on both instruments was 1839 (54.8%), 2505 (63.5%) and 
2473 (51.3%) respectively (fig 3.10.).
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Figure 3.10. There was a large overlap between runs of the same biological replicate 
on different instruments (A, B, C); 90% (A), 91% (B) and 86% (C) of leading proteins 
identified on the LCQ-Orbitrap with >2 peptides were also identified on the Orbitrap 
Velos with >2 peptides
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There was a large overlap between the three different biological replicates. The 
number of leading proteins identified and quantified with ^1 peptide in all 3 
biological replicates was 2096 proteins (44.3% total proteins) on the LTQ-Orbitrap. 
The number of proteins identified with s=l peptides in at least 2 of the biological 
replicates was unsurprisingly higher still; of the 4729 leading proteins identified 
69.5% (3285) were identified in at least 2 biological replicates. In comparison, on the 
Orbitrap Velos 48.6% (3090) of the 6358 leading proteins identified with ssl peptide 
were observed in all 3 biological replicates. The number of leading proteins identified 
in at least 2 of the biological replicates with s=l peptide was 70.6% (4489). Therefore, 
these data demonstrate that the majority of proteins were quantified on at least 2 
occasions from different biological replicates increasing the ease of discriminating 
between reproducible changes and rogue data points from a single biological sample.
However, the confidence in proteomic data is increased if multiple peptides are used 
for identification and quantification as relying on only 1 peptide can lead to error in 
identification and quantification due to error introduced by experimental variability or 
the software used during post-run analysis of the raw mass spectral data. The samples 
run on the LTQ-Orbitrap had 42.9% (1546) of the 3607 leading proteins identified 
with ^2 peptides observed in all 3 biological replicates. The number of proteins 
identified with ^2 peptides in at least 2 of the biological replicates was 69.4% (2504) 
of the total leading proteins identified with ^2 peptides. In comparison, on the 
Orbitrap Velos 45.8% (2404) of the 5246 leading proteins identified with ^ 2  peptides 
were observed in all 3 biological replicates (fig 3.11). The number of leading proteins 
identified in at least 2 of the biological replicates with ^2 peptides was 69.3% (3635). 
It is clear, therefore, that the use of the SILAC proteomic methodology identified and 
quantified a large number of proteins suitable for further analysis. In addition, due to 
the large overlap between identifications from the three biological replicates, and the 
confidence inferred from multiple peptide protein identification these data are suitable 
for the analysis of up and down-regulation of protein as reproducible changes to the 
proteome should be apparent.
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Figure 3.11. Overlap of leading proteins identified and quantified with >2 peptides 
using MaxQuant. A large overlap existed between 3 separate biological replicates run 
on a LTQ-Orbitrap (A) or an Orbitrap Velos instrument (B). 43% of proteins 
identified on the LTQ-Orbitrap and 46% of proteins identified on the Orbitrap Velos 
were present in all 3 replicates. 69% and 69% of proteins were identified in at least 2 
replicates on the LTQ-Orbitrap and Orbitrap Velos instruments respectively.
3.2.7. Expression of Neurotrophins and Neuronal Markers in SN4741 Cells
The aim of the work is to elucidate the effect of 24(5),25-epoxycholesterol in 
neuronal development. A group of proteins with an established role in neuronal 
development are the neurotrophins (Hempstead 2006). Thus, the dataset was mined 
for the presence of the neurotrophins brain derived neurotrophic factor (BDNF), glial 
cell-derived neurotrophic factor (GDNF), ciliary neurotrophic factor (Cntf), 
neurotrophin 3 (Ntf3), neurotrophin 4 (Ntf4) and nerve growth factor (NGF). None of 
these neurotrophins were detected in the data set (table 3.3).
In addition, neuronal markers from different stages of neuronal development were 
present (table 3.3). Nestrin and SOX2 that are markers of neuronal progenitor cells 
were identified. Nestrin was down-regulated in some but not all of the biological 
replicates after treatment with 24(5),25-epoxycholesterol. Doublecortin a marker of 
early neuronal development was identified but another marker neurogenic 
differentiation 1 was not. The mature neuronal markers beta III tubulin (Tubb3) and 
microtubule-associated protein 2 (MAP2) were identified in all 3 biological replicates. 
Thus, a number of markers from different stages of neuronal development were 
identified although 24(5),25-epoxycholesterol had no reproducible effect on their 
expression.
No dopaminergic neuron markers were identified (table 3.3). However, it is important 
to note that a given protein may be expressed but not be present in the dataset due to 
the technicalities of proteomics. Low abundance proteins may not be identified. In 
addition, protein identification is reliant on the peptides generated by the action of 
trypsin. In this regard very short peptides do not furnish enough sequence information 
to allow confident identification from which protein they are derived. In addition, if a 
peptide is poorly ionised (e.g. due to a number of acidic amino acids) then it is 
unlikely to be detected.
Table 3.3. Neurotrophins and neuronal markers expressed in SN4741 cells identified 
in SILAC experiments. Normalised SILAC ratios shown are 24(»S),25- 
epoxycholesterokcontrol. Neurotrophins (brain derived neurotrophic factor (BDNF), 
glial cell-derived neurotrophic factor (GDNF), ciliary neurotrophic factor (Cntf), 
neurotrophin 3 (Ntf3), neurotrophin 4 (Ntf4), nerve growth factor (NGF)) were not 
detected in any experiment. Markers of neuronal progenitor cells (Nestin (Nes), 
transcription factor SOX-2 (SOX2)) were detected. Early neuronal markers 
(doublecortin (DCX), neurogenic differentiation 1 (Neurodl). Mature neuronal 
markers (beta III tubulin (Tubb3), microtubule-associated protein 2 (MAP2)) were 
identified in all experiments, whereas (RNA binding protein fox-1 homolog 3 
(Rbfox3; NeuN)) was not. Dopaminergic markers (GTP cyclohydrolase 1 (Gchl), 
aromatic L-amino acid decarboxylase (Ddc), tyrosine hydroxylase (Th) were not 
detected.
Biological Replicate 1 2 3
Technical Replicate 1 2 1 2 1 2
Protein
Bdnf / / / / / /
Gndf / / / / / /
Cntf / / / / / /
Ntf3 / / / / / /
Ntf4 / / / / / /
Ngf / / / / / /
Nes 0.535 0.665 0.786 0.771 0.868 0.916
Sox2 / / 1.048 1.302 1.139 0.943
Dcx / / 0.927 0.865 / 1.151
Neurodl / / / / / /
Tubb3 1.117 1.226 0.957 1.015 0.888 0.798
Map2 1.086 0.990 0.951 0.783 0.831 /
Rbfox3 / / / / / /
Gchl / / / / / /
Ddc / / / / / /
Th / / / / / /
3.2.8. Analysis of proteomic data
In each dataset the ratio of identified proteins had a normal distribution. The protein 
identification and quantification data generated from Maxquant was analysed to class 
proteins as ‘no change’, ‘up-regulated’ or ‘down-regulated’ using a previously 
published method (Graumann et al. 2008). The median was calculated and an increase 
or decrease the equivalent to 2 standards deviations (the arithmetic mean and standard 
deviation are not used in this method to prevent outliers having a pronounced effect) 
away from the median was classed as changed. Therefore, due to the use of the 
variation of the data in its calculation, the ratio between the heavy, medium and light 
SILAC states that serve as the boundary between ‘no change’ and ‘up’ or ‘down- 
regulation’ varied between datasets (table 3.4). This method identified a small portion 
of the total number of proteins as up- and down- regulated after treatment with 
24(5),25-epoxycholesterol or GW3965 (table 3.4). The leading proteins identified as 
changed were then searched to determine reproducible trends in protein expression 
changes across the 6  datasets.
Table 3.4. Number of proteins identified as ‘no change’, ‘up-regulated or ‘down 
regulated’ from each biological replicate on LTQ-Orbitrap or Orbitrap Velos 
instruments after treatment with 24(5),25-epoxycholesterol. The ratio cut-offs for 
what was classed as a change in protein expression (i.e. up or down regulation) are 
shown. Proteins were identified with s=2 peptides.
Biological
Replicate
1 2 3
Instrument LTQ-
Orbitrap
Orbitrap
Velos
LTQ-
Orbitrap
Orbitrap
Velos
LTQ-
Orbitrap
Orbitrap
Velos
Ratio Cut-off (up/down) 1.23/0.73 1.23/0.71 1.35/0.76 1.34/0.76 1.18/0.74 1.19/0.73
Up-regulated 78 158 116 195 227 233
No change 1855 2848 2534 3344 2471 3951
Down-regulated 106 150 89 171 181 235
In order to ensure no changes of interest were missed the proteomic datasets were also 
examined in detail by analysing every protein identified as up or down regulated to 
attempt to identify proteins of interest. In total, from all the biological and technical 
replicates, 1072 different proteins were identified as up-regulated in total and 864 
proteins were identified as down-regulated (Appendix 1 and 2). No proteins were 
excluded from this analysis and therefore a large number of proteins were identified 
with only 1 peptide. For these proteins identified with 1 peptide there is the possibility 
of experimental error having a larger effect on the quantification. In addition, a 
number of proteins were only identified in only one biological replicate. For these 
proteins there is no contradictory data but conversely no validatory data. Therefore, it 
is important to recognise the limitations of these data however they could yield 
valuable information.
The proteins identified as up and down regulated (Appendix 1 and 2) were examined 
to determine which proteins had no contradictory data. In total, 229 proteins were 
classed as up-regulated and had no contradictory data (table 3.5) whereas 285 proteins 
were classed as down-regulated (table 3.6).
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The data were then analysed using the bio-informatic software DAVID 
(http://david.abcc.ncifcrf.gov/) in order to determine if there are any links between the 
identified proteins that have previously been identified in the literature. The software 
identifies significant enrichment of gene ontology (GO) terms i.e. the process or 
processes in which the gene(s) function are over represented in the data set.
In total 15 GO terms were significantly enriched in the down-regulated proteins (table
3.7.) whereas no GO terms were identified as significantly enriched from the up- 
regulated proteins. It is obvious from the identified GO terms that the overarching 
factor in these terms is the effect on lipid small molecules. The 8 most significantly 
enriched terms are related to the biosynthesis and processing of sterols, cholesterol, 
steroid and lipids. Thus, it is clear, and unsurprising, that treatment of SN4741 cells 
with 24(S),25-epoxycholesterol results in alterations in the biosynthesis and 
processing of a variety of lipid molecules.
Table 3.7. Gene Ontology terms identified as enriched after DAVID bio-informatic 
analysis. GO terms significantly enriched after p-value correction (Benjamini) are 
shown. Proteins up and down regulated were analysed independently but all 
significantly enriched GO terms identified were from the down regulated proteins 
data.
Term Count Fold Enrichment p-value Benjamini
Sterol biosynthetic process 13 30.96 2.59E-15 3.32E-12
Cholesterol biosynthetic process 12 37.28 3.33E-15 2.17E-12
Sterol metabolic process 16 14.85 1.39E-13 6.05E-11
Cholesterol metabolic process 15 15.31 6.34E-13 2.06E-10
Steroid biosynthetic process 14 14.09 1.43E-11 3.72E-09
Steroid metabolic process 17 7.54 8.37E-10 1.82E-07
Lipid biosynthetic process 19 4.76 9.65E-08 1.80E-05
Lipid metabolic process 29 2.98 4.01E-07 6.53E-05
Alcohol metabolic process 19 3.77 2.93E-06 4.23E-04
Oxidation reduction 26 2.76 7.11E-06 9.25E-04
Isoprenoid biosynthetic process 6 19.49 1.08E-05 0.001
Isoprenoid metabolic process 7 10.21 5.74E-05 0.006
Transport 54 1.65 1.52E-04 0.015
Establishment of localization 54 1.64 1.81E-04 0.017
Cellular lipid metabolic process 18 2.67 4.19E-04 0.036
In addition to the GO terms identified the analysis of the down-regulated proteins 
identified a number of KEGG pathways as enriched (table 3.8) though only 2 
pathways had significant Benjamini corrected p-values. Again, unsurprisingly, the 
most significantly enriched pathways were those related to steroid biosynthesis and 
terpenoid backbone synthesis. These pathways have a large number of previously 
identified SREBP2 regulated proteins. It is interesting to note that despite not being 
significantly enriched after correction of the p-value the KEGG pathways of both 
Alzheimer’s and Parkinson’s disease, 2 neurodegenerative diseases, were identified as 
enriched.
Table 3.8. KEGG Pathways identified as enriched by DAVID bio-informatic analysis 
of down regulated proteins. Benjamini is the corrected p-value required after multiple 
analysis.
Kegg Pathway Count IPI Number Fold Enrichment p-value Benjamini
Steroid biosynthesis 8 IPI00338068, IPI00137471, 
IPI00474810, IPI00169958, 
IPI00130988, IPI00316067, 
IPI00128692,1PI00458711, 
IPI00133526
32.15 1.77E-09 2.08E-07
Terpenoid
backbone
biosynthesis
7 IPI00849448, IP100319950, 
IPI00756996, IPI00120457, 
IPI00133709, IPI00331707, 
IPI00228253
34.15 2.09E-08 1.22E-06
Cardiac muscle 
contraction
6 IPI00224210,1PI00121550, 
IPI00131176, IPI00114377, 
IPI00129516, IP100225390
5.25 5.18E-03 0.183
Oxidative
phosphorylation
7 IPI00224210, IPI00131176, 
IPI00313841, IPI00114377, 
IPI00318645, IPI00129516, 
IPI00225390
3.68 0.01 0.275
Parkinson's disease 7 IPI00648249,1PI00224210, 
IPI00131176, IP100923056, 
IPI00114377, IP100129516, 
IPI00225390
3.60 0.01 0.249
Natural killer cell
mediated
cytotoxicity
6 IPI00133132, IP100322542, 
IPI00881074, IPI00136110, 
IPI00856542, IPI00665857
3.36 0.03 0.461
Alzheimer's disease 7 IPI00224210, IPI00131176, 
IPI00114377, IPI00117124, 
IPI00665857, IPI001295I6, 
IPI00225390
2.63 0.05 0.555
Calcium signalling 
pathway
7 IPI00471089, IPI00133132, 
IPI00466672, IPI00626433, 
IPI00831180, IPI00263265, 
EPI00665857
2.50 0.06 0.578
Biosynthesis o f 
unsaturated fatty 
acids
3 IPI00129362, IPI00117142, 
IPI00318108
7.59 0.06 0.537
Focal adhesion 7 IPI00626433, IPI00117829, 
IPI00136110, IPI00828653, 
IPI00421218, IPI00136701, 
IPI00110508
2.41 0.07 0.550
Butanoate
metabolsim
3 IPI00135189, IPI00331707, 
IPI00228253
5.54 0.099 0.672
The proteins identified as up-regulated were also analysed to identify enriched 
pathways (table 3.9). No significant changes in enrichment were identified after 
correction of the p-value. Thus, it appears that treatment of SN4741 cells with lOpM 
24(5),25-epoxycholesterol fails to up-regulate specific pathways en masse but rather 
up-regulates single unrelated proteins.
Table 3.9. Kegg Pathways identified as enriched by DAVID bio-informatic analysis 
of up-regulated proteins. Benjamini is the corrected p-value required after multiple 
analysis.
Kegg Pathway Count IPI Number Fold Enrichment p-value Benjamini
Metabolism of xenobiotics 
by cytochrome P450
5 IPI00323911 
IPI00890112 
IPI00111222 
IPI00554953 
IPI00134432 
IPI00153143
7.01 0.005 0.415
Drug metabolism 5 IPI00323911 
IPI00890112 
IP100111222 
IP100554953 
IPI00134432 
IPI00153143
6.17 0.008 0.344
Ribosome 4 IPI00880213 
IPI00466820 
IPI00849113 
IPI00869475
4.16 0.068 0.916
Fc gammaR-mediated 
phagocytosis
4 IPI00272878 
IPI00229848 
IPI00655177 
IPI00117274
3.78 0.086 0.904
As mentioned earlier some of the proteins identified had weak evidence of changes in 
expression either due to a low number of peptides or due to the fact that they were not 
identified in all biological replicates. Thus, in order to determine proteins with 
stronger evidence of expression changes the data presented in table 3.5. and table 3.6. 
were re-examined. Proteins identified with only 1 peptide were excluded. In addition, 
proteins only identified in 1 biological replicate were also excluded. Finally, proteins 
only identified with low-scoring peptides or where there was a large variability 
between peptides were excluded. The flowchart for data analysis is shown in figure 
3.12. Thus, reliable, reproducible data was extracted from the data (table 3.10).
Total proteins
Proteins classified as up 
or down regulated
Proteins with contradictory 
data removed
Proteins identified with only 
1 peptide removed
Proteins identified in only 1 
biological replicate removed
Peptides analysed for good 
Mascot score and 
reproducibility of expression
Combined for final table of 
observed reproducible changes
Down
285
864
129
1072
229
6692
Figure 3.12. Flowchart of data analysis showing the process by which protein 
expression data was rejected in order to identify reproducible changes in the 
proteome. Of the 6692 unique proteins identified in the 3 biological replicates only 47 
(0.7%) had strong, reproducible evidence of a change in protein expression.
It can be seen that previously identified changes associated with inhibition of 
SREBP2 processing by oxysterols are reliably observed in all 3 biological replicates 
after treatment with lOpM 24(5),25-epoxy cholesterol (table 3.10). The synthetic LXR 
ligand GW3965, as expected, had no effect on the transcription of these genes. It is 
important to recognise that despite these proteins being previously identified and well 
characterised as regulated by SREBP2, and therefore, by oxysterols via INSIG, it is 
critical to the reliability of the SILAC experimental design that known changes 
expected with 24(5),25-epoxycholesterol are identified successfully in order to have 
confidence that other unexpected changes are true. In addition, ABCA1 expression 
was up-regulated after treatment with both 24(5),25-epoxycholesterol and GW3965. 
ABCA1 expression is dependent on LXR activation. As both 24(5),25- 
epoxycholesterol and GW3965 are ligands for LXR it again validates the 
methodology that a predicted change is observed after analysis of the proteomic data.
A number of proteins reproducibly identified as having a changed expression had 
links to cholesterol, phospholipids or fatty acids (table 3.10). However, other proteins, 
with no apparent link to lipids were also identified as having a changed expression. 
For example, two proteins that were reproducibly observed as being up regulated 
were Golgi apparatus protein 1 and macrophage colony stimulating factor.
Table 3.10. Summary of reproducible changes in protein expression. For the 3 
biological replicates the mean SILAC ratio compared to control derived from the 
Orbitrap and Velos instruments is shown.
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3.3. Discussion
The proteomic analysis of SN4741 cells after treatment with 24(5),25- 
epoxycholesterol and GW3965 identified a large number of proteins. In total, 6692 
unique proteins were identified with z>\ peptide in the 3 biological replicates (figure
3.12). However, the majority of proteins in each replicate were identified with 2 or 
more peptides (table 3.2). Thus, it is clear that the experimental approach of strong 
cation exchange to reduce the sample complexity followed by LC-MS was successful 
when judged by the total number of observed proteins in the experiments. In addition, 
the SILAC labelling adopted gave a wealth of data that required painstaking analysis 
to extract the most reliable data. From a technical perspective, it was clear that the 
Orbitrap Velos was the instrument that performed better as it consistently identified 
more peptides, and therefore proteins, than the LTQ-Orbitrap instrument (table 3.2).
A large number of proteins were identified as having an altered expression after 
treatment with 24(5),25-epoxy cholesterol. In total 1072 up-regulated and 864 down- 
regulated proteins were identified in the 3 biological replicates (Appendix 1, 
Appendix 2). However, analysis of these proteins identified a significant number with 
contradictory data in a different data set (e.g. up-regulated in one dataset but no 
change in the others; Appendix 1, Appendix 2). The analysis of the data to remove 
these proteins led to a large proportion of them to be rejected as having a change in 
protein expression. After removal of contradictory proteins 229 (21.4%) up-regulated 
proteins and 285 (33.0%) down regulated proteins remained (table 3.5, table 3.6, fig
3.12). These data give a clear indication of the necessity of multiple biological 
replicates in proteomic studies.
The proteins identified as changed were then analysed by using the online software 
DAVID in order to identify GO terms and pathways significantly up or down- 
regulated in the data set. No GO terms or KEGG pathways were up-regulated with 
statistical significance. Therefore, it appears from these data that 24(5),25- 
epoxycholesterol up-regulates individual proteins and not whole pathways. In 
comparison, there was significant down regulation of 15 GO terms (table 3.7). In 
addition, 2 KEGG pathways were down-regulated after Benjamini correction - steroid 
biosynthesis and terpenoid backbone biosynthesis. It is unsurprising that these 
pathways are down-regulated as their expression is controlled by SREBP2.
The proteins identified in tables 3.5 and 3.6 have no contradictory data. However, the 
majority of the identified proteins have been identified as having a change in 
expression have only weak evidence to support the observation. A reliance on a 
SILAC ratio measurement from a single peptide can lead to experimental error. 
Similarly a protein observed in only one biological replicate can have an erroneous 
measurement. This is clear from the number of proteins with observed changes in 
expression being rejected as due to having contradictory data in a different biological 
replicate (figure 3.12). Thus, proteins that were only identified with one peptide or in 
one biological replicate were rejected.
The final analysis of the identified proteins was to examine their individual peptides 
used to identify the protein. The Mascot scores and the reproducibility of the SILAC 
ratios between peptides used to identify and quantify the same protein were examined. 
Proteins identified only with peptides with low Mascot scores were rejected. In 
addition, proteins identified with a number of unique peptides with a large variation in 
the SILAC quantification ratio were also rejected. This ensured that the proteins 
remaining were identified in multiple biological replicates, with multiple peptides and 
that the peptides used for identification had good Mascot scores and low variability of 
the SILAC ratio. Thus, the final 47 proteins presented in table 3.10 are the proteins 
with the most robust evidence of changes in expression. The rejection of the vast 
majority of the proteins identified as changed is a necessary evil in order to have the 
final outcome of a reliable, but much smaller, set of data.
It is clear that from the data presented here the SILAC proteomic approach was 
successful in identifying proteins, both known and novel, which are sensitive to 
24(5),25-epoxy cholesterol treatment and with a reproducible response (table 3.10). 
Both instruments identified expected SREBP2 regulated changes in protein 
expression of enzymes involved in the cholesterol synthesis pathway after 24(5),25- 
epoxycholesterol treatment. It is unlikely that any observed changes were due to 
toxicity as it was shown that 24(5),25-epoxycholesterol was non-toxic to SN4741 
cells (fig 3.1; fig 3.2; fig 3.3). In addition, the rigorous criteria by which the data was 
analysed meant that the protein expression data presented here are trustworthy.
However, further validation of these data is required in order to determine how 
24(5),25-epoxycholesterol induces the observed changes in protein expression. Thus
in the next chapter work will be conducted in order to elucidate the mechanisms 
involved.
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4.1. Introduction
24(5),25-epoxy cholesterol induces changes in the proteome of SN4741 cells. This 
effect is apparent in the proteomic data presented in Chapter 3 where 47 proteins were 
identified as changed reliably and reproducibly (table 3.10). Therefore, there is 
already evidence these proteins are sensitive to 24(5),25-epoxycholesterol. However, 
further analysis is required in order to validate the results and elucidate the 
mechanism by which 24(5),25-epoxycholesterol induces these changes.
It is already known that 24(5),25-epoxycholesterol can increase gene expression by 
activating the transcription factor LXR (section 1.1.5.2.). In addition, previous work 
has shown that oxysterols can prevent gene transcription regulated by SREBP2 
(section 1.1.5.1). Thus, there is precedent for oxysterols inducing changes in gene 
expression by altering transcription of mRNA. Therefore, in order to investigate 
whether the observed changes in protein expression correlated with a change in the 
transcription of mRNA qPCR can be performed. These experiments will lead to 
understanding the mechanism by which 24(5),25-epoxycholesterol is inducing the 
observed changes.
In addition, further analysis of the protein expression changes at the protein level can 
be performed to validate and clarify the observed data in the SILAC proteomic 
experiments. An obvious example would be the use of Western blotting in order to 
confirm changes in protein expression. In addition, other techniques can be used to 
examine specific attributes of a protein observed as having changed. For example, 
ELISA can be used to examine if changes in expression correlate to changes in 
secretion of a given protein.
It is possible that secondary effects may influence changes in both protein expression 
and localisation as oxysterols reduce cholesterol synthesis due to inhibition of 
SREBP2. Thus, in the presence of 24(5),25-epoxycholesterol the cholesterol content 
of SN4741 cells will be reduced. Cholesterol is an essential component of membranes 
and therefore a reduction in the cholesterol level may disrupt the cellular membrane
and lead to changes in protein expression and localisation. Therefore, the observed 
protein expression changes in the SILAC experiments may be due to changes in the 
cellular cholesterol level. In this instance immunofluorescence may be used as an 
adjunct to examine changes in the localisation of a protein after treatment with 
24(5),25-epoxycholesterol.
In summary, the aim of this chapter is to further investigate and discuss the changes 
identified in the SILAC quantitative proteomic experiments.
4.2. Results
4.2.1. Validation of Known Oxvsterol Regulated Genes Identified by SILAC
The SILAC proteomic data led to the identification of known SREBP2 regulated 
genes in the cholesterol synthesis pathway to be identified reproducibly as down- 
regulated after treatment with 10pM 24(5),25-epoxycholesterol (table 3.10). The 
synthetic LXR ligand GW3965, as expected, did not down-regulate these genes. 
However, from these data it appears that GW3965 treatment resulted in the up- 
regulation of squalene synthase. It is important to recognise that despite these proteins 
being previously identified and well characterised as regulated by SREBP2, and 
therefore, by oxysterols via INSIG, it is critical to the reliability of the SILAC 
experimental design that known changes expected with 24(5),25-epoxycholesterol are 
identified successfully in order to have confidence that other unexpected changes are 
true.
Low density lipoprotein receptor (LDLR), another SREBP2 regulated gene, was 
observed as down regulated by 24(5),25-epoxycholesterol and not by GW3965 at the 
protein and mRNA level (table 3.10; figure 4.1). Interestingly, the protein expression 
of LDLR was not classed as down regulated after treatment with the LXR agonist 
GW3965 though it tended toward a reduced expression; LXR activation has been 
reported to increase LDLR protein degradation by inducing IDOL mediated 
ubiquitination in hepatocytes and macrophages (Zelcer et al. 2009). To determine if 
this effect on LDLR was a cell type specific effect initially IDOL expression was 
measured in SN4741 cells by qPCR. IDOL protein was not identified in the proteomic 
data set however IDOL mRNA was detected in SN4741 cells (figure 4.2). Therefore, 
these proteomic data indicate that in SN4741 cells the predominant mechanism of 
LDLR regulation is through SREBP2.
Figure 4.1. SN4741 reverse transcription qPCR. qPCR was performed on RNA 
extracted from SN4741 cells treated with vehicle, lpM  GW3965 or lOpM 24(5),25 
epoxycholesterol. Data shown is presented as mean fold change in mRNA expression 
compared with control; n=3, compared with control * p<0.05, Student’s t-test; A 
p<0.01, Student's t-test, ♦ p<0.001, Student's two tailed t-test.
A number of other genes previously identified as regulated by oxysterols had changes 
in their expression identified. The LXR regulated gene ABCA1, when identified was 
up-regulated after treatment with 24(5),25-epoxycholesterol and GW3965 (table 
3.10). StarD4 was down regulated in the presence o f 24(5),25-epoxycholesterol but 
not with GW3965 at the protein and mRNA level (table 3.10; figure 4.1) which tallies 
with reported SREBP2 regulation (Soccio et al. 2005).
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Figure 4.2. IDOL is expressed in SN4741 cells. RT-qPCR indicated the presence of 
IDOL mRNA in SN4741 cells. cDNA was used neat and at dilutions of 1:10, 1:100 
and 1:1000 and qPCR amplification and melt curve plots are shown.
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4.2.2. Ligand Binding Induces Un-Regulation of Liver X Receptor 6 (LXRB)
Liver X receptor (LXR) is a nuclear receptor for which oxysterols are the natural 
ligand (see section 1.1.5.2). LXR has two isoforms LXRa and LXRp. LXRa was not 
identified in any of the proteomic data sets. However, in the proteomic data LXRp 
was identified as up-regulated in the presence of lOpM 24(5), 25-epoxy cholesterol and 
lp,M GW3965 (table 3.9). Therefore, it appears from these data that activation of 
LXRp by either a natural or synthetic ligand causes an increase in its expression. 
Therefore, the effect of 10p,M 24(5),25-epoxycholesterol and lp,M GW3965 on
1 *1-1
LXRp expression at the mRNA level was measured using RT-qPCR to examine if 
this change in the protein level was due to increased transcription. LXRa mRNA 
expression was also analysed as LXRa has been reported to be self regulating in 
human macrophages and murine adipose tissue (Laffitte et al 2001, Whitney et al 
2001, Li et al 2002, Ulven et al 2004). However, in contradiction, there have been 
conflicting reports of no change in expression of LXRa after ligand activation in 
murine RAW264.7 macrophages and primary murine macrophages (Laffitte et al 
2001, Li et al 2002). Therefore, this effect appears to be cell type specific. In SN4741 
cells the expression of LXRa does not appear to self regulating; no change at the gene 
expression level of LXRa was observed after treatment with GW3965 or 24(5),25- 
epoxycholesterol. Treatment of SN4741 cells with the LXR ligands (24(5^),25- 
epoxycholesterol or GW3965) did not affect the level of LXRp mRNA expression.
4.2.3. Fatty Acid Synthesis
The complexity of fatty acid synthesis regulation is demonstrated in these data. Some 
SREBPlc regulated genes (acetyl-CoA carboxylase 1, long-chain-fatty-acid Co A 
ligase 3, fatty acid synthase) involved in fatty acid synthesis were increased after 
GW3965 treatment (table 3.10), but, despite the induction of SREBPlc mRNA (fig. 
4.1) the expression of these genes were not changed after treatment with 24(5),25- 
epoxycholesterol. Similarly, the previously reported SREBP1 regulated gene, M idl- 
interacting protein (Ecker et al 2010) was up-regulated in the presence of GW3965 
but not 24(5),25-epoxycholesterol. Interestingly, two genes, fatty acid desaturase 2 
and lipin 1, that have been identified as SREBP1 regulated were unaffected by 
GW3965 (table 3.10; Horton et al 2003). These genes, Fatty acid desaturase 2 and 
lipin 1 were however down-regulated after treatment with 24(5),25-epoxycholesterol 
(table 3.5.).
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Figure 4.3. Synthesis of the monounsaturated fatty acid oleic acid. The enzymes fatty 
acid synthase and acetyl-CoA carboxylase-1 are regulated by SREBPlc and were 
identified as up-regulated after treatment with GW3965.
4.2.4. Phospholipid Synthesis
Reproducible changes were observed in the proteomic data of proteins involved in the 
synthesis of phospholipids (figure 4.4.) after treatment with lOpM 24(S),25- 
epoxycholesterol including ethanolamine-phosphate cytidylyltransferase and collagen 
type IV alpha-3-binding protein.
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Figure 4.4. Simplified schematic of phospholipid synthesis. Ethanolamine-phosphate 
cytidylyltransferase was identified as down-regulated after treatment with 24(5),25- 
epoxycholesterol.
4.2.5. Decreased expression of Ethanolamine-phosphate cytidylyltransferase
Ethanolamine-phosphate cytidylyltransferase (PCyt2) is an enzyme involved in 
phospholipid biosynthesis and catalyses the reaction of cytidine triphosphate with 
ethanolamine phosphate yielding cytidine diphosphate-ethanolamine (CDP- 
ethanolamine) and diphosphate. CDP-ethanolamine is then processed further 
generating phosphatidylethanolamine. Phosphatidylethanolamine is major component 
of biological membrane and is found in all cells but is particularly abundant in the 
central nervous system (Bakovic et al 2007 for review).
In the proteomics datasets PCyt2 was identified and quantified as down regulated 
reproducibly after treatment with 24(<S),25-epoxycholesterol but not with GW3965 
suggesting a SREBP2 mediated mechanism (table 3.10). The mean reduction in 
ethanolamine-phosphate cytidylyltransferase protein expression after 24(5),25- 
epoxy cholesterol treatment was 33% less than that of control cell ethanolamine- 
phosphate cytidylyltransferase expression. In order to validate these data Western 
blotting was performed in SN4741 whole cell lysates. Treatment with 24(5),25-
epoxycholesterol was shown to down regulate PCyt2 correlating with the proteomics 
data (fig 4.5). Densitometry analysis showed that PCyt2 was reduced by 15% in 
24(50,25-epoxycholesterol treated cells. This was less than observed in the proteomic 
experiments but highlighted the same trend. There was no significant change with 
GW3965
Control 24S. 2 5-epoxy cholesterol GW3965
Figure 4.5. W estern blotting confirm ed the observed dow n-regulation o f 
phosphoethanolamine cytidylyltransferase (PCyt2) in SN4741 cells. 10pM 24(£')25 
epoxycholesterol decreased the expression of PCyt2 (lane 2) whilst 1 pM GW3965 
had no effect on PCyt2 expression (lane 3). Both GW3965 and 24(S)2 5 
epoxycholesterol induced ABCA1 (A lanes 2 and 3). Densitometry showed a 
significant (p^O.05) decrease in PCyt2 expression of 15% compared with control 
(n=3, Student's t-test).
4.2.6. Increased expression of Collagen type IV alpha-3-binding protein
Collagen type IV alpha-3-binding protein (col4a3bp; Ceramide transfer protein; 
Goodpasture antigen-binding protein; StAR-related lipid transfer protein 11) transfers 
ceramide from where it is synthesised in the endoplasmic reticulum to the Golgi 
apparatus where it is utilised in the synthesis of the phospholipid sphingomyelin 
(Hanada et al 2007 for review). Collagen type IV alpha-3-binding protein has been 
associated with oxysterol binding protein (OSBP) and the presence of 25- 
hydroxy cholesterol promotes activation of collagen type IV alpha-3-binding protein 
mediated transfer of ceramide to the Golgi apparatus and, therefore, an increased rate 
of sphingomyelin synthesis (Perry & Ridgeway 2006). In addition, phosphorylation of 
OSBP at serine240 by protein kinase D impairs the Golgi localisation of collagen type 
IV alpha-3-binding protein (Nhek et al 2010). These data suggest a regulatory role 
for oxysterols in ceramide processing. Interestingly, in some vertebrate species 
collagen type IV alpha-3-binding protein may have a role in embryo development as 
in a zebrafish knockout model it appears to play an anti-apoptotic role and is required 
for normal skeletal muscle and brain growth (Granero-Molto et al 2008).
The proteomics showed that collagen type IV alpha-3-binding protein expression 
increased reproducibly after treatment with 24(5),25-epoxy cholesterol (table 3.10). 
No change was observed after treatment with GW3965 suggesting an LXR 
independent mechanism. The identification of collagen type IV alpha-3-binding 
protein was from multiple peptides and from all biological replicates lending 
confidence that this observation is a true change (table 3.6). The mean increase in 
collagen type IV alpha-3-binding protein expression after 24(5),25-epoxycholesterol 
treatment was 45% more than that of control cell collagen type IV alpha-3-binding 
protein expression.
In order to determine if the increase observed at the protein level was due to increased 
transcription RT-qPCR experiments were performed. The mRNA expression of 
collagen type IV alpha-3-binding protein increased modestly after 24(5),25- 
epoxycholesterol treatment for 24 hours (fig. 4.1). The increase was of a similar 
magnitude to the change in protein expression seen in the proteomics data. And whilst 
this increase was statistically significant the p value was close to the 0.05 limit
(p=0.046). No change was observed in collagen type IV alpha-3-binding protein 
mRNA expression after treatment with GW3965.
4.2.7. 24(5rL25-epoxvcholesterol Effects Caveolin-1 Expression and Localisation
Caveolin-1, a 20-22kDa protein, is a membrane protein that has multiple functions 
including roles in endocytosis and cell signalling (reviewed in Parton & Simons 2007; 
Hansen & Nichols 2010). Caveolin-1 forms hairpin loops protruding from the plasma 
membrane into the cytoplasm by having the C and N termini of the protein anchored 
to the lipid bilayer. Caveolin can oligomerise with itself and these homooligomers 
associate with cholesterol and sphingomyelin in order to form caveolae. Caveolae are 
invaginations in the plasma membrane wall that have many intracellular functions. 
Each caveolae domain has been estimated to contain 100-200 caveolin proteins and 
~10x the number of cholesterol molecules. These hydophobic parts of the membrane 
are termed lipid rafts.
Caveolin-1 was identified in the SILAC proteomic experiments as down regulated 
(table 3.10). Caveolin-1 was identified in all three biological and technical replicates. 
The mean reduction in caveolin-1 protein expression after 24(5), 25-epoxy cholesterol 
treatment was 30% less than that of control cell caveolin-1 expression. Western 
blotting was performed in order to validate this result. Caveolin-1 showed a decrease 
in protein expression after 24 hours when measured by immunoblotting (fig 4.6). 
Densitometry indicates that this observed decrease, when normalised to actin was 
similar to that observed in the proteomic data for both 24(5)25 epoxycholesterol and 
GW3965. Caveolin-1 was reduced by 32% in 24(5),25-epoxycholesterol treated cells 
and 15% in GW3965 treated cells. This was comparable to the observations in the 
proteomic experiments.
It has been reported that caveolin-1 expression is regulated, at least in part, by 
changes in the level of cholesterol (Hailstones et al 1998). Moreover, it appears that 
oxysterols (7-ketocholesterol, 7a-hydroxycholesterol) can influence the transcription 
o f caveolin-1 (Fielding et al 1997). Therefore, to analyse whether the observed 
effects on caveolin-1 expression on SN4741 cells was due to changes in transcription 
RT-qPCR experiments were performed.
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Figure 4.6. Western blotting confirmed the observed down-regulation of caveolin-1 in 
SN4741 cells. lOpM 24(5)25-epoxycholesterol and 1 pM GW3965 decreased the 
expression o f caveolin-1 (lane 2). Results are indicative o f 3 independent 
experiments. Densitometry showed a significant (p<;0.05) decrease in caveolin-1 
expression of 32% after 24(5)25-epoxycholesterol treatment but no significant change 
after GW3965 treatment compared with control (n=3, Student's t-test).
Caveolin-1 expression showed no change at the mRNA level after treatment with 
GW3965 or 24(5),25-epoxycholesterol (fig 4.1). At the protein level 24(5),25- 
epoxycholesterol induced changes in caveolin-1 that was identified in the proteomics 
data (table 3.10) and by Western blotting (fig 4.6). This implies that the effect of 
24(5),25-epoxycholesterol is due to post-translational effects. As mentioned earlier, 
lipid rafts that form the subcellular location of caveolin-1 have an abundance of
cholesterol and are usually found on the plasma membrane. Changes in the 
intracellular cholesterol could potentially affect caveolin-1 by disrupting the 
composition of lipid rafts. This implies that oxysterols could interfere with caveolin-1 
localisation by inhibiting cholesterol synthesis. In order to test this hypothesis 
immunofluorescence confocal microscopy was undertaken in order to observe the 
effect in caveolin-1 localisation that oxysterols induced in SN4741 cells.
SN4741 cells fixed in 4% paraformaldehyde showed predominant plasma membrane 
labelling of caveolin-1 (fig 4.7) Exposure of the SN4741 cells to 24(5),25- 
epoxy cholesterol led to a loss of caveolin-1 from the membrane and a predominantly 
intracellular location. Incubation with lpM  GW3965 did not change the localisation 
pattern observed. GW3965 induces ABCA1 to export cholesterol but does not reduce 
cholesterol synthesis. The experimental approach was performed in serum free 
conditions and therefore this observation might be due to the inability of media to 
accept the exported cholesterol. Whether there would be a different observation in 
vivo is unclear. In addition other oxysterols were tested. Oxysterols with the greatest 
affinity for Insig (Radhakrishnan et al. 2007) and, therefore, the greatest antagonism 
of SREBP2 regulated gene transcription led to a more pronounced change in 
localisation. 245-hydroxycholesterol, 25-hydroxycholesterol and 27- 
hydroxy cholesterol treatment (all at lOpM) resulted in localisation being disrupted 
similarly to 24(5),25-epoxy cholesterol. In comparison, 7a-hydroxy cholesterol and 
19-hydroxy cholesterol, 2 oxysterols that are classed as having intermediate or 
minimal SREBP2 inhibitory effects respectively, showed a negligible effect on the 
distribution of caveolin-1 (fig 4.8).
To analyse if the effects of 24(5),25-epoxy cholesterol, 245-hydroxycholesterol, 25- 
hydroxycholesterol and 27-hydroxycholesterol were due to inhibition of cholesterol 
synthesis, and therefore intracellular cholesterol depletion, SN4741 cells were co­
incubated with lOp-M oxysterol and 250pM cholesterol (fig 4.7; fig 4.8). The 
presence of cholesterol antagonised the changes in caveolin-1 localisation observed 
after oxysterol treatment alone with a normalisation of signal to the plasma 
membrane. This suggests that caveolin-1 localisation is regulated, at least partially, by 
changes in the intracellular cholesterol level. Therefore, these data show that 
24(5),25-epoxycholesterol, and other oxysterols, can induce changes in protein
expression and localisation due to indirect effects either by inducing changes on the 
cellular cholesterol level or by disrupting lipid rafts.
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Figure 4.7. Confocal microscopy performed on paraformaldehyde fixed SN4741 cells. 
Caveolin-1 labelled with monoclonal antibody and using appropriate Alexa 488 
labelled secondary. Vehicle treated control cells (A) has a predominant distribution 
of caveolin-1 on the plasma membrane. Treatment with lpM  GW3965 (B) and lOpM 
24(5),25-epoxycholesterol (C) led to a reduction in signal located on the cell surface 
and to a predominantly internal distribution o f caveolin-1. Co-incubation of lOpM 
24(5),25-epoxycholesterol with 250pM cholesterol resulted in caveolin-1 localisation 
to partially normalise to the plasma membrane (D).
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Figure 4.8. Confocal microscopy performed on paraformaldehyde fixed SN4741 cells. 
Caveolin-1 labelled with monoclonal antibody and using appropriate Alexa 488 
labelled secondary. lOpM 245-hydroxycholesterol (24(S)-OHChol, A), 10pM 25- 
hydroxycholesterol (25-OHChol. C), lOpM 27-hydroxycholesterol (27-OHChol, E) 
led to a reduction in signal located on the cell surface and to a predominantly internal 
distribution of caveolin-1. Co-incubation of lOpM 24S'-hydroxycholesterol, lOpM 25-
hydroxycholesterol, lOpM 27-hydroxycholesterol with 250pM cholesterol resulted in 
caveolin-1 localisation to partially normalise to the plasma membrane (B, D, F). 
lOpM 19-hydroxy cholesterol (19-OHChol, G) and lOpM 7a-hydroxycholesterol 
(7a-OHChol, I) showed no change in signal located on the cell surface. Co­
incubation of lOpM 19-hydroxy cholesterol and 10pM 7a-hydroxycholesterol with 
250pM cholesterol had no effect (H, J).
4.2.8. Changes in miscellaneous proteins
Other proteins, with no apparent link to cholesterol, phospholipids or fatty acids were 
also identified as having a changed expression. 2 proteins that were reproducibly 
observed as being up regulated were Golgi apparatus protein 1 and macrophage 
colony stimulating factor.
4.2.8.1 Golgi sialoglvconrotein MG-160
Golgi sialoglycoprotein MG-160 (ESL1; GLG1; E-selectin ligand 1; Golgi apparatus 
protein 1) is a protein associated with the membrane of the Golgi apparatus though its 
function is unknown (Gonatas et al 1989). It is however, expressed early in embryo 
development of some vertebrate species suggesting a potential role in development. In 
chick embryos Golgi sialoglycoprotein MG-160 has been observed as expressed after 
3 days with high levels in the notochord, neural tube, somites, and cartilage (Stieber et 
al 1995).
The proteomics showed that Golgi sialoglycoprotein MG-160 expression increased 
reproducibly after treatment with 24(5),25-epoxycholesterol (table 3.10). No change 
was observed after treatment with GW3965 suggesting an LXR independent 
mechanism. The mean increase in Golgi sialoglycoprotein MG-160 expression after 
24(5),25-epoxycholesterol treatment was 36% more than that of control cells Golgi 
sialoglycoprotein MG-160 protein expression. The identification of Golgi 
sialoglycoprotein MG-160 was from multiple peptides and from all biological 
replicates lending confidence that this observation is a true change. To identify this 
protein at least 3 unique peptides were used whilst the maximum was 22 unique
peptides and thus the large number of peptides identified lends weight to the observed 
changes in protein expression. However, as a note of caution, no further validation 
was undertaken.
4.2.8.2. Increased Expression of Macrophage Colony Stimulating Factor
Macrophage colony stimulating factor (MCSF; Colony stimulating factor 1, CSF-1), 
was identified in the SILAC experiments as up-regulated reproducibly in SN4741 
cells after IOjiM 24(5),25-epoxycholesterol but not lpM  GW3965 (table 3.10). 
MCSF is a a-helical cytokine whose primary role is a inducer of mononuclear cell 
activity by promoting the survival, proliferation and differentiation of monocytes and 
macrophages (Sweet & Hume 2003 for review) and acts through MCSF receptor 
(MCSF-R; c-fms). MCSF deficient mice are macrophage deficient but also suffer 
from osteopetrosis due to a reduction in osteoclast numbers (Yoshida et al 1990; 
Wiktor-Jedrzejczak et al 1990). In addition, MCSF deficient mice are infertile 
suggesting a role in reproduction (Pollard et al 1991). The absence of MCSF results 
in mental retardation due to abnormal brain development (Michaelson et al 1996). 
Thus, MCSF is essential for healthy development.
SN4741 cells are a neuronal cell line and therefore due to the implication of 
oxysterols in brain development the observed proteomic change in MCSF expression 
warranted further analysis. MCSF was identified in all three biological replicates and 
5 of the 6  technical replicates. The mean increase in MCSF protein expression after 
24(5),25-epoxycholesterol treatment was -34%  more than that of control cell MCSF 
expression (table 3.10). However, the change in the proteomic data was unable to be 
validated by Western blotting the same lysates (fig 4.9). Immunoblotting of SN4741 
whole cell lysates showed no change in the level of MCSF after lOpM 24(5),25- 
epoxycholesterol or lpM  GW3965 treatment. Densitometry indicates that neither 
treatment had an effect on the observed level of MCSF.
Figure 4.9. Western blotting o f SN4741 lysates probing for MCSF. No significant 
change was observed in MCSF protein expression by Western blotting compared with 
control after treatment with lOpM 24(S'),25-epoxycholesterol or lpM  GW3965 (n=3, 
Student’s t-test).
To determine if the observed change in the proteomic data resulted from an increase 
to the transcription of the MCSF gene qRT-PCR was performed. The transcription of 
MCSF was not increased in the presence of GW3965, 7a-hydroxycholesterol and 7(3- 
hydroxycholesterol. In contradiction a modest, but significant, increase was observed 
after treatment with 24(5),25-epoxycholesterol, 24(S)-hydroxycholesterol, and 25-
hydroxycholesterol (fig 4.10). 24(5),25-epoxycholesterol, 24(S)-hydroxycholesterol 
and 25-hydroxycholesterol led to a ~1.5 fold increase in the mRNA level after 24 
hours of treatment. The oxysterols that caused an increase in MCSF were oxygenated 
on the side chain and natural efficacious ligands for LXR. However, as GW3965 did 
not induce any change in the mRNA level o f MSCF it can be inferred that the 
mechanism of action is not through LXR.
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Figure 4.10. qPCR showing mean fold change in MCSF expression in SN4741 cells. 
Treatment with sidechain oxygenated oxysterols resulted in a modest but statistically 
significant increase in MSCF expression after 24 hours in an apparently LXR 
independent mechanism as lpM  GW3965 treatment did not result in an observable 
change in expression. lOpM 2 4 (5 ),25 -epoxycho lestero l, lOpM 2 4 (5 )- 
hydroxycholesterol and lOpM 25-hydroxycholesterol increased expression of MCSF 
~1.5fold. Ring oxygenated oxystero ls (7a-hydroxycho lestero l or 7(3- 
hydroxycholesterol) did not significantly change the expression of MCSF. Compared 
with control, n=3, * p<0.05. Student’s t-test; ** p<0.01, Student’s t-test.
In order to determine if the increased expression of MCSF observed at the protein 
level in the SILAC proteomic data and at the mRNA level in the qPCR data resulted 
in an increased secretion from SN4741 cells an enzyme linked immunosorbant assay 
(ELISA) was performed (fig 4.11). The ELISA allowed the detection of MCSF in the 
cell culture medium of SN4741 cells treated with vehicle, lpM  GW3965 or 10pM 
oxysterol (2 4 (5 ),2 5 -ep o x y ch o les te ro l, 2 4 (5 )-h y d ro x y c h o le s te ro l, 25-
hydroxycholesterol. 7a-hydroxycholesterol, 7 |3-hydroxycholesterol). The 
concentration of the internal control, supplied as part of the kit, calculated by standard 
curve fell into the acceptable limits for the assay. MCSF secretion was detected at low 
levels in SN4741 cells with the concentration in the cell culture media o f ~70pg/ml. 
No differences were observed in the secreted MCSF level between different treatment 
groups (ANOVA p>0.05).
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Figure 4.11. ELISA assay of secreted MCSF concentration in SN4741 cell 
supernatant. No significant difference in MCSF secretion was observed with lpM  
GW3965 or IOjiM oxysterol treatment (n=3, ANOVA).
4.2.9. Increased MCSF mRNA expression in THP1 human monocytes.
As mentioned earlier (section 4.2.8.2) MCSF is a cytokine and its biological role 
includes the inducement of monocytes to differentiate to macrophages. Therefore, 
following the data from the SN4741 cells that MCSF was modestly up-regulated after 
oxysterol treatment, experiments were undertaken in THP1 human monocytes in 
order to determine the effect, if any, oxysterols were inducing.
In THP1 monocytes there was a large response to oxysterols at the mRNA level (fig 
4.12). All oxysterol treatments (24(5),25-epoxycholesterol, 24(5)-hydroxycholesterol, 
25-hydroxycholesterol, 7a-hydroxycholesterol, 7(3-hydroxycholesterol) resulted in an 
up-regulation in MCSF expression. The greatest response, with a 35 mean fold change 
compared with control was 25-hydroxycholesterol. The other oxysterols tested 
(24(5),25-epoxycholesterol, 24(5)-hydroxycholesterol, 7a-hydroxycholesterol, 7(3- 
hydroxycholesterol) gave a reduced but still significant response. These oxysterols 
gave a varied response with 7a-hydroxycholesterol < 24(5),25-epoxycholesterol < 
24(5)-hydroxycholesterol < 713-hydroxy cholesterol < 25-hydroxycholesterol. 
Interestingly, there was no change with GW3965 suggesting an LXR independent 
mechanism. This is supported by the data that shows that 7a-hydroxycholesterol, an 
oxysterol classed as a poor activator of LXRa and LXR(3 (Janowski et al. 1999), is 
inducing changes in MCSF expression.
Figure 4.12. qPCR showing mean fold change in MCSF expression in THP1 
monocytes. Treatment with sidechain oxygenated oxysterols resulted in a significant 
increase in MCSF expression. 25-hydroxycholesterol treatment resulted in the greatest 
observed change after 24 hours in an apparently LXR independent mechanism as 
lpM  GW3965 treatment did not result in an observable change in expression c.f. 
control. lOpM 24(S),25-epoxycholesterol, lOpM 24(S)-hydroxycholesterol (p<0.05, 
Student's t-test) and lOpM 25-hydroxycholesterol (p<0.01, Student’s t-test) increased 
MCSF expression. Unlike in SN4741 cells the cholesterol ring oxygenated oxysterols 
7a-hydroxycholesterol and 7|3-hydroxycholesterol also induced significant increases 
in MCSF gene expression. Compared with control, n=3, * p<0.05, Student’s t-test; ** 
p<0.01, Student’s t-test, ***p<0.001, Student’s t-test.
In order to determine if the observed increase in MCSF mRNA was coupled with an 
increase at the protein level immunoblotting was performed. Western blotting was 
performed using anti-MCSF primary antibody supplied with a MCSF ELISA kit for 
detection was used to probe for MCSF. The antibody is directly linked to horseradish 
peroxidase and therefore required no secondary antibody before detection using 
chemiluminescence. Western blotting o f whole cell lysates did not identify a 
difference in the level of MCSF in THP1 monocytes after 24 hour treatment with
GW3965, 24(.S,),25-epoxycholesterol or 25-hydroxycholesterol (figure 4.13). Thus, 
the significant increase observed at the mRNA level appears not to be reproduced post 
translationally at the protein level.
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Figure 4.13. Western blot showing no change in MCSF protein expression in THP1 
monocytes. No increase was observed in MCSF expression after treatment with lpM  
GW3965, lOpM 24(1Sr),25-epoxycholesterol or lOpM 25-hydroxycholesterol for 24 
hours (n=l).
As shown previously in THP1 monocytes there is a large increase in MCSF mRNA 
expression following oxysterol treatment (fig 4.12) that is not corroborated at the 
protein level (fig. 4.13). It is possible, though unlikely, that no change in MCSF 
protein was due to increased secretion from the cells of newly synthesised protein. 
Thus, creating a situation whereby protein synthesis is increased but impossible to 
detect by examination of whole cell lysate due to the protein being secreted leading to 
no net change. Therefore, an enzyme linked immunosorbant assay (ELISA) was 
performed. The ELISA assay was performed on cell culture media taken from human 
THP1 monocytes treated with vehicle, GW3965, or various oxysterols (24(*S),25- 
epoxycholesterol, 24(S )-hydroxycholestero l, 25-hydroxycholestero l, 7 a -  
hydroxycholesterol, 7|3-hydroxycholesterol; fig 4.14). This assay was performed in 
order to determine if the significant up-regulation of MCSF expression observed at
the mRNA level corresponded to an increase in secretion of MCSF. The MCSF 
concentration for all treatments, when quantified with a standard curve, fell below the 
concentration of the lowest concentration standard (78.125pg/ml) and therefore from 
these data it appears that oxysterol treatment alone does not directly stimulate MCSF 
secretion in THP1 cells.
Figure 4.14. ELISA assay of secreted MCSF concentration in THP1 cell supernatant. 
All treatments were below the concentration of the most dilute MCSF standard. Thus, 
THP1 monocytes appear not secrete MCSF in the presence of oxysterols.
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4.3. Discussion
SREBPlc is the main transcription factor responsible for the regulation of fatty acid 
synthesis. The transcription of SREBPlc is induced by LXRa, however the 
processing of SREBPlc is inhibited by Insig binding. As oxysterols mediate both 
LXRa activation and Insig inhibition there is a balance between the two opposing 
effects. In some cases, such as SREBPlc regulated genes acetyl-CoA carboxylase 1 
and fatty acid synthase the net effect after 24(5),25-epoxycholesterol is no change at 
the protein level whilst GW3965 increased the expression of these genes due to the 
lack of the Insig inhibitory effect. However, for other genes also regulated by 
SREBPlc, such as fatty acid desaturase 2 (table 3.10), it appears that the binding of 
Insig overcome the effect of increased SREBP1 causing a reduction in gene 
expression after treatment with 24(5),25-epoxycholesterol. These effects may be cell 
type specific as the SREBPlc induction is due to LXRa whose expression varies 
between different tissues.
The nuclear receptor LXRp, for which oxysterols are the natural ligand, was 
identified as up-regulated after treatment with both 24(5),25-epoxy cholesterol and the 
synthetic ligand GW3965 suggesting a LXR dependent mechanism. It is interesting 
that LXRp was not increased at the mRNA level (fig 4.1), i.e. that transcription was 
not increased, as there is some evidence that the binding of ligand to LXRP prevents 
degradation of the nuclear receptor (Kim et al 2009). Cells were transfected with 
FLAG tagged LXRp and, after cycloheximide treatment to prevent new protein 
synthesis, the degradation of the protein was measured. The binding of ligand to 
LXRp slowed the degradation of LXRp. Therefore, we hypothesise that the increase 
at the proteomic level is due to a decrease in degradation of LXRp but with no 
decrease in protein production. These data are the first to show that ligand binding can 
increase the level of endogenous LXRp protein.
It appears that the presence of 24(5),25-epoxycholesterol has differential effects on 
members of the StAR-related lipid transfer protein family of transporters. StAR- 
related lipid transfer protein 4 (Stard4) is regulated by SREBP2 and transports 
cholesterol (Soccio et al 2005). At both the protein and mRNA level Stard4 is down- 
regulated after 24(5),25-epoxycholesterol treatment (table 3.10; fig. 4.1).
Interestingly, the converse is true of Collagen type IV alpha-3-binding protein 
(col4a3bp; StAR-related lipid transfer protein 11, Stardll). At both the protein and 
mRNA level Collagen type IV alpha-3-binding protein is up-regulated after 24(5),25- 
epoxycholesterol treatment (table 3.10; fig. 4.1). Collagen type IV alpha-3-binding 
protein transports ceramide from the endoplasmic reticulum to the Golgi apparatus 
where it is synthesised to sphingomyelin. Interestingly, an LXR responsive gene, 
ABCG1, exports both cholesterol and sphingomyelin (Kennedy et al 2001; Sabol et 
al 2005; Sano et al 2007). Therefore, the increase in Collagen type IV alpha-3- 
binding protein might be a homeostatic feedback to prevent reduced levels of 
sphingomyelin by increasing the rate of synthesis of the phospholipid. Indeed, this 
hypothesis fits the observation that the presence of 25-hydroxycholesterol promotes 
activation of Collagen type IV alpha-3-binding protein mediated transfer of ceramide 
to the Golgi apparatus and, therefore, an increased rate of sphingomyelin synthesis 
(Perry & Ridgeway 2006).
It appears that oxysterols have multiple roles in membrane homeostasis. It has been 
shown that the enzyme phosphoethanolamine cytidylyltransferase (PCyt2) that is 
required for phosphoethanolamine synthesis is down-regulated after 24(5),25- 
epoxycholesterol treatment. During the period where this work was undertaken it has 
been independently reported in the literature that PCyt2 is regulated by SREBP2 and, 
therefore, oxysterols in mouse NIH3T3 fibroblasts (Ando et al 2010). Therefore, 
these data presented here corroborates the previously reported data generated from a 
different cell type and shows that 24(5),25-epoxycholesterol regulates PCyt2 in 
SN4741 neurons by modulating SREBP induced transcription. However, another 
enzyme previously reported to be regulated by SREBP2, phosphocholine 
cytidylyltransferase (Pcytl) was identified in the proteomics data as having no change 
in expression (table 3.10.; Kast et al 2001).
The expression and localisation of the membrane protein caveolin-1 appears to be 
influenced indirectly by 24(5),25-epoxycholesterol. Caveolin-1 was observed as 
down-regulated at the protein level but unchanged at the mRNA level (table 3.10; fig. 
4.1; fig 4.6). Two major components of lipid rafts are caveolin-1 and cholesterol and 
thus we hypothesise that the level of the two are interdependent and that in this case a 
change in the intracellular cholesterol level is responsible for the observation of 
decreased protein expression. This hypothesis is supported by the confocal
microscopy data that demonstrates that oxysterols with a high affinity for Insig affect 
the localisation of caveolin-1 and that this effect can be negated by co-incubating with 
cholesterol (fig 4.7; fig 4.8). This relationship, could potentially explain the 
observation that in apolipoprotein E (ApoE) knockout mice there was an increased 
expression of brain caveolin-1 (Gaudreault et al 2004). As ApoE is a cholesterol 
transporter this implicates a role for cholesterol homeostasis dysregulation in the 
observed up-regulation. An isoform of apolipoprotein E termed ApoE4 has been 
implicated in Alzheimer’s disease. Thus, cholesterol dysregulation may explain the 
increased expression of caveolin-1 observed in the frontal cortex and hippocampus of 
Alzheimer’s disease patients compared with age matched control patients (Gaudreault 
et al 2004).
The SILAC data also identified changes unassociated with lipid metabolism and 
membrane homeostasis. It is interesting that MCSF was identified as increased at the 
protein and mRNA level after oxysterol treatment in SN741 neurons and, at the 
mRNA level, in THP1 monocytes (table 3.10; fig 4.10; fig 4.12). MCSF expression 
appears to be required for normal brain development in mice (Michaelson et al 1996) 
and has been associated with two disease states also associated with oxysterols; 
artherosclerosis and Alzheimer’s disease (section 1.1.6.). In artherosclerosis MCSF 
expression is increased in endothelial cells after treatment with low density 
lipoprotein (Rajavashisth et al 1990). Indeed, in MCSF knockout mice there was a 
marked decrease in artherosclerotic lesions after feeding with an atherogenic diet 
(Qiao et al 1997) and in low density lipoprotein receptor knockout mice 
artherogenesis was significantly reduced after MCSF was knocked out (i.e. double 
knockout LDLR -/-, op/op, Rajavashisth et al. 1998). Therefore, it is possible that the 
oxysterol component of low density lipoprotein is a mediator in this increase of 
MCSF due to the measured induction of MCSF mRNA in monocytes (fig 4.12).
MCSF has been associated with Alzheimer’s disease though its role is unclear. The 
expression of MCSF has been shown to associate with Ap plaques in Alzheimer’s 
patients brains and that in the cerebrospinal fluid of Alzheimer’s patients the level of 
MCSF is elevated ~5-fold compared with control (Du Yan et al. 1997). Also, in a 
mouse model of Alzheimer’s increased expression of MCSF-R has been observed in 
microglia in transgenic AbPPV717F mice suggesting a role for its ligand MCSF
(Murphy et al. 2000). Indeed, in two studies from the same group it appears that 
MCSF is beneficial as knockout MCSF mice (these mice were not an Alzheimer’s 
model) had an increased number of amyloid plaques (Kaku et al. 2003) and injection 
of MCSF to these mice reduced the deposition of Ap (Kawata et al. 2005). However, 
there is contradictory evidence as an independent study did not observe Ap deposits 
in MCSF knockout mice (Kondo et al. 2009). Transgenic mice with the chimeric 
human/mouse Ap precursor protein (APPSwe) gene and the human presenilin 1 gene 
(A246E variant) injected with MCSF had reduced Ap deposits and an increase in the 
number of microglia (Boissonneault et al. 2009). As microglia have been shown to be 
able to clear Ap this increase might be relevant (Majunder et al. 2007). However, the 
benefit of MCSF activated microglia is unclear as there is evidence that they can 
augment toxicity induced by Ap (Li et al. 2004).
The mechanism by which oxysterols increase the expression of MCSF appears to be 
independent of LXR as GW3965 shows no activity whilst ring oxygenated oxysterols 
such as 7P-hydroxycholesterol and 7a-hydroxycholesterol induce significant 
increases in MCSF mRNA in THP1 monocytes. A nuclear receptor that has been 
shown to regulate MCSF expression is PPARy (Bonfield et al. 2008). Similarly to 
LXR, PPARy is a nuclear receptor that requires heterodimerisation with RXR when 
activated. PPARy activation causes a decrease in MCSF expression (Bonfield et al. 
2008). Therefore it appears that PPARy activation has an inverse effect to treatment 
with oxysterols. This leads to the hypothesis that oxysterols can inhibit PPARy 
activity. Indeed, there has been recent evidence to suggest that 25-hydroxycholesterol 
can inhibit PPARy (Xu et al. 2012).
The large (~3 5-fold) up-regulation in MCSF mRNA expression in THP1 cells after 
25-hydroxycholesterol treatment may indicate that this is a part of an immune 
response. A large increase in the enzyme cholesterol-25-hydroxylase and its product 
25-hydroxycholesterol is seen after exposure to lipopolysaccharide (section 1.1.7). 
The role of this increase in 25-hydroxycholesterol is currently unclear. Therefore, part 
o f the response to infection may be to induce MCSF production to promote the 
differentiation of monocytes to macrophages and/or recmit macrophages to the site of 
infection. However, no increase in MCSF was identified in THP1 cells at the protein
level measured either by ELISA or Western blot. Therefore, it is possible that the 
synthesis and secretion of MCSF protein is controlled post-translationally and 
requires a secondary signal in order for the observed increase in mRNA expression to 
be converted to increased protein.
It is important to note that the experiments presented here were only conducted 3 
times and that the low number of replicates may influence the statistical analysis. 
Ideally a sample size greater than 3 would have been used which would increase the 
power of Student’s t-test. Unfortunately, time and financial constraints were in place 
limiting the number of replicates performed. It is however common for biological 
papers, even in high impact ‘good’ journals to combine a sample size of 3 with 
Student’s t-test (e.g. Zelcer et al. 2009).
In summary, the SILAC proteomic approach has identified a large number of proteins 
with confidence in their quantification and identification due to the use of multiple 
peptides. This approach has led to the observation of expected changes such as down 
regulation of the cholesterol synthesis pathway. In addition, a number of the proteins 
observed as having their expression changed were related to the composition of 
cellular membranes. Thus, as 24(5),25-epoxycholesterol is the most abundant 
oxysterol in murine embryonic brain it is likely that it plays a role in embryonic lipid 
homeostasis. Increased expression of LXRp after ligand binding and the LXR 
independent increase in MCSF expression were also observed. Therefore, as 24(5),25- 
epoxycholesterol induces LXRp and MCSF and that these proteins are required for 
normal brain development we hypothesise that the role of this oxysterol is an 
important one for embryonic neurogenesis.
C h a p t e r  5: P h o s p h o p r o t e o m i c  a n a l y s i s  o f  2 4 ( 5 ) , 2 5 -
e p o x y c h o l e s t e r o l  AND 25-HYDROXYCHOLESTEROL t r e a t m e n t  in  
S N 4 7 4 1  c e l l s
5.1. Introduction.
A common post-translational modification of proteins is phosphorylation. It has been 
estimated that around 30% of proteins will at some point during their expression (i.e. 
not simultaneously) be phosphorylated (Larsen et al 2005). Protein phosphorylation 
is important for the transmission of signals within eukaryotic cells and thus, plays an 
important role in the regulation of diverse cellular processes. The reversible addition, 
or subtraction, of a phosphate group to proteins can result in the activation, or 
deactivation, of enzymes due to a conformational shift in their tertiary structure. This 
change can result in an enzyme having its activity restricted by altering the binding 
pocket that recognises the target molecule or by modifying the active site of enzyme 
activity. Serine, threonine and, less commonly, tyrosine amino acids can be 
phosphorylated in eukaryotic organisms. Protein phosphorylation is regulated 
enzymatically; enzymes classed as kinases add a phosphate group to a protein 
whereas a phosphatase does the reverse.
The major role for oxysterols is in cholesterol homeostasis (section 1.1.5). However, 
in addition to their regulatory role oxysterols can affect protein phosphorylation. 
There is evidence to show that oxysterols effect the phosphorylation of extracellular 
signal regulated kinase (ERK1/2) (Yoon et al 2004, Lemaire-Ewing et al 2009). 
Cholesterol stabilises a phosphatase complex containing oxysterol binding protein 
(OSBP) as a scaffold, the serine/threonine phosphatase PP2A and the tyrosine 
phosphatase HePTP that decreases the phosphorylation of ERK 1/2 (Wang et al 
2003, Wang et al 2005). By competing with cholesterol 25-hydroxycholesterol 
causes the disassembling of the phosphatase complex and, therefore, the presence of 
oxysterol up-regulates ERK 1 phosphorylation at the thr202/tyr204 amino acid 
residues and ERK 2 at thrl85/tyrl87. ERK 1/2 is an important signalling molecule 
and a known oncogene. It has roles in a number of different biological functions 
including cell growth, differentiation and apoptosis (Avruch 2007). The up-regulation 
of ERK 1/2 phosphorylation has been shown in a number of different cell lines either
by depletion of cholesterol with cyclodextrin or with treatment with oxysterols (table 
4.1; Furuchi & Anderson 1998, Yoon et al 2004, Agassandian et al 2005, Calleros et 
al 2006, Kim et al 2007, Jin et al 2008, Lemaire-Ewing et al 2009). This effect 
seems to be a feature of oxysterols generally as a number of diverse oxysterols have 
been shown to initiate this effect including 7p-hydroxycholesterol, 2 2 - 
hydroxycholesterol, and 25-hydroxycholesterol.
It is unclear whether treatment with oxysterols only affects ERK 1/2 of the mitogen 
activated protein kinase (MAPK) family as there has been contradictory evidence 
regarding other MAPKs (e.g. JNK) (Ares et al 2000, Yoon et al 2004). In addition, it 
is unclear as to what pathways downstream of ERK 1/2 are up/down-regulated due to 
the activation of ERK1/2. Furthermore, it is possible that phosphorylation on other 
proteins other than MAPKs could be affected by the destabilisation and deactivation 
of the PP2A/HePTP phosphatase complex. It has been demonstrated in the literature 
that oxysterols can cause changes to phosphorylation, however, the full extent and 
significance of these has yet to be assessed (table 5.1).
Table 5.1. Summary of studies analysing effects of oxysterol treatment or 
cyclodextrin cholesterol depletion on ERK phosphorylation. * = No information 
regarding conformation. All changes were demonstrated using Western blotting. 
MpCD= methyl-P-cyclodextrin. HpCD= 2-hydroxypropyl-p-cyclodextrin. OHChol = 
hydroxy cholesterol.
Oxysterol Cell-line Condition Effect on Phospho- 
ERK
Reference
n/a Rat-1 Serum starved 24-40hrs 
2% HpCD lhr 
EGF 50ng/ml (0-10min)
Increase after 3min 
c.f. control.
Furuchi 
& Anderson 
1998
7p-OHChol Human aortic 
smooth 
muscle
5pg/ml 5-20min 
Serum starved 24hrs 
Serum free treatments
Increase after 5min 
c.f. control
Max. response after 
lOmin.
Ares et al. 
2000
n/a Fibroblasts
/Hela
20pM PD98059 for 
10m in then 0.5-2% 
MpCD 15min
Increase with all 
concentrations M0CD 
c.f.control.
Wang et al. 
2003
22(R)-OHChol KMBC 30pM 
Serum starved 24hrs 
Time course
Increase after 2hrs.
No control or total- 
ERK data presented.
Yoon et al. 
2004
22-OHChol * MLE 5-30pM 
Serum free treatments 
Time course
Increase after 15min. 
Persisted for 6hours.
Agassandian 
et al. 2005
25-OHChol NIH3T3 2.5pM 
With serum 
48hours
~2 fold increase
No total-ERK data 
presented.
Calleros et 
al. 2006
n/a HaCaT lOmM M0CD lhr 
Serum starved 24hrs
Increase after 60min 
c.f. control.
Kim et al. 
2007
n/a Normal
human
melanocytes
ImM M0CD 
Time course. 
With serum.
Increase after 6 hours. 
Persisted for 48hours.
No control data 
presented.
Jin et al, 
2008
7p-OHChol
25-OHChol
THP-1 50pM 
Time course. 
With serum.
Max. increase at 
6hours.
7p-OHChol = ~6-fold
25-OHChol = -3-fold.
Lemaire- 
Ewing et al. 
2009
In embryonic mouse brain 24(5),25-epoxycholesterol is present at a concentration 
greater than expected (Wang et al 2009). The role that it plays is unclear it is possible 
that it acts beyond its activity as a ligand for SREBP and LXR and induces changes in 
post-translational modifications such as phosphorylation. Indeed, this is feasible as 
there is, as previously described, evidence that oxysterols can induce changes in ERK 
phosphorylation. Interestingly, previous work has shown a link between ERK activity 
and normal dopaminergic neuronal development. It has been shown that dopamine D2 
receptors in mesenphalic neuronal primary cell cultures activate ERK (Kim et al. 
2006). This in turn activates the transcription factor Nurrl that is important for normal 
dopaminergic neuron development, (Kim et al. 2006). Further work by the same 
group showed that striatal-enriched protein tyrosine phosphatase, a ERK phosphatase, 
also has an effect on normal dopaminergic neuron development (Kim et al. 2008). 
Gene silencing of striatal-enriched protein tyrosine phosphatase using siRNA reduced 
by -25% the number of tyrosine hydroxylase positive mesenphalic neuronal primary 
cells. In addition, another paper, again by the same group, demonstrated that Wnt5a 
protein acted through dopamine D2 receptors to increase the number of tyrosine 
hydroxylase positive cells in mesenphalic neuronal primary cell cultures by -25%  
(Yoon et al. 2011). Wnt5a protein induced ERK phosphorylation that appeared to be 
mediated by EGFR signalling; small molecule inhibition of EGFR abolished the 
effect of Wnt5a on ERK phosphorylation and the increase in tyrosine hydroxylase 
positive neurons. It has also been shown, by an independent group, that ERK has a 
role to play in midbrain dopaminergic neurogenesis (Jaeger et al 2011). In this case it 
appears that small molecule inhibition of ERK phosphorylation, for 2 days, triggers 
the differentiation of stem cells into dopaminergic neurons. However, ERK 
phosphorylation is then required in order to consolidate this effect. To demonstrate 
this, a small molecule MEK inhibitor PD0325901 used continuously for 5 days had no 
effect on Lmxla and Foxa2 (markers of dopaminergic neurogenesis) whereas 2 days 
treatment with PD0325901 followed by 3 days without significantly increased both. 
Thus, it appears that the regulation of ERK is important in normal dopaminergic 
neurogenesis.
Therefore, in order to evaluate changes to protein phosphorylation in SN4741 
neuronal cells after treatment with oxysterols, 25-hydroxycholesterol and 24(5),25-
epoxy cholesterol, a SILAC (section 1.2.3.1.) phosphoproteomic approach was 
employed.
Phosphoproteomics is the analysis of post-translational phosphorylation on a global 
protein level. However, phosphopeptides are difficult to analyze as the higher 
abundance of unmodified peptides leads to low signal intensities and low ionization 
efficiency (Thingholm et al 2009). Therefore, phosphoproteomics relies on the 
enrichment of the phosphopeptides allowing the modified peptide to be observed 
rather than the much more abundant unmodified peptides. A number of 
phosphoenrichment techniques are available that allow the concentration of 
phosphopeptides (section 1.2.4.3.). In the work presented here a strong cation 
exchange fractionation step was used prior to immobilised metal ion affinity 
chromatography (IMAC). IMAC relies on the chelation of positively charged metal 
ions to beads creating a stationary phase that will bind to negatively charged 
phosphopeptides. Therefore, non-phosphorylated peptides will not bind to the metal 
ions and will be present in the initial flow through and phosphopeptides can be eluted 
subsequently and analysed using LC-MS/MS using a multistage activation method 
(section 1.2.2.3.).
Thus, the aim of the work is to investigate the phosphoproteomic changes in SN4741 
cells, a neuronal cell line derived from the substantia nigra of embryonic mice, treated 
with 25-hydroxycholesterol and 24(5),25-epoxycholesterol.
5.2. Results
5.2.1. Effect of 25-hvdroxvcholesterol on ERK Phosphorylation
Initially Western blotting was perform ed exam ining the effect o f 25- 
hydroxycholesterol in Hela cells. This was performed to observe previously reported 
changes in ERK phosphorylation in transfected Hela cells after 25-hydroxycholesterol 
treatment (Wang et al. 2005). An increase in phosphorylated ERK was observed after 
6 hours treatment which persisted until 24 hours (fig. 5.1). This slow onset of action 
suggests a secondary or tertiary effect o f 25-hydroxycholesterol on ERK 
phosphorylation. The phosphoERKl/2 antibody used detects phosphorylation on 
thr202/tyr204 (ERK1) or thrl 85/tyrl 87 (ERK2) when either amino acid residue or 
both are phosphorylated.
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Figure 5.1 25-hydroxycholesterol treatment increases ERK 1/2 phosphorylation in 
Hela cells. IOjiM 25-hydroxycholesterol in serum free media increased ERK 1/2 
phosphorylation over time in Hela cells (20pg lysate loaded) with a corresponding 
decrease in the SREBP2 regulated gene squalene synthase (n=l). No serum starvation 
was performed prior to treatment.
The role o f oxysterols in neuronal development is the area o f interest in this research 
and therefore phosphoproteomic experiments were to be conducted in SN4741 cells 
derived from embryonic murine substantia nigra. SN4741 cells are dissimilar to Hela 
as they are neuronal not epithelial and are derived from mouse instead of human. 
Therefore, after the initial experim ent in Hela cells the effect o f 25-
hydroxy cholesterol on phospho-ERK was examined in SN4741 cells. A number of 
experiments were performed (table 5.2) using different methodologies though these 
experiments proved inconclusive with a number of contradictory observations. 
However, the effect of 25-hydroxycholesterol on phospho-ERK might be cell type or 
species specific and therefore we proceeded with SILAC experiments to examine the 
phosphoproteome as a whole.
Table 5.2. Summary of Western blot experiments analysing effect of 25- 
hydroxycholsterol on SN4741 cell phospho-ERK levels. All treatments performed in 
serum free media. H(3CD=2-hydroxypropyl-(3-cyclodextrin; EGF=epidermal growth 
factor; 25-OHChol=25-hydroxycholesterol.
Treatment Treatment
time
Observed change in ERK 
phosphorylation c.f. control
Serum
starved?
lOpM 25-OHChol 24 hours Down No
lOpM 25- OHChol 24 hours No change No
25 pM 25- OHChol 2 hours No change 24 hours
25 pM 25- OHChol 3 hours Down 24 hours
25pM 25- OHChol 3 hours Up 24 hours
2% HpCD + EGF 2 hours No change 24 hours
2% HPCD + EGF 1 hours No change 24 hours
2% HpCD + EGF 1 hours No change 24 hours
5.2.2. Strong Cation Exchange and IMAC
Strong cation exchange chromatography was used in order to reduce the complexity 
o f  the peptide mixture. The performance of the column was evaluated prior to use as 
shown previously (fig. 3.5). The presence of a phosphate group on 
serine/threonine/tyrosine residues of peptides results in a more anionic molecule. 
Strong cation exchange chromatography separates molecules based on their charge, 
with cationic molecules retained longer so phosphopeptides would elute earlier from 
the column. Therefore, the fraction collection was shortened at the beginning of the 
run when compared with the fractionation conducted for the protein expression
proteomics (fig. 3.6). It can be seen that the largest number of phosphopeptides as a 
percentage of the total number of peptides in the fraction were eluted at the beginning 
of the strong cation exchange run in both biological replicates (fig. 5.2; fig. 5.3).
In early fractions the majority of peptides eluted are phosphorylated (e.g. fractions 5 
and 3 respectively for the 2 biological replicates). In addition, a large number of 
phosphopeptides eluted in the middle of the run. It can be seen that this is the time 
where the majority of peptides elute from the SCX column and therefore a large 
number of phosphopeptides here is unsurprising. However, as a proportion of the total 
this is much lower than early fractions. In these ‘middle’ fractions a large number of 
non-phosphorylated peptides were observed. The IMAC approach employed for 
phosphopeptide enrichment should, in theory, only bind phosphorylated peptides. 
Therefore, it is likely that the detection of these non-phosphorylated peptides is due to 
non-specific interactions between the IMAC beads and anionic residues.
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Figure 5.2. Strong Cation Exchange chromatography trace of SILAC peptides and 
phosphopeptides from the first biological replicate. A) The UV (X=214nm) 
chromatogram highlights the large number of peptides present on the column. The 
time interval for fraction collection is indicated B) In this example a total of 4513 
unique peptides were identified. Of these 1232 were unique phosphopeptides. 
Phosphopeptides eluted throughout the run but predominantly in early fractions. In 
fraction 5 the majority (84%) were identified as phosphopeptides. In later fractions 
very few phosphopeptides were detectable.
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Figure 5.3. Strong Cation Exchange chromatography trace of SILAC peptides and 
phosphopeptides from the second biological replicate. A) The UV (X=214nm) 
chromatogram highlights the large number of peptides present on the column. The 
time interval for fraction collection is indicated B) In this example a total of 7990 
peptides were identified. O f these 845 were unique phosphopeptides. 
Phosphopeptides eluted throughout the run but predominantly in early fractions. In 
fraction 3 the majority (68%) were identified as phosphopeptides. In later fractions 
very few phosphopeptides were detectable.
5.2,3. C18 Reverse Phase LC-MS/MS of SILAC phosphopeptides
The peptide mixture fractions derived from IMAC phosphoenrichment were dried 
under vacuum and resuspended in H2O/0 .1% formic acid to be analysed by LC- 
MS/MS. In order to test the performance of the reverse phase C18 column 
performance prior to running the SN4741 derived SILAC samples trypsin digested 
bovine serum albumin (lOOfmol; BSA) was used. This allowed validation of both 
chromatography and mass spectrometry performance. In order to ensure the complete 
removal of the BSA peptides prior to running the SILAC SN4741 phosphopeptide 
samples a blank run was performed injecting 80% acetonitrile.
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Figure 5.4. Reverse Phase LC-MS/MS SILAC phosphopeptide separation. An 
example chromatogram (fraction 5 o f 1st biological replicate; fig. 5.2) is shown that 
exemplifies the fact that phosphopeptides co-eluting from the strong cation exchange 
chromatography step can be separated by Cl 8 reverse phase chromatography.
SILAC phosphopeptides were injected on to the HPLC system and separated over a 2 
hour gradient. It can be seen from the example in figure 5.4 that a fraction obtained 
from strong cation exchange chromatography and subsequently enriched using IMAC 
is still a complex sample but the peptides present can be separated on the Cl 8 column. 
Peptides eluting from the column were then analysed by mass spectrometry. Peaks 
with characteristic features o f peptides were identified by the initial mass 
spectrometry scan and if they conformed to pre-selected criteria were chosen for 
fragmentation (see Materials and Methods section 2.7.11). As previously described 
the initial MS scan is critical to SILAC success as this scan is used for quantification. 
Similarly to spectra observed in total protein these SILAC envelope patterns have a 
triplet motif that was indicative of labelled peptides (see fig 5.5. for example of a 
SILAC triplet). In the analysis of phosphopeptides fragmentation of the peptide is 
critical for the analysis of both the backbone sequence and identification of the 
location of post-translational modification(s). MS2 fragmentation is often insufficient 
to identify both peptide sequence due to extensive neutral loss of the relatively labile
phosphate bond instead of backbone fragmentation. Thus, in MS spectra the 
dominant peak is often the precursor ion with a neutral loss of 98Da or 80Da 
(representing H3PO4 or HPO3 respectively). Therefore multistage activation was 
employed to allow identification of phosphopeptide sequence.
Multistage activation is a pseudo MS3 process. In this process a selected precursor ion 
is selected for fragmentation then subjected to further fragmentation at the m/z where 
the neutral loss ion, in theory, should be. The fragments from both activations are then 
combined into one spectrum which is, in effect, a hybrid of MS and MS spectra. The 
peptide LLHEDLDES(ph)DDDVDEK has a monoisotopic mass of 1965.88Da and 
can be seen as doubly charged ion at 983.9 m/z (3.21 ppm mass error; fig 5.5A) was 
selected for fragmentation. It can be seen that in the multistage activation spectra (fig 
5.5B) that the peptide has been fragmented to yield sequence information. There is no 
dominant neutral loss peak. A number of ions are present that identify phosphorylated 
and neutral loss versions of the same peptide demonstrated by a neutral loss of 98Da 
(fig. 5.5B; fig 5.5C)
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Figure 5.5. Phosphopeptide SILAC MS scan and multistage activation. The doubly 
charged phosphopeptide LLHEDLDES(ph)DDDVDEK is derived from Arf-GAP 
with SH3 domain, ANK repeat and PH domain-containing protein 2. The peptide has 
a monoisotopic mass of 1965.88Da was observed as a doubly charged ion (A). After 
the light SILAC phosphopeptide precursor ion at 983.90 m /z  was selected for 
fragmentation it was analysed using multistage activation. Neutral loss o f the
phosphate group(s) results in a loss of 98Da (B) and therefore multistage activation 
allows the observation of both neutral loss and backbone fragmentation resulting in 
identification of the sequence and phosphorylation site of the peptide (C).
The probability of the correct post-translational modification assignment is given by a 
post-translational modification (PTM) score. This value gives an indication of the 
probability differential between different amino acid residues on the peptide 
backbone. Examples o f ‘good’, ‘moderate’ and ‘poor’ spectra are shown in figure 5.6. 
It can be seen from these spectra that the quality of the multistage activation 
fragmentation spectra is integral to the identification of sequence and phosphorylation 
that can be seen by the Mascot and post-translational modification scores of the 3 
peptides. The Mascot scores are 89.71, 41.39 and 23.91 and the PTM score 341.18, 
124.18 and 94.36 for the ‘good’ ‘moderate’ and ‘poor’ phosphopeptides. The ‘good’ 
spectrum has a large number of strong peaks above the background giving it high 
scores and making it a good spectrum for identification (fig 5.6A) as a large number 
of b and y ions were identified that allows identification of the phosphorylated amino 
acid. A neutral loss of 98 was observed from the y4 to y n  but only on the bi6 and big 
ions indicating the probable location o f the phosphorylation on the 
GHSDSSASESEVSLLS(ph)PVK. It is clear that the ‘poor’ spectrum (fig 5.6C) has a 
lower peak intensity c.f. background that limits the reliability of the spectra for 
identification of b and y ions which is reflected in its lower scores.
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Figure 5.6. Phosphopeptide SILAC multistage activation MS/MS spectra. A) a ‘good’ 
spectra that identified the light SILAC peptide GHSDSSASESEVSLLS(ph)PVK 
from serine/threonine-protein phosphatase 4 regulatory subunit 2 (Mascot score = 
89 .71 ; PTM score  = 3 4 1 .1 8 ; P hospho  s ite  p ro b a b ility  =
GHSDSSASESEVSLLS(l)PVK). B) A ‘moderate’ spectra that identified the light 
SILAC peptide SGAQASSTPLS(ph)PTR from Lamin-A/C (Mascot score = 41.39; 
PTM  s c o r e  = 1 2 4 . 1 8 ;  P h o s p h o  s i t e  p r o b a b i l i t y  = 
SGAQASS(0.006)T(0.062)PLS(0.931 )PTR). C) A ‘poor’ spectra that identified the 
peptide GDLGASSPS(ph)MK from Ahnak protein (Mascot score = 23.91; PTM score 
= 94.36; Phospho site probability = GDLGAS(0.048)S(0.048)PS(0.904)M K.
The PTM score does not, however, give an indication of whether the phosphorylation 
site identification site is unequivocal. It merely gives an indication of the differential 
between other sites on the peptide. For exam ple, the peptide 
AS(ph)EDESDLEDEEEKSQEDTEQK derived from DNA replication licensing 
factor MCM3 was identified with a Mascot score of 96.69, and a high PTM score of 
359.53 due to a large differential between the potential phosphorylation sites on the 
peptide (Phospho scores differentials = AS(0)EDES(0)DLEDEEEKS(- 
104.96)QEDT(-111.59)EQK). However, the correct phosphorylation site cannot be 
identified as by examining the phosphorylation probabilities on the peptide 
AS(0.5)EDES(0.5)DLEDEEEKSQEDTEQK it is not possible to distinguish between 
two serine residues (fig 5.7). These spectra are derived from the same sample and 
precursor ion therefore it is possible that this inability to distinguish is due to a mixed 
population being present. Alternatively, the phosphate group might be transferred 
during tandem MS to a different amino acid residue in the peptide which is a 
phenomenon that has been demonstrated to occur (Palumbo & Reid 2008). This effect 
could be the cause of these observed contradictory phosphorylation site 
identifications. Thus, spectra generated from multistage activation are can be used for 
identification of phosphopeptide sequence and site of post-translational modification 
though caution is required. All the scores and probabilities generated by the bio- 
informatic software need to be taken into account to avoid false identification of 
phosphopeptides.
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Figure 5.7. Phosphopeptide SILAC m ultistage activation scans for the 
phosphopeptide AS(ph)EDESDLEDEEEKSQEDTEQK. The peptide is derived from 
DNA replication licensing factor MCM3. The phosphopeptide was identified with a 
Mascot score of 96.69, and a high PTM score of 359.53. The phosphorylation site 
could not be identified unequivocally as equally probable were the peak assignment 
for the two phosphopeptides A S(ph)ED ESD LED EEEK SQ ED TEQK  (A) and 
ASEDES(ph)DLEDEEEKSQEDTEQK (B).Thus, the phosphorylation probabilities 
on the peptide AS(0.5)EDES(0.5)DLEDEEEKSQEDTEQK.
5.2.4. Phosphopeptide Identifications
Overall in the 2 biological replicates there were 7606 and 13499 peptides (table 5.3.). 
Of these 4513 (59%) and 7990 (59%) unique peptides were identified. However, not 
all of these peptides were identified as phosphorylated. In total 1266 (17% of total) 
and 1383 (10% of total) phosphopeptides were identified. The number of unique 
phosphopeptides was lower with 1232 (27% of total unique peptides) and 845 (11% 
of total unique peptides) identified respectively. The large majority o f the 
phosphopeptides identified were phosphorylated on serine or threonine amino acid 
residues. For the 2 biological replicates <1% of the phosphopeptides identified were 
phosphorylated on tyrosine residues. These data suggest that the phosphoenrichment 
worked despite the obvious fact that a large number of non-modified peptides remain.
Table 5.3. The number of peptides identified in 2 biological replicates. Peptides had a 
mascot score s25 and had a ratio between the SILAC sates generated. Starting 
material refers to the total amount of protein trypsin digested in the biological 
replicate
Replicate 1 2
Starting Material 2mg 4mg
Total peptides 7606 13499
Unique 4513 7990
ST total 1261 1378
ST unique 1227 840
Y total 5 5
Y unique 5 5
A large number of phosphopeptides were identified in each biological replicate. The 
LTQ Orbitrap identified in total 1232 and 845 unique phosphopeptides in terms of 
peptide sequence and phosphorylation site from each biological replicate respectively. 
There was an overlap between samples with 414 unique phosphopeptides with 
identical peptide sequence and phosphorylation site identified (fig. 5.8.). Therefore, a 
total of 1663 unique phosphopeptides were identified in total.
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Figure 5.8. Venn diagram of phosphopeptides identified with unique sequence and 
site of modification. In the 2 biological replicates a total o f 1232 and 845 unique 
phosphopeptides were identified with a Mascot score ^25 and a SILAC ratio 
generated. 414 phosphopeptides were identified in both biological replicates.
5.2.5. Analysis of Phosphopeptides For Novel Phosphorylation Sites
The 414 phosphopeptides identified as being present in both biological replicates 
were examined further to determine if the observed post-translational modifications 
had been previously reported. The bio-informatic software MaxQuant generates data 
tables and one column is labelled 'Known Site'. This column indicates if the site has 
been previously reported to be phosphorylated. O f the 414 phosphopeptides 203 
peptides were identified as phosphorylated on serine, 24 on threonine and 2 on 
tyrosine. Therefore, 185 phosphopeptides were classed as having a previously 
unreported phosphorylation site. In order to determine if any of these phosphorylation 
sites were novel the current canonical sequence and post translational modification 
status of each protein was examined using the protein database Uniprot 
(www.uniprot.oru accessed 02-04-2012). Of the 185 phosphorylation sites 56 were
identified as not currently having experimental evidence to demonstrate
phosphorylation i.e. 129 were listed on Uniprot as having been observed
experimentally (table 5.4).
These 56 phosphopeptides can be split into phosphosites that have been predicted ‘by 
similarity’ (due to similarity with homologous sites on other proteins or species) and 
those that are not listed on Uniprot at present. 10 (of the 56) phosphopeptides gave 
experimental validation of ‘by similarity’ predicted sites whilst 46 peptides gave 
evidence for previously unknown post-translational modifications. The novel nature 
of these phosphorylation sites means that as they have not been elucidated 
experimentally previously it is impossible to validate them using antibodies as none 
are commercially available. However, the probability o f the correct site of 
phosphorylation is calculated by the software and is shown in table 5.5. The majority 
(37/46, 80%), of phosphorylation sites were identified in both biological replicates 
with a probability of ^0.9 indicating there is confidence in the identification of the 
phosphorylation site on these peptides. Indeed, for 13 of the phosphopeptides the 
probability of the phosphorylation site was 1, i.e. unequivocal, in both biological 
replicates. However, there was equivocal data on the phosphorylation site on 9 
phosphopeptides (table 5.5). Therefore, for 37 phosphopeptides there is a high 
confidence in these data due to a high mascot score and phosphorylation site location 
probability
Table 5.4. Phosphopeptides identified in both replicates that are currently listed, on 
Uniprot.org (accessed 02/04/12), as not having experimental evidence to demonstrate 
post-translational modification at these phosphorylation sites. Some sites are listed as 
‘by similarity’ as they have been predicted due to similarity to other sites or species. 
Mascot scores are listed to indicate probability of correct identification.
Gene Sequence and Phosphorylation site Amino
Acid
Position
Site known on 
Uniprot
Mascot Score from 
Replicate
1 2
Map4 AAVGVTGNDITT(ph)PPNK 658 Not listed 52.63 54
Pal AEEEGKGS(ph)QEEAGR 53 Not listed 55.03 51.41
Anln AS(ph)SPVTAATFITENR 292 Not listed 34.63 64.27
Mcphl ASSFYGSAS(ph)PNHLR 273 Not listed 43.29 35.01
Hirip3 AVES(ph)TDEDHQTDLDAK 134 Not listed 36.12 45.56
Flna C(me)GQSAAVAS(ph)PGGSIDSR 16 Not listed 53.4 41.72
Larpl ES(ph)PRPPAAAEAPAGSDGEDGGR 335 By similarity 47.37 46.24
Sntb2 GPAGEAS(ph)ASPPVR 88 Not listed 36.99 38.41
Gtf2fl GTSRPGTPS(ph)AEAASTSSTLR 391 By similarity 43.03 35.53
Kiaa0913 HTGMASIDSSAPETTSDSS(ph)PTLSR 1158 Not listed 39.97 60.26
Tdpl HV SS(ph)PDVTTAQK 119 Not listed 32.78 32.9
Ralbpl IAQEIASLS(ph)KEDVSK 463 By similarity 48.23 52.17
Fzrl INENEKS(ph)PSQNR 72 Not listed 35.33 36.45
Myo9b KETPS(ph)PEMETAAQK 1142 Not listed 36.71 30.67
Spg20 KS(ph)PEQESV STAPQR 126 Not listed 39.11 51.42
Camsap2 LDGES(ph)DKEQFDDDQK 1137 Not listed 42.61 35.62
Speccl LGSSPTS(ph)SC(me)NPTPTK 136 Not listed 31.81 27.02
Rg9mtd2 LGTS(ph)DGEEER 24 Not listed 58.13 25.1
Thumpd2 LLQGS(ph)PEQGEAVTR 172 Not listed 35.55 40.41
Ranbp2 LNSNNSAS(ph)PHR 837 Not listed 40.56 51.76
Ppfibpl LPTKPETS(ph)FEEGDGR 417 Not listed 28.15 30.17
Tp53bpl LPTSEEERS(ph)PAK 1675 By similarity 25.34 25.63
Usp32 LSN S(ph)KENLDTSK 1423 Not listed 28.62 35.16
Zc3hl3 NTEEPSS(ph)PVRK 110 Not listed 32.47 32.42
Phf3 NTVDIVDKPENS(ph)PQR 377 Not listed 50.04 50.63
Filip 11 PAS(ph)PSAPLQDNR 1080 Not listed 59.06 41.67
Irsl PASVDGSPV S(ph)PSTNR 343 By similarity 27.92 42.29
Larpl PATGISQPPTT (ph)PTGQATR 1315 Not listed 48.09 40.79
Chtfl8 PC(me)PAG S(ph)PGN VNR 70 Not listed 43.42 38.29
Gigyf2 PGTPS(ph)DHQPQEATQFER 385 Not listed 64.14 47.33
Bopl PHMS(ph)PASLPGK 11 Not listed 32.9 28.18
Zc3hlla PLSSSSVLQES(ph)PTK 677 Not listed 67.72 34.78
Affl P V GNISH S(ph)PK 140 Not listed 35.66 31.23
Sosl RPESAPAESS(ph)PSK 1153 Not listed 35.23 42.41
Rbmxrt RSTPS(ph)GPVR 165 Not listed 53.29 40.18
Srrm2 RVPS(ph)PTPVPK 2535 Not listed 30.7 47.53
Kiaa0284 S(ph)GRSPEPDPAPPK 840 Not listed 33.59 25.25
Bag3 S(ph)GTPVHC(me)PSPIR 289 Not listed 42.66 40.41
Sqstm 1 S(ph)RLTPTTPESSSTGTEDK 266 By similarity 69.05 74.88
FralOacl S(ph)RSPPSEEASK 248 Not listed 43.14 33.29
Anln SC(me)TKPS(ph)PSK 66 Not listed 29.48 28.03
Birc6 SDS(ph)VTGHTSQK 465 Not listed 25.93 37.29
Srrm2 SESDSSPDS(ph)KPK 1521 Not listed 48.28 35.64
Larp4 SNAVS(ph)PTR 642 By similarity 28.32 25.02
FralOacl SRS(ph)PPSEEASK 250 Not listed 43.14 33.29
Chd8 T(ph)ASPSPLRPDAPVEK 1995 By similarity 25.73 27.58
Api5 TSEDTSS(ph)GSPPKK 462 By similarity 41.21 57.63
Papola TSS(ph)PNKEESPK 648 Not listed 26.95 31.16
Prrc2b TTHASSDGPET(ph)PSK 823 Not listed 25.72 29.61
Phldb2 TTPSLS(ph)PHFSSATMGR 958 By similarity 32.55 48.44
Cbx8 VDDKPSS(ph)PGDSSK 164 Not listed 47.38 33
Hdgfrp2 VMTVTA VTTT ATS(ph)DR 137 Not listed 76.11 51.2
Dnmtl VPALAS(ph)PAGSLPDHVR 15 Not listed 36.18 56.18
Arppl9 VT (ph)SPEKAEE AK 22 Not listed 34.2 28.94
Arppl9 VTS(ph)PEKAEEAK 23 Not listed 34.2 28.94
Anapcl VTS(ph)TPQKPQAEQEENR 901 Not listed 52.09 26.45
Table 5.5. Probabilities of phosphopeptides identified in both replicates that are not 
currently listed, on Uniprot.org (accessed 02/04/12), as not phosphorylated at these 
sites. Underlined phosphopeptides indicate a high probability of correct 
phosphorylation site identification.
Sequence and 
Phosphorylation site
Gene Phosphorylation Site Probabilities
1 2
AAV G VTGNDITT ( dMPPN 
K
Map4 AAVGVTGNDIT(0.07)T(0.93)P
PNK
AAVGVTGNDIT(0.01 )T(0.99)P 
PNK
AEEEGKGSf ohlOEE AGR Pal AEEEGKGS( 1)QEEAGR AEEEGKGS( 1 )QEEAGR
AS(ph)SPVTAATFITENR Anln AS(0.5)S(0.5)PVTAATFITENR AS(0.5)S(0.5)PVTAATFITENR
ASSFYGSASfDhlPNHLR Mcphl ASSFY GS(0.001 )AS(0.999)PNH 
LR
ASSFYGS(0.078)AS(0.922)PNH
LR
AVESfDhlTDEDHOTDLDA
K
Hirip3 AVES(0.994)T(0.006)DEDHQT
DLDAK
AVES(0.997)T(0.003)DEDHQT
DLDAK
C( melGOSAA VASt dMPGG 
SIDSR
Flna CGQSAA VAS( 1 )PGGSIDSR CGQSAA VAS(0.903)PGG 
S(0.097)IDSR
GPAGEAStohlASPPVR Sntb2 GPAGEAS(0.994)AS(0.006)PPV
R
GPAGEAS(0.992)AS(0.008)PPV
R
HTGMASIDSSAPETTSDSS
(ph)PTLSR
Kiaa0913 HTGMASIDSSAPETTS(0.001 )D 
S(0.16)S(0.82)PT(0.019)L 
S(0.001)R
HTGMASIDSSAPETTSD 
S(0.007)S(0.993)PT(0.001 )LSR
HVSStphlPDVTTAOK Tdpl HVS(0.044)S(0.956)PDVTTAQ
K
H V S(0.004)S(0.996)PD VTTAQ 
K
INENEKS(ph)PSQNR Fzrl INENEKS(0.961)PS(0.039)QNR INENEKS(0.5)PS(0.5)QNR
KETPSt ohlPEMETAAOK Myo9b K£TPS( 1 )PEMETAAQK KETPS( 1 )PEMETAAQK
KS( dMPEOES V ST APOR Spg20 KS( 1)PEQESVSTAPQR KS( 1 )PEQESVSTAPQR
LDGESIdMDKEOFDDDOK Camsap2 LDGES( 1 )DKEQFDDDQK LDGES(1)DKEQFDDDQK
LGSSPTS(ph)SC(me)NPTP
TK
Speccl LGS(0.014)S(0.098)PT(0.098) 
S(0.771 )S(0.014)CNPT(0.002)PT 
(0.002)K
LGS(0.019)S(0.025)PT(0.106) 
S(0.712)S(0.106)CNPT(0.025)P 
T(0.006)K
LGTSt dMDGEEER Rg9mtd2 LGTS( 1 )DGEEER LGTS( 1 )DGEEER
LLOGSfDhlPEOGEAVTR Thumpd2 LLQGS( 1)PEQGEAVTR LLQGS( 1 )PEQGEA VTR
LNSNNSASfohlPHR Ranbp2 LNSNNS(0.005)AS(0.995)PHR LNSNNS(0.002)AS(0.998)PHR
LPTKPETSfohlFEEGDGR Ppfibpl LPTKPET(0.08)S(0.92)FEEGDG
R
LPTKPET(0.068)S(0.932)FEEG
DGR
LSNSf dMKENLDTSK Usp32 LSNS( 1 )KENLDTSK LSNS( 1 )KENLDTSK
NTEEPSSt dMPVRK Zc3hl3 NTEEPS(0.005)S(0.995)PVRK NTEEPS(0.057)S(0.943)PVRK
NT VDIVDKPEN St dMPOR Phf3 NT VDIVDKPEN S( 1 )PQR NTVDI VDKPEN S( 1 )PQR
PAS( DhlPS APLODNR Filip 11 PAS(0.994)PS(0.006)APLQDNR PAS( 1 )PSAPLQDNR
PAT GISOPPTT tDhlPT GOA 
TR
Larpl PATGISQPPT(0.066)T(0.928)PT 
(0.005)GQATR
PATGISQPPT(0.001)T(0.908)PT
(0.091)GQATR
PCI me^ PAGSf ohlPGNVNR Chtfl 8 PCPAGS( 1 )PGN VNR PCPAGS( 1 )PGN VNR
PGTPSt DhlDHOPOEATOFE Gigyf2 PGT(0.062)PS(0.938)DHQPQEA PGT(0.084)PS(0.916)DHQPQE
R TQFER ATQFER
PHMS(ph)PASLPGK Bopl PHMS( 1 )PASLPGK PHMS(0.5)PAS(0.5)LPGK
PLSSSSVLOESfohlPTK Zc3hlla PLSSSSVLQES(0.997)P
T(0.003)K
PLSSSSVLQES(0.996)P
T(0.004)K
PVGNISHSfohlPK Affl PVGNISHS(1)PK PVGNISHS(1)PK
RPESAPAESS(ph)PSK Sosl RPESAPAES(0.054)S(0.892)P
S(0.054)K
RPESAPAES(0.084)S(0.915)P 
S(0.001)K
RSTPSf dMGPVR Rbmxrt RSTPS(1)GPVR RST(0.001 )PS(0.999)GPVR
RVPSC dMPTPVPK Srrm2 RVPS( 1 )PTPVPK RVPS( 1 )PTP VPK
S(ph)GRSPEPDPAPPK Kiaa0284 S(0.86)GRS(0.14)PEPDPAPPK S(0.84)GRS(0.16)PEPDPAPPK
S(ph)GTPVHC(me)PSPIR Bag3 S(0.827)GT(0.173 )PVHCPSPIR S(0.827)GT(0.173)PVHCPSPIR
SfohlRSPPSEEASK FralOacl S(0.935)RS(0.065)PPSEEASK S(0.919)RS(0.081 )PPSEEASK
SCfmelTKPSlDhlPSK Anln SCTKPS(1)PSK SCTKPS(1)PSK
SDSfohWTGHTSOK Birc6 S(0.026)DS(0.974)VTGHTSQK S(0.024)DS(0.976)VTGHTSQK
SESDSSPDSIdMKPK Srrm2 SESDSSPDS( 1 )KPK SESDSSPDS( 1 )KPK
SRSfDh)PPSEEASK FralOacl S(0.001 )RS(0.996)PPS(0.003)EE 
ASK
S(0.022)RS(0.975)PPS(0.002)EE
ASK
TSS1 ohlPNKEESPK Papola TSS( 1 )PNKEESPK T(0.002)S(0.007)S(0.991 )PN KE 
ESPK
TTHASSDGPETlohlPSK Prrc2b TTHASS(0.007)DGPET(0.993)P
S(0.001)K
TTHASSDGPET (1 )PSK
VDDKPSSfohlPGDSSK Cbx8 VDDKPS(0.004)S(0.996)PGDSS
K
VDDKPS(0.008)S(0.992)PGDSS
K
VMTVTA VTTT ATSf dMDR Hdgfirp2 VMTVTA VTTT AT(0.003) 
S(0.997)DR
VMTVTA VTTTAT(0.004) 
S(0.996)DR
VP ALA Si nh 1PAGSLPDHV 
R
Dnmtl VPALAS(0.993)P AGS(0.007)LP 
DHVR
VPALAS(0.999)PAGS(0.001 )LP 
DHVR
VTlDhlSPEKAEEAK Arppl9 VT(0.929)S(0.071 )PEKAEEAK VT(0.955)S(0.045)PEKAEEAK
VTSt DhtPEKAEE AK Arppl9 VT(0.045)S(0.955)PEKAEEAK VT(0.045)S(0.955)PEKAEEAK
VTS(ph)TPQKPQAEQEEN
R
Anapcl VT(0.123)S(0.754)T(0.123)PQK 
PQAEQEENR
VT(0.098)S(0.805)T(0.098)PQK
PQAEQEENR
5.2.6. Analysis of Phosphopeptide Motifs
Enzymes classed as kinases carry out phosphorylation of proteins. Kinases recognise 
amino acid sequences on their target that direct the phosphorylation of the site. The 
analysis of previously determined substrates of kinases has led to consensus 
sequences recognised by a given kinase. These amino acid sequences are termed 
motifs. The knowledge of the motif can be utilised to predict phosphorylation sites or 
the kinase responsible for a given phosphorylation. However, by analysing sequence 
alone they do not take into account secondary or tertiary structures present in the 
protein. Thus, the 3 dimensional structure of the protein is critical and caution is 
required if extrapolating kinase activity from amino acid sequence alone (Kennedy & 
Krebs 1991).
Despite this the simplicity of the consensus sequence of the motifs have made them 
useful tools in the study of kinases and prediction of their substrates. For example, in 
the case of ERK (MAPK) the motif required, as a minimum, for kinase activity is a 
serine or threonine residue followed by a proline at the C-terminal side (S/TP). 
However, a proline residue is often found at the -2 position. Thus, the optimum motif 
for ERK2 is PXS/TP, where X is any amino acid residue (Davis 1993).
The site of phosphorylation and its relationship to the amino acid sequence of 
identified phosphopeptides is analysed by the MaxQuant software in order to give a 
predicted kinase. This information is presented as a ‘best m otif. Thus, the analysis of 
probable kinases acting on the phosphopeptides identified might yield information 
regarding the effect of oxysterol treatment on certain enzymes and pathways. From 
the datasets a large number of different kinases were identified as being probable 
enzymes for the phosphorylation sites identified (table 5.6).
Table 5.6. Frequency of phosphopeptide ‘best m otif in each biological replicate.
Biological replicate
Best Motif 1 2
CAMK2 56 45
CDK1 46 37
CDK2 94 71
CHK1/2 19 10
CK1 116 75
CK2 163 68
ERK/MAPK 43 34
FHA KAPP 14 13
GSK3 41 27
NEK6 35 27
PKA 115 69
PKA/AKT 78 52
PKC 1 1
PKD 15 15
Polo box 47 41
WW GroupIV 75 69
Other 56 33
None 218 158
Therefore, in order to examine if  there were any correlation between oxysterol 
treatment and changes in kinase/phosphatase activity the 6 most abundant motifs were 
examined in order to determine if they had a normal distribution when analysed with 
the SILAC ratio. The 6 best motifs analysed were CDK2, CK1, CK2, PKA, 
PKA/AKT, WW GroupIV (fig 5.9.). In addition, ERK/MAPK was analysed. The 
SILAC ratio had a normal distribution when plotted for the phosphopeptides 
identified with each motif. Therefore the data suggest that for peptides with these 
motifs the treatment with 24(5),25-epoxycholsterol are not having an effect on these
kinases. If the oxysterol was inducing changes in the phosphorylation a skewed 
distribution would be apparent.
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Figure 5.9. Distribution of phosphopeptide ‘best m otif with SILAC ratio. Graphs 
indicate the distribution of motifs in the first (A) and second (B) biological replicate. 
Both biological replicates showed a normal distribution of the most abundant ‘best’ 
phospho motifs when plotted against un-normalised SILAC ratio after 24CS),25- 
epoxycholesterol treatment. These data suggest no effect o f the oxysterols on these 
kinases. The median un-normalised SILAC ratio value for total peptides after 
24(5),25-epoxycholesterol treatment was 0.59 and 0.81 respectively for the two 
biological treatments (15.87 percentile = 0.50 and 0.69 respectively, 84.13 percentile 
= 0.66 and 0.95 respectively).
5.2.7. Quantitative Analysis of Chanties in Phosphorylation
As the samples were SILAC labelled this allowed the analysis of quantitative changes 
in the phosphorylation status o f the SN4741 cells upon treatment with 25- 
hydroxycholesterol and 24(5),25-epoxycholesterol. Thus, in order to elucidate
reproducible changes in the phosphoproteome the data sets were examined for
phosphopeptides reproducibly identified by the SILAC labelling as up or down
regulated.
Due to the fact that phosphorylation in signalling pathways is transient and occurs 
without a change in total protein expression individual phosphopeptides were 
analysed instead of the overall protein expression in order to examine the 
phosphorylation state of the SN4741 cells. To this end, peptides common to both 
biological replicates with a Mascot score ^25 and a SILAC ratio were examined for 
reproducible up or down regulation of the phosphopeptides. The un-normalised 
SILAC ratio was used for analysis. The median un-normalised SILAC ratio value 
after 25-hydroxycholesterol treatment (i.e. 25-hydroxycholesterol:control) was 0.66 
and 0.75 respectively for the two biological treatments. The 15.87 percentile figure 
which gives an estimation of the standard deviation gave values of 0.53 and 0.61 for 
the 2 biological replicates. After 24(5),25-epoxycholesterol treatment the median un- 
normalised SILAC ratio value was 0.59 and 0.81 respectively for the 2 biological 
replicates. The 15.87 percentile figure was 0.50 and 0.69 respectively.
Table 5.7. Median SILAC un-normalised ratios for the 2 phosphoproteomic data sets. 
The median un-normalised 25-hydroxycholesterol:control and 24(5),25- 
epoxy cholesterol:control ratios are shown as well as the 15.87 and 84.13 percentile 
ranges for the data.
Ratio 25-OHChol :Control Ratio 245,25-EC :Control
Median 15.87
Percentile
84.13
Percentile
Median 15.87
Percentile
84.13
Percentile
Replicate
1 0.66 0.53 0.77 0.59 0.50 0.66
2 0.75 0.61 0.93 0.81 0.69 0.95
A number of phosphopeptides were identified as being up or down regulated after 
treatment with 25-hydroxycholesterol or 24(5),25-epoxycholesterol. In total 87 unique 
peptides were identified as up-regulated and 65 down-regulated after treatment with 
25-hydroxycholesterol. 101 unique phosphopeptides were identified as up-regulated 
and 68  down-regulated after treatment with 24(5),25-epoxycholesterol (a complete list 
o f all phosphopeptides identified as changed is shown in appendix 3, appendix 4, 
appendix 5 and appendix 6 ). However, a number of these phosphopeptides had 
contradictory data between the 2 datasets. Therefore, these phosphopeptides were 
removed and the remaining peptides are shown below (tables 5.8, 5.9, 5.10, 5.11)
Table 5.8. Phosphopeptides identified as down-regulated after treatment with
24(5),25-epoxycholesterol (24(5),25-EC). Un-normalised SILAC phosphopeptide
ratios are displayed
Mascot Score Ratio Ratio
25-OHChol 24(iS),25-EC
:Control :Control
Replicate 1 2 1 2 1 2
Phosphopeptide Gene IPI
Number
EEVAS(ph)EPEEAASPTTPK Nop56 IPI00318048 48.39 / 0.358 / 0.413 /
SQET(ph)PEKPR Msll IPI00110256 30.08 / 0.650 / 0.408 /
GEGERS(ph)DEENEEK Po!r3g IPI00463147 60.57 / 0.671 / 0.408 /
HS(ph)VTGYGDC(me)AAGAR Jub IPI00453693 35.36 / 0.440 / 0.404 /
GDVS(ph)EDEPSLGR Rnmt IPI00453849 32.67 / 0.598 / 0.400 /
RPMEEDGEEKSPS(ph)K I1G IPI00130591 34.61 / 0.410 / 0.400 /
RIS(ph)GLIYEETR
Histlh4
a IPI00623776 35.15 / 0.267 / 0.400 /
SRLTPT(ph)TPESSSTGTEDK Sqstml IPI00133374 69.05 / 0.392 / 0.398 /
ADS(ph)DSEDKGEESKPK Cbxl IPI00129466 40.05 / 0.347 / 0.393 /
NNVMT(ph )S PNVHL K. Cenpcl IPI00114808 34.17 / 0.284 / 0.390 /
GVQAGNSDT(ph)EGGQPGR Acini 1PI00121136 32.19 / 0.811 / 0.387 /
NGLSQPS(ph)EEEVDIPKPK Ddx21 IP100120691 42.24 / 0.323 / 0.384 /
LPSGSGPASPTT(ph)GSAVDIR Ahnak IPI00553798 65.09 / 0.339 / 0.378 /
GSGEASSDSIDHS(ph)PAK
Suv39h
2 IPI00111417 26.96 / 0.174 / 0.377 /
KTS(ph)LSDSTTSAYPGDAGK
Rab3ga
Pi IPI00749720 39.80 / 0.593 / 0.377 /
GHYEVTGS(ph)DDEAGK Ahnak IPI00553798 58.36 / 0.168 / 0.371 /
S(ph)ESSGNLPS V ADTR Akapl IPI00230591 29.82 / 0.390 / 0.371 /
SNS(ph)FSDER Ahnak IPI00553798 29.85 / 0.154 / 0.366 /
RLS(ph)QSDEDVIR Wdr26 IPI00226275 83.20 29.45 0.399 0.357 0.365 0.414
GGVTGSPEASLSGS(ph)KGDLK Ahnak IPI00553798 43.68 / 0.119 / 0.363 /
LPSDSSASPPLSQT(ph)TPNKDADD
QAR Eya3 IPI00411085 40.03 / 0.518 / 0.348 /
S(ph)PSRPLPEVTDEYK Ssb 1PI00134300 26.42 / 0.551 / 0.346 /
GGVTGSPEAS(ph)ISGSK.GDLK Ahnak IP100553798 43.68 / 0.135 / 0.346 /
AS(ph)AVSPEKAPM(ox)TSK Tcofl IPI00115660 34.02 / 0.345 / 0.346 /
DSVPAS(ph)PGVPAADFPAETEQS
KPSK Top2a IPI00122223 25.31 / 0.116 / 0.342 /
KGDDS(ph)DEEDLC(me)J SNK Stardl3 IPI00857002 57.82 / 0.027 / 0.317 /
S(ph)SPPVEHPAGTSTTDNDVIIR Rail 4 IPI00453820 35.31 / 0.170 / 0.308 /
GDQVSQNGLPAEQGS(ph)PR Sptbnl IPI00319830 58.12 / 0.654 / 0.208 /
SHS(ph)LDDLQGDADVGK Sashl IPI00338954 / 58.75 / 0.525 / 0.538
LESHGSS(ph)EESLQVQEK Vcan IPI00875672 / 42.02 / 0.497 / 0.535
ANTSS(ph)DLEKDDDAYK Ranbp2 IP100337844 / 40.08 / 0.436 / 0.533
MSPNETLFLES(ph)TNK Rragc IPI00468702 / 32.32 / 0.407 / 0.530
AES(ph)PETSAVESTQSTPQK. Pds5b IPI00845638 41.44 63.25 0.594 0.288 0.437 0.520
LEPAPLDSS(ph)PAVSTHEGSK Renbp IPIOO124826 / 31.06 / 0.584 / 0.515
(ac)S(ph)ET APV AQAASTATEKPAA 
AK
Histlhl
a IPI00228616 / 53.02 / 0.439 / 0.514
PQSP VIQ AT AGS(ph)PK Arfgef2 IPIOO 13 7087 / 41.94 / 0.350 / 0.511
VS(ph)PVPSPSQPAR Micall IPIOO116371 / 25.71 / 0.435 / 0.486
IDQGS(ph)HTAGESSTR Tdpl IPI00222253 / 34.56 / 0.416 / 0.476
S(ph)PASTSSVNGTPGSQLSTPR Dclkl IPI00468380 / 43.36 / 0.459 / 0.472
AQGHS(ph)PVNGLLK Ccnl2 IPI00310772 / 25.94 / 0.493 / 0.464
HNS(ph)TTSSTSSGGYR Abil IPI00798483 / 57.32 / 0.536 / 0.443
TASRPEDTPDSPSGPSS(ph)PK Lrrcl6a IPI00474873 / 46.92 / 0.216 / 0.439
AGYTT(ph)DESSSSSLHTTR Fxr2 IPIOO126389 / 38.76 / 0.551 / 0.358
LYNSEESRPYT(ph)NK Crkrs IPI00648022 / 49.10 / 0.205 / 0.338
PQSAS(ph)PAKEEQK Palm IPIOO 129298 / 30.20 / 0.390 / 0.196
Table 5.9. Phosphopeptides identified as up-regulated after treatment with 24(5),25-
epoxycholesterol (24(5),25-EC). Un-normalised SILAC phosphopeptide ratios are
displayed
Mascot Score Ratio
25-OHChol
:Control
Ratio
24(5),25-EC
rControl
Replicate 1 2 1 2 1 2
Phosphopeptide Gene IPI
Number
KDS(ph)ISEDEMVLR Wdtcl IPIOO108450 43.30 / 0.82 / 1.66 /
GGIDNPAIT(ph)SDQEVDDKK
Arhgap
5 IPIOO124298 40.63 / 0.92 / 1.13 /
KQIT(ph)VEELVR Plecl IPI00400215 38.61 / 0.62 / 1.07 /
PTGGLRDS(ph)EAEK Hirip3 IPI00222813 29.49 / 1.03 / 1.06 /
DELADElANSS(ph)GK Myh9 IPIOO 123181 29.65 / 1.17 / 0.97 /
GPEVEGS(ph)PVSEALR Brwdl IPI00654074 37.76 / 0.55 / 0.95 /
LLQDSSS(ph)PVDLAK Ncoa2 IPIOO 116968 29.72 / 1.12 / 0.92 /
IKPDEDLPS(ph)PGSR Gli3 IPIOO123429 42.62 / 0.78 / 0.91 /
IKDPDLT(ph)TPDSK Ckap2 IPI00470092 44.82 / 0.79 / 0.85 /
SEVQAHS(ph)PSR Mtap2 IPI00895965 31.21 / 0.91 / 0.85 /
ADS(ph)PAGLEAAR
Kiaa028
4 IP100380953 35.46 / 0.78 / 0.84 /
GGSS(ph)EELHDSPR Hdgfip2 IPIOO116442 34.55 / 0.74 / 0.81 /
ASS(ph)EDTLNKPGSASSGVAR Speccl IPI00798550 33.64 / 0.89 / 0.80 /
KGS(ph)LDYLK Luzpl IPI00322204 30.67 / 0.71 / 0.80 /
HGPAQAVTGTSVTS(ph)PIK Ccnt2 IPI00654257 47.80 / 0.74 / 0.79 /
NS(ph)PNNISGISNPPGTPR Ssbp3 IPI00341944 51.85 / 0.82 / 0.79 /
KLS(ph)SGDLR Phldbl IPI00330246 30.55 / 0.68 / 0.79 /
RAS(ph)LSDIGFGK Pctk3 IP100111168 49.16 / 0.60 / 0.78 /
IKDPDLTT(ph)PDSK Ckap2 IPI00470092 44.82 / 0.95 / 0.78 /
K.GT (ph)GDC(me)SDEE VDGK Myh9 IPI00123181 49.18 / 0.84 / 0.78 /
SQDAT V S(ph)PGSEQSEK Zc3hcl IPI00465879 50.16 / 0.53 / 0.78 /
GQGT(ph)PPSGPGVGR Wbp7 IPI00857289 27.74 / 0.61 / 0.77 /
QESLKS(ph)PEEEDQQAFR Nes IPI00453692 36.61 / 0.67 / 0.76 /
TQSSS(ph)C(me)EDLPSTTOPK Cask IPI00776341 25.68 / 0.46 / 0.76 /
RFS(ph)M(ox)EDLNK Pctk3 IPI00111168 47.88 / 0.69 / 0.76 /
DDISEIQSLASDHS(ph)GR Tjpl IPIOO135971 31.83 / 0.57 / 0.76 /
C(me)IFMSETQS S(ph)PTK Pias2 IPI00453655 30.79 / 0.47 / 0.75 /
QDVDNAS(ph)LAR Vim IPI00227299 31.40 / 0.72 / 0.75 /
QEFSS(ph)EEMTK Vcaml IP100126834 25.88 / 0.83 / 0.74 /
(ac)SDQEAKPST(ph)EDLGDKK Sumol IPIOO124593 33.58 / 0.78 / 0.73 /
DC(me)AKS(ph)DDEESLTLPEK Nfkbl IPI00719890 52.31 / 0.80 / 0.73 /
PAVVS(ph)PLSLSTEAR Crtcl IPI00469761 43.71 / 0.80 / 0.73 /
YVSGSS(ph)PDLVTR Ptpnl4 IPI00122168 49.84 / 0.73 / 0.73 /
ASPDQNASTHT(ph)PQSSAK Clintl IPI00648186 34.63 / 0.78 / 0.73 /
SSGSLS(ph)PGLETEDPLEAR
Tnkslb
Pi IPI00459443 36.91 / 0.68 / 0.73 /
TASESISNLSEAGS(ph)VK Clipl IPI00857273 31.00 / 0.98 / 0.72 /
AQTPESC(me)GSVT(ph)PER Filip 11 IPI00755058 30.92 / 0.94 / 0.72 /
SAT(ph)LETKPESK Ifngrl IPI00323231 25.38 / 0.64 / 0.72 /
SDEEDRAS(ph)EPK Zc3hl8 IPI00673693 27.94 / 0.79 / 0.72 /
VEESSEIS(ph)PEPK Uspl IPI00330276 40.56 / 0.57 / 0.72 /
S(ph)LEGENHDPLSSWK Nes IPI00453692 45.85 / 0.68 / 0.72 /
MHASSTGSS(ph)C(me)DLSK Cdgap IP100125505 27.19 / 0.54 / 0.72 /
AKT(ph)PVTLK Tmpo IPI00828976 41.32 / 0.58 / 0.72 /
SSS(ph)FGSVSTSSTSSK Snxl6 IPI00331029 / 54.62 / 1.42 / 5.00
SGFGGMSS(ph)PVlR Nupl07 IPI00221767 / 40.37 / 2.57 / 2.07
TEEDRENTQIDDTEPLS(ph)PVSNS
K
Trp53bp
1 IP100229801 / 28.80 / 2.58 / 1.90
SEDRPS(ph)SPQVSVAAVETK
Trp53bp
1 1PI00229801 / 48.56 / 2.07 / 1.70
PAS(ph)PLSGPR
D2Wsu
81e 1PI00224127 / 29.84 / 1.80 / 1.65
GEVAPKET(ph)PKK
Marcksl
1 IPI00281011 / 26.82 / 2.27 / 1.65
TVGNVS(ph)PTAQMVQR Rbm7 1PI00133061 / 28.20 / 1.41 / 1.65
LHSAQLS(ph)PVDETPATQSQLK Mlfl ip 1P100459115 / 36.63 / 1.95 / 1.62
QEGAQENVKNS(ph)PVPR Gmnn IPI00131716 / 30.64 / 2.56 / 1.60
TTS(ph)PDLFESQSLTSASSK Epo2 IPI00336844 / 27.33 / 1.25 / 1.55
AGS(ph)SPTQGAQNEAPR Tcf20 IPI00407458 / 30.95 / 1.46 / 1.51
AS(ph)SHSSQSQGGGSVTK Lmna IPI00620256 / 58.67 / 2.60 / 1.51
C(me)QETESNEEQSIS(ph)PEKR Akapl2 IPIOO 123709 / 85.89 / 1.19 / 1.49
LATSS(ph)PEQSWPSTFK Pml IPI00229072 / 29.49 / 1.18 / 1.43
KQNET ADEAT(ph)TPQAK Nolcl IPI00720058 / 43.74 / 1.50 / 1.42
EIITEEPS(ph)EEEADMPKPK Ddx21 IPIOO120691 / 31.38 / 1.69 / 1.38
AEEDEILNRS(ph)PR Canx IPIOO119618 / 25.35 / 1.51 / 1.35
GPEVTSQGVQTSS(ph)PAC(me)K Atxn2 IPIOO117229 / 25.10 / 1.07 / 1.30
ASGQAFELILS(ph)PR Stmnl IPI00551236 / 30.07 / 0.87 / 1.30
AVGEEQRS(ph)EEPK Akapl2 IPIOO123709 / 31.72 / 1.15 / 1.30
Table 5.10. Phosphopeptides identified as down-regulated after treatment with 25-
hydroxycholesterol (25-OHChol). Un-normalised SILAC phosphopeptide ratios are
displayed
Mascot Score Ratio Ratio
25-OHChol 24(S),25-EC
:Control rControl
Replicate 1 2 1 2 1 2
Phosphopeptide Gene IPI
Number
SPDEATAADQES(ph)EDDLSASR Farpl IPI00356904 26.44 / 0.349 / 0.465 /
TEEVLSPDGSPSKS(ph)PSK Add3 IPI00387580 38.11 / 0.349 / 0.439 /
ADS(ph)DSEDKGEESKPK Cbxl IPIOO129466 40.05 / 0.347 / 0.393 /
EELEQQT(ph)DGDC(me)DEEDDDK
DGEVPK Sec62 IPI00134398 57.28 / 0.346 / 0.532 /
EDAPPEDKES(ph)ESEAK Cds2 IPI00468999 26.03 / 0.346 / 0.594 /
ERQES(ph)ESEQELVNK Pdcdll IPI00551454 39.77 / 0.345 / 0.560 /
AS(ph)AVSPEKAPM(ox)TSK Tcofl IPI00115660 34.02 / 0.345 / 0.346 /
ADS(ph)DSEDKGEESKPK Cbxl IPIOO129466 40.05 / 0.344 / 0.451 /
LPSGSGPASPTT(ph)GSAVDIR Ahnak IPI00553798 65.09 / 0.339 / 0.378 /
IGPLGLS(ph)PK Rpll2 IPI00463634 45.65 / 0.333 / 0.426 /
EIITEEPS(ph)EEEADM(ox)PKPK Ddx21 IP100120691 56.99 / 0.330 / 0.443 /
NGLSQPS(ph)EEEADIPKPK Ddx21 IPIOO 120691 36.77 / 0.325 / 0.431 /
NGLSQPS(ph)EEEVDIPKPK Ddx21 IPI00120691 42.24 / 0.323 / 0.384 /
NISEES(ph)PLTHR Pask IPI00400044 32.53 / 0.322 / 0.610 /
S(ph)PAKEPVEQPR Spen IPI00828562 25.27 / 0.321 / 0.464 /
RVSGS(ph)ATPNSEAPR Ddx51 IPI00396728 58.55 / 0.306 / 0.460 /
S(ph)HTGEAAAVR Bcl2113 IPI00321499 35.83 / 0.288 / 0.467 /
NNVMT(ph)SPNVHLK Cenpcl IPIOO114808 34.17 / 0.284 / 0.390 /
RVS(ph)GSATPNSEAPR Ddx51 IPI00396728 58.55 / 0.278 / 0.427 /
YLEIDS(ph)DEESR Sdadl IPI00387439 33.64 / 0.276 / 0.529 /
DDS(ph)GAEDNVDTHQQQAENST
VPTADSR Rspryl IPI00223590 27.35 / 0.275 / 0.445 /
LSQVNGATPVS(ph)PIEPESK.
Mybbpl
a IPI00331361 33.48 / 0.272 / 0.461 /
RIS(ph)GLIYEETR
Histlh4
a IPI00623776 35.15 / 0.267 / 0.400 /
GS(ph)HC(me)SGSGDPAEYNLR Lmna IPI00620256 32.11 / 0.257 / 0.488 /
LSQVNGAT(ph)PVSPIEPESK
Mybbpl
a IPI00331361 33.48 / 0.254 / 0.436 /
SST(ph)PLPTVSSSAENTR Tmpo IPI00896574 55.29 / 0.246 / 0.516 /
SPFNSPSPQDS(ph)PR Nfic IPIOO137501 40.52 / 0.213 / 0.435 /
GSGEASSDSIDHS(ph)PAK
Suv39h
2 IPI00111417 26.96 / 0.174 / 0.377 /
S(ph)SPP VEHPAGTSTTDND VIIR Rail4 IPI00453820 35.31 / 0.170 / 0.308 /
GHYEVTGS(ph)DDEAGK Ahnak IPI00553798 58.36 / 0.168 / 0.371 /
SNS(ph)FSDER Ahnak IPI00553798 29.85 / 0.154 / 0.366 /
GGVTGSPEAS(ph)ISGSKGDLK Ahnak IPI00553798 43.68 / 0.135 / 0.346 /
GGVTGSPEASISGS(ph)KGDLK Ahnak IPI00553798 43.68 / 0.119 / 0.363 /
DSVPAS(ph)PGVPAADFPAETEQS
KPSK Top2a IPIOO122223 25.31 / 0.116 / 0.342 /
SGAAEEDDS(ph)GVEVYYR Pdcdll IPI00551454 41.08 / 0.104 / 0.592 /
KGDDS(ph)DEEDLC(me)ISNK Stardl3 IPI00857002 57.82 / 0.027 / 0.317 /
MSPNETLFLES(ph)TNK Rragc IPI00468702 / 32.32 / 0.407 / 0.530
SPSPSPTS(ph)PGSLR Dclkl IPI00468380 / 51.87 / 0.398 / 0.582
PQSAS(ph)PAKEEQK Palm IPIOO129298 / 30.2 / 0.390 / 0.196
LS(ph)PAYSLGSLTGASPR Phldbl IPI00330246 / 34.03 / 0.369 / 0.573
SGTSTPTTPGSTAITPGT(ph)PPSYS
SR Mtap2 IPI00895463 / 69.16 / 0.360 / 0.661
TASRPEDTPDSPSGPSS(ph)PK Lrrcl6a IPI00474873 / 46.92 / 0.216 / 0.439
LYNSEESRPYT(ph)NK Crkrs IPI00648022 / 49.1 / 0.205 / 0.338
Table 5.11. Phosphopeptides identified as up-regulated after treatment with 25-
hydroxycholesterol (25-OHChol). Un-normalised SILAC phosphopeptide ratios are
displayed
Mascot Score Ratio Ratio
25-OHChol 24(£),25-EC
:Control :Control
Replicate 1 2 1 2 1 2
Phosphopeptide Gene IPI
Number
HGS(ph)DPAFGPSPR Fam83h IPI00227516 28.43 / 1.795 / 0.658 /
DELADEIANSS(ph)GK Myh9 IPI00123181 29.65 / 1.166 / 0.970 /
S(ph)STSGSASSLESGVYR Gtsel IPI00268247 63.04 / 1.152 / 0.614 /
AQT(ph)PESC(me)GSVTPER Filipll IPI00755058 30.92 / 1.120 / 0.637 /
LLQDSSS(ph)PVDLAK Ncoa2 IPIOO 116968 29.72 / 1.118 / 0.919 /
RQS(ph)LTSPDSQSTR Herd IPI00676574 33.46 38.87 1.064 0.991 0.698 0.776
GS(ph)PEDGSHEASPLEGK Rbm20 IPI00849187 51.26 / 1.055 / 0.586 /
PTGGLRDS(ph)EAEK Hirip3 IPI00222813 29.49 / 1.035 / 1.064 /
KLEVS(ph)PGDEQSNVETR Gnl3 IPI00222461 73.45 / 0.988 / 0.431 /
TASESlSNLSEAGS(ph)VK Clipl IPI00857273 31 / 0.975 / 0.725 /
IKDPDLTT (ph)PDSK Ckap2 IPI00470092 44.82 / 0.954 / 0.782 /
AQTPESC(me)GSVT(ph)PER Filipll IPI00755058 30.92 / 0.944 / 0.724 /
GGlDNPAIT(ph)SDQEVDDKK
Arhgap
5 IPIOO 124298 40.63 / 0.924 / 1.125 /
SNS(ph)NSSSVITTEDNK Filipll IPI00755058 77.83 / 0.922 / 0.623 /
SEVQAHS(ph)PSR Mtap2 IPI00895965 31.21 / 0.907 / 0.849 /
TTSTSNPSS(ph)PAPDWYK Atrx IPI00857253 38.08 / 0.892 / 0.604 /
ASS(ph)EDTLNKPGSASSGVAR Speed IPI00798550 33.64 / 0.887 / 0.805 /
YMSSDTT(ph)SPELR Sin3a IPIOO117932 27.09 / 0.883 / 0.580 /
YIASVQGSAPS(ph)PR Ranbp2 IPI00337844 36.79 / 0.875 / 0.596 /
EKEEEETS(ph)PDTSIPR ArhgefS IPI00855144 48.09 / 0.868 / 0.565 /
AS(ph)SHSSQSQGGGSVTK Lmna IPI00620256 / 58.67 / 2.595 / 1.511
TEEDRENTQIDDTEPLS(ph)PVSNS
K
Trp53bp
1 IPI00229801 / 28.8 / 2.576 / 1.904
SGFGGMSS(ph)PVlR Nupl07 IPI00221767 / 40.37 / 2.574 / 2.074
QEGAQENVKNS(ph)PVPR Gmnn IPI00131716 / 30.64 / 2.565 / 1.603
GEVAPKET(ph)PRK
Marcksl
1 IPI00281011 / 26.82 / 2.274 / 1.651
SEDRPS(ph)SPQVSVAAVETK
Trp53bp
1 IPI00229801 / 48.56 / 2.071 / 1.704
LHSAQLS(ph)PVDETPATQSQLK Mlflip IPI00459115 / 36.63 / 1.947 / 1.619
PAS(ph)PLSGPR
D2Wsu
81e IPI00224127 / 29.84 / 1.802 / 1.652
T(ph)SMGGTQQQFVEGVR Ctnnbl IPI00125899 / 48.59 / 1.721 / 1.130
EIITEEPS(ph)EEEADMPKPK Ddx21 IPI00120691 / 31.38 / 1.693 / 1.383
HLFSS(ph)TENLAAR
Rabllfi
Pi IPI00169485 / 39.84 / 1.665 / 1.264
NWTEDIEGGISS(ph)PVK Nfic IPI00137501 / 32.95 / 1.656 / 1.073
TTVYYQS(ph)PLESKPR Atad2 IP100135252 / 41.56 / 1.532 / 1.139
T(ph)GSLQLSSTSIGTSSLK Coblll IPI00762331 / 31.52 / 1.526 / 0.746
AEEDEILNRS(ph)PR Canx IPI00119618 / 25.35 / 1.506 / 1.350
K.QNET ADE AT (ph)TPQ AK Nolcl IPI00720058 / 43.74 / 1.498 / 1.422
SRLTPTTPES(ph)SSTGTEDK Sqstml IPI00133374 / 74.88 / 1.485 / 0.733
IALESVGQPEEQMESGNC(me)S(ph)
GGDDDWTHLSSK Sqstml IPI00133374 / 27.33 / 1.471 / 0.787
AGS(ph)SPTQGAQNEAPR TcQO IPI00407458 / 30.95 / 1.457 / 1.514
KAPLTLAGS(ph)PTPK. Wiz IP100263016 / 39.77 / 1.455 / 1.147
KLDTFQSTS(ph)PK Ddx24 IPI00113576 / 27.61 / 1.453 / 1.063
SRLT(ph)PTTPESSSTGTEDK Sqstml IPI00133374 / 74.88 / 1.435 / 0.821
SSS(ph)FGSVSTSSTSSK Snxl6 1P100331029 / 54.62 / 1.416 / 4.998
TVGNVS(ph)PTAQMVQR Rbm7 IP100133061 / 28.2 / 1.414 / 1.646
SRLTPTT(ph)PESSSTGTEDK Sqstml IPI00133374 / 74.88 / 1.408 / 0.841
TEMDKS(ph)PFNSPSPQDSPR Nfic 1PI00137501 / 35.42 / 1.371 / 1.118
Removal of the phosphopeptides only identified in 1 biological replicate reduced the 
total number of phosphopeptides considerably. In total 2 phosphopeptides were 
identified as changed (1 down-regulated, and 1 up-regulated) in both biological 
replicates after treatment with 25-hydroxycholesterol (table 5.12.). In the case of these 
phosphopeptides they are in the lowest or highest 15.87 percentile range and thus can 
be considered greater than 1 standard deviation away from the median. The median 
ratio after 24(5),25-epoxycholesterol was 0.59 (15.87 percentile = 0.5) and 0.81 
(15.87 percentile = 0.69) for the two biological replicates respectively. Thus, only one 
peptide (RLS(ph)QSDEDVIR) was in the 15.87 percentile range in both biological 
replicates after treatment with 24(5),25-epoxy cholesterol. It is interesting to note that 
the protein from which this phosphopeptide is derived has been associated with 
MAPK signalling (Zhu et al. 2004). There is evidence that MAPK (AKA ERK) 
phosphorylation can be influenced by oxysterols and, in addition, ERK appears to 
have a role in dopaminergic neurogenesis (section 5.1).
Table 5.12. Phosphopeptides identified as having change in expression after treatment 
with 25-hydroxycholesterol (25-OHChol) or 24(5),25-epoxycholesterol (24(5),25- 
EC). All the peptides had a probability of identification of the correct phosphorylation 
site of ^ 0.98. Un-normalised SILAC phosphopeptide ratios are displayed. Values in 
bold were classed as changed
Mascot Score Ratio
25-OHChol
:Control
Ratio
24(S),25-EC
:Control
Replicate 1 2 1 2 1 2
Phosphopeptide Gene IPI Number
RLS(ph)QSDEDVIR Wdr26 IPI00226275 83.2 29.45 0.36 0.36 0.40 0.41
RQS(ph)LTSPDSQSTR Herd IPI00676574 33.46 38.87 1.06 0.99 0.69 0.77.
Both phosphopeptides identified as changed (table 5.12) have no commercially 
available antibodies it was impossible to validate these changes. This inability to 
reproduce the observed changes by a different technique is critical as when analysed 
as a population the ratio of the phosphopeptides that were identified in both biological 
replicates were variable (fig. 5.10). Indeed, in some cases the phosphopeptides 
identified when quantified changed in opposite directions. Points in the upper left 
quadrant of the graph represent phosphopeptides that have increased in one replicate 
and decreased in the other (fig. 5.10). Thus, despite strong evidence to suggest that the 
peptide identification and phosphorylation site is correct without further experimental 
evidence it is difficult to have certainty to the changes in the quantification of the 
phosphorylation.
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Figure 5.10. Poor correlation in peptide ratio between biological replicates. There is 
poor correlation in the ratios of the phosphopeptides common to both biological 
replicates after treatment with 25-hydroxycholesterol. The un-normalised ratio of the 
phosphopeptide (A) has a poor correlation with a number of peptides having opposite 
responses in a number of cases (top left quadrant). The normalised phosphopeptide 
ratios had a similar trend (B). Normalisation occurs in each experiment to take into 
account any error introduced by protein mixing. (C) As a contrast peptide ratios from 
2 biological replicates treated with 24(5'),25-epoxycholesterol and analysed for 
changes in protein expression (Chapter 3) showed a much better correlation in 
normalised peptide ratio between different biological samples.
5.2.8. Peptide Methvlation
In an attempt to increase the specificity of the IMAC by reducing non-specific 
binding peptide methylation was undertaken. To methylate acidic amino acids and the 
C-terminus carboxylic acid peptides were incubated with methanolic hydrochloric 
acid. This methylation would, in theory prevent non-specific binding to the IMAC 
column as the non-phosphate negatively charged acidic moieties are blocked by the 
methyl group. Therefore to examine this method 2.25mg of SILAC SN4741 lysate 
was fractioned using strong cation exchange, treated with methanolic acid, 
phosphoenriched using IMAC and analysed by LC-MS/MS. This resulted in a total of 
4510 peptides (2067 unique) being identified with a total Mascot score ^25 and a 
SILAC ratio generated. 1082 of these 4510 peptides were phosphorylated. In total 609 
unique phosphopeptides were identified. However, when examining peptide 
methylation only 716 of the total peptides were identified with a methylation either on 
an aspartic (D) or glutamic acid (E) residue or on the C-terminus. Of these only 425 
were unique peptides. In addition, often the same peptide was methylated in different 
and/or multiple places. For example the peptide ALAAAGYDVEK from Histone 
H I.2 has 3 potential methylation sites one aspartic acid residue (D), one glutamic acid 
residue (E) and the C-terminus. This peptide was identified with 5 different 
combinations of methylation (table 5.13.). The 5 peptides eluted from the Cl 8 column 
at different rates and therefore the total amount of peptide with the same amino acid 
sequence was split between the different retention times.
Table 5.13. Incomplete methylation increases complexity o f the peptide mixture. In
this example one peptide sequence was identified 5 times with different levels of
methylation
Peptide Sequence Mascot Score Retention Time
ALAAAGYD(me)VE(me)K_(me) 58.27 55.025
ALAAAGYDVE(me)K_(me) 50.81 51.578
ALAAAGYD(me)VEKJme) 34.84 50.173
ALAAAGYD(me)VE(me)K 41.49 52.224
ALAAAGYDVE(me)K 40.82 47.177
However, this dataset did contain some phosphopeptides and these were analysed to 
confirm the novel sites previously observed (table 5.5). Thus, analysis of the 609 
unique phosphopeptides allowed further confirmation of 5 novel phosphorylation sites 
(table 5.14).
Table 5.14. Phosphopeptides with a novel site of phosphorylation identified in 3 
independent experiments.
Sequence and 
Phosphorylation site
Gene Phosphorylation Site Probabilities Mascot Score
ASSFYGSAS(ph)PNHLR Mcphl ASSFYGS(0.007)AS(0.993)PNHLR 43.72
HVSS(ph)PDVTTAQK Tdpl HVS(0.054)S(0.946)PDVTTAQK 30.83
KS(ph)PEQESVSTAPQR Spg20 KS(0.999)PEQES(0.001)VSTAPQR 38.85
MTVDIVDKPEN S(ph)PQR PhD NTVDI VDKPENS( 1 )PQR 58.37
RSTPS(ph)GPVR Rbmxrt RSTPS( 1)GPVR 40.09
5.3. Discussion
The basis of these experiments was to identify changes in phosphorylation induced by 
oxysterols in SN4741 cells. Therefore, in order to elucidate reproducible changes in 
the phosphoproteome the data sets were examined for phosphopeptides reproducibly 
identified by the SILAC labelling as up-or down regulated. A limitation of the study 
was a use of only one time point for the SILAC experiments. As phosphorylation is a 
transient, reversible modification it is possible that some changes induced by 
oxysterol treatment were not observed due to examining the phosphoproteome at the 
‘wrong’ time point.
However, 2 phosphopeptides were identified as having a changed expression after 
treatment with 25-hydroxycholesterol (table 5.12). The peptides identified had good 
Mascot scores and a high probability that the phosphorylation is assigned to the 
correct amino acid. Interestingly, WD repeat-containing protein 26 (Wdr26) which the 
previously reported phosphopeptide RLS(ph)QSDEDVIR (Sweet et a l 2009) is 
derived from has previously been associated with MAPK signalling (Zhu et al 2004); 
a pathway also associated with oxysterols and dopaminergic neurogenesis. This 
phosphopeptide was classed as changed after treatment with 25-hydroxycholesterol or 
24(5),25-epoxycholesterol. However, the independent validation of the observed 
change in these phosphopeptides was unable to be achieved due to the lack of a 
commercially available antibody.
With the lack of validation it is difficult to draw conclusions beyond unequivocal 
identification as in these experiments the reproducibility of the phosphopeptide 
quantification was ambiguous due to the fact that in some cases the same 
phosphopeptide was identified up or down regulated in different biological replicates 
(fig 5.10). Thus, these data throw into doubt the reliability of the very few 
reproducible changes observed after treatment with 25-hydroxycholesterol and 
24(5),25-epoxycholesterol. To a certain extent these results are unsurprising as 
phosphorylation is a transient modification that can react quickly to a broad range of 
stimuli. These data highlight the technical difficulties in identifying reproducible 
changes in the phosphoproteome.
However, with this methodology, utilising strong cation exchange chromatography 
and IMAC phosphoenrichment, a large number of phosphopeptides were identified by 
mass spectrometry in each biological replicate. In the two biological replicates 1232 
and 845 unique phosphopeptides were identified, 27% and 11% of the total unique 
peptides. In total 1663 phosphopeptides were identified with a Mascot score ^25. 
Thus, in 2 biological replicates a proportion of the total phosphopeptides identified 
(414/1663, 24.9%) were observed in both data sets with Mascot scores ^25. The 
reproducible observation of the same phosphopeptide in different biological replicates 
is a major challenge of phosphoproteomics and others have reported similar 
difficulties (Engholm-Keller et al 2012).
Of the 414 phosphopeptides identified in both data sets 56 were identified as not 
currently having experimental evidence to demonstrate phosphorylation. Further 
analysis of these peptides allowed confident identification o f 37 novel 
phosphorylation sites.
These data indicate that strong cation exchange chromatography followed by IMAC 
resulted in phosphopeptide enrichment. However, the number of phosphopeptides 
identified could be improved by improving the methodology. To this end peptide 
methylation was examined as a methodology to reduce the amount of non-specific 
binding to the IMAC column. However, from the data presented here the current 
methodology is unsuitable. The methylation is incomplete as shown by the data that 
only a subsection of the total population (716/4510) were identified as methylated. 
Furthermore, peptides identified as methylated did not react completely (table 5.13). 
Incomplete methylation means that unspecific binding to the column may still occur. 
Indeed, it appears that methylation, in some cases, does not prevent non specific 
binding (table 5.13). In addition the incomplete nature of the methylation may mean 
that some phosphopeptides have more than one retention time for the same sequence. 
This may lead to some of these low abundance, poorly ionisable peptides to not be 
detected at all. Thus methylation in some cases may be counterproductive. Therefore, 
other options to increase the number of phosphopeptide identifications may be 
preferable.
One option is to use another phosphoenrichment method sequentially after IMAC. In 
this case the peptide flow through from the IMAC columns would be subjected to
further stages of phosphoenrichment. Titanium dioxide (TiCb) has previously been 
used for this purpose after IMAC phosphoenrichment and resulted in a greater number 
of peptides identified (Thingholm et al 2008). Another option is to use multiple 
sequential rounds of phosphoenrichment using the same technique. This approach has 
recently been performed using titanium dioxide which resulted in the identification of 
-4000 phosphorylation sites (Sharma et al 2012). Using these approaches could 
increase the number of phosphopeptides identified and increase further the 
identifications common to independent biological replicates.
A second approach to improve the number of phosphopeptides identified might be to 
change the quantification approach. As shown in chapter 3 SILAC is a powerful 
technique for quantitative proteomics. However, in the case of phosphoproteomics 
some of its inherent characteristics might be considered weaknesses. SILAC is reliant 
on the triplet of peaks, seen in the MS scan, that are derived from the same peptide 
sequence but containing isotope labelled arginine or lysine in order to quantify 
peptides and, therefore, proteins. Therefore, this means for each peptide sequence 
there are 3 precursor ions in the spectra. For evaluation of total protein expression this 
is not an issue. However, the low abundance of phosphopeptides, coupled with their 
poor ability to ionise, might mean that due to splitting the total intensity from a given 
phosphopeptide over 3 peaks might result in the peptide being below the detection 
limit. Thus, an isobaric labelling, such as iTraq (section 1.2.3.2) might provide a 
better option for the quantitative analysis of phosphopeptides. iTraq labelling is 
performed on peptides prior to mixing and results in a covalent bond between amine 
groups of peptides and the iTraq reagent. The resultant labelling is isobaric between 
different groups and is only apparent in the MS2 fragmentation spectra where reporter 
ions are used to quantify different treatment groups. Therefore, due to the isobaric 
nature of the iTraq labelling the initial precursor ion, unlike SILAC, is a single peak. 
This fact may increase the number of low intensity phosphopeptides identified whilst 
retaining the ability to quantify changes between different treatment groups.
One option to improve the reliability of the phosphopeptide quantification would be to 
analyse the non-phosphorylated peptide mixture eluted on the IMAC 
phosphoenrichment by LC-MS/MS. Therefore, they could be used in combination 
with the phosphoenriched samples, but processed by LC-MS/MS independently, in
order to normalise the phosphorylation of a given phosphopeptide to total protein 
expression. This can be done automatically by bio-informatic software whilst 
analysing data. This would give a more reliable estimation of the change in 
phosphorylation as the effect of experimental error in protein mixing would be 
adjusted for. By analysing the phosphopeptide alone this normalisation to protein is 
impossible as commonly the phosphopeptide is the only peptide used for 
identification of any protein and thus when normalised to protein results a ratio of 1.
In summary, the phosphoproteomic analysis of SN4741 cells led to the identification 
of a large number of phosphopeptides. Indeed, these data resulted in the identification 
of a number of novel phosphorylation sites in the mouse proteome. The work 
presented here does not investigate the role the identified phosphorylation sites play in 
the cell. It does, however, provide experimental evidence that these post translational 
modifications occur providing a basis for future elucidation. Unfortunately, the 
quantitative phosphoproteomics proved less successful. Phosphorylation is a transient 
and highly responsive post-translational modification and when compared to total 
protein expression that is, relatively, stable the analysis of the phosphoproteome is 
inherently more difficult. Thus, these data indicate the large technical challenge 
involved in quantitative phosphoproteomic studies.
C hapter  6: G eneral  D iscussion
Proteomics as a technology is still in its infancy. The power of this experimental 
approach is to analyse the global effects of treatments on protein expression and post- 
translational modifications. In this case the effect of 24(5),25-epoxycholesterol or 
GW3965 on protein expression and 24(5),25-epoxycholesterol or 25- 
hydroxycholesterol on the phosphoproteome. The data presented here highlight the 
effectiveness of proteomic experimental design in the ability to identify quantifiable 
changes in protein expression is clear. In the experiments analysing protein expression 
thousands of proteins were identified and quantified the majority of which with 2 or 
more peptides. The SILAC approach employed identified expected changes in protein 
expression after treatment with 24(5),25-epoxycholesterol or GW3965. These 
observations in known changes (e.g. the LXR regulated gene ABCA1) lend weight to 
the observed unexpected changes and, in addition, act as a positive control for 
treatment uptake. The SILAC methodology for quantifying protein expression 
changes presented here could easily be applied to any cell type or treatment.
Nevertheless, challenges remain. The selection of a peptide for fragmentation is 
reliant, to a certain extent, on chance as there is no guarantee that a protein of interest 
will be identified. This can be seen in tables 3.5. and 3.6 where a number of proteins 
are not identified in all three biological replicates. This is especially true of proteins of 
interest that are of low abundance as peptides with a weaker signal are at risk of not 
being selected for fragmentation and therefore identified. In addition, as SILAC data 
consists of light, medium and heavy peptides the spectra generated are inherently 
more complex. This could result in fragmentation of the same peptide in different 
SILAC states over a lower abundance unique peptide. In addition, the increased 
complexity might mask lower abundance peptides by having precursor ion peaks from 
other peptides superimposed on them. However, despite these potential limitations the 
SILAC data presented here identified a number of novel 24(5),25-epoxycholesterol 
induced protein changes.
Cholesterol itself is an integral part of cell membranes therefore it is perhaps 
unsurprising that a number of the novel 24(5),25-epoxycholesterol changes observed 
are related to membrane composition. The presence of 24(5),25-epoxycholesterol 
inhibits cholesterol synthesis and therefore may lead to membrane alteration (fig 6.1).
Two proteins involved directly or indirectly in phospholipid synthesis, 
phosphoethanolamine cytidylyltransferase and collagen type IV alpha-3-binding 
protein, were identified as changed after 24(5),2 5-epoxy cholesterol treatment. 
Phosphoethanolamine cytidylyltransferase (PCyt2), a independently reported 
SREBP2 regulated gene identified whilst this work was being conducted (Ando et al 
2010), is required for phosphoethanolamine synthesis and is down-regulated after 
24(5),25-epoxycholesterol treatment (table 3.10). Collagen type IV alpha-3-binding 
protein (col4a3bp; StAR-related lipid transfer protein 11, S tardll) is up-regulated 
after 24(5),25-epoxycholesterol treatment at both the protein and mRNA level (table 
3.10; fig. 4.1). This protein transports ceramide from the endoplasmic reticulum to the 
Golgi apparatus where it is synthesised to sphingomyelin. In addition to the changes 
in the proteins involved in lipid synthesis caveolin-1, the lipid raft component, was 
identified as down-regulated after 24(5),25-epoxycholesterol treatment which based 
on confocal microscopy data appears to be related to changes in cholesterol levels 
(table 3.10; fig 3.17; fig.3.18; fig. 3.19). In order to investigate this hypothesis it could 
be possible to investigate the cholesterol level of 24(5),25-epoxycholesterol treated 
SN4741 cells to see if there is a correlation between cholesterol level and caveolin-1 
expression. Indeed, mass spectrometry could be used to analyse all the components of 
the plasma membrane. Thus, quantification of phospholipids and cholesterol could 
determine the effect of the observed protein changes in relation to membrane lipids.
It is clear that 24(5),25-epoxy cholesterol has an effect on caveolin-1 expression and 
localisation. Further investigations into the effect of 24(5),25-epoxycholesterol on 
protein localisation in SN4741 cells could be conducted using a proteomics approach. 
Subcellular fractionation could be used in order to examine the protein expression in 
certain parts of the cell. Subcellular fractionation allows different components of the 
cell to be isolated and therefore analysed separately. Thus, it could be possible to 
combine subcellular fractionation with, for example, SILAC labelling in order to 
quantify changes to protein distribution after a treatment. This approach would allow 
the identification of changes in membrane protein composition and protein 
translocation (e.g. cytoplasm to nucleus) where the total protein expression remains 
constant.
24(5),25-epoxycholesterol was shown to increase macrophage colony stimulating 
factor (MCSF) in SN4741 cells at both the protein and mRNA level. It is interesting
to note that MCSF is required for normal brain development and that, also, 24(5),25- 
epoxycholesterol is present at higher than expected levels in embryonic mouse brain 
(Michaelson et al. 1996; Wang et al 2009). A role for LXR in ventral midbrain 
development has been demonstrated (Sacchetti et al 2009) however, it is unlikely this 
increase in MCSF expression in SN4741 cells is LXR controlled as, the synthetic 
ligand, GW3965 had no effect. Indeed the ring oxygenated oxysterols 7|3- 
hydroxycholesterol and 7a-hydroxycholesterol, which are considered weak LXR 
agonists, induced significant increases in MCSF mRNA in THP1 monocytes.
The lack of effect after GW3965 implies that a LXR independent mechanism is 
responsible for the observed increase in MCSF expression. Unfortunately, due to time 
restraints it was beyond the scope of this work to examine in detail the mechanism by 
which oxysterols induce this effect. However, a number of possibilities exist through 
which oxysterols could induce this observed effect on MCSF expression. A nuclear 
receptor that has been shown to regulate MCSF expression is PPARy (Bonfield et al 
2008). Similarly to LXR, PPARy is a nuclear receptor that requires heterodimerisation 
with RXR when activated. PPARy activation causes a decrease in MCSF expression 
(Bonfield et al 2008). Therefore it appears that PPARy activation has an inverse 
effect to treatment with oxysterols. This leads to the hypothesis that oxysterols can 
inhibit PPARy activity. Indeed, there has been recent evidence to suggest that this is 
the case with 25-hydroxycholesterol inhibiting PPARy (Xu et a l 2012). It appears 
that PPARy inhibits MCSF expression through repressing NF-kB mediated 
transcription (Bonfield et al 2008). Furthermore, evidence of oxysterols inducing NF- 
kB translocation has recently been reported (Aye et al 2012; Xu et al 2012). Thus, 
one hypothesis is that the observed increase in MCSF expression is due to inhibition 
of PPARy and increased translocation of NF-kB. Another potential mechanism for the 
increase in MCSF expression via NF-kB activation is through ERK signalling. 
Inhibition of ERK can decrease NF-kB activity (Vanden Berghe et al 1998) therefore 
as oxysterols can increase ERK phosphorylation (Yoon et al 2004, Lemaire-Ewing et 
al 2009) it is possible that MCSF expression is increased through this pathway. Thus, 
it is possible that there is a link between the results observed for MCSF at the protein 
and mRNA level and the initial basis for the phosphoproteomic studies presented 
here. Experimental evidence would be required to confirm the pathway through the
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Figure 6.1. The effect of 24(5),25-epoxycholesterol on SN4741 neuronal cells. It is 
hypothesised that 24(5),25-epoxycholesterol induces a number of changes in cell 
membranes through direct (e.g. reducing the synthesis of cholesterol) and indirect 
(e.g. inducing changes in caveolin-1 expression and localisation) mechanisms. In 
addition, LXR independent up-regulation of Golgi sialoglycoprotein MG-160 (ESL1) 
and macrophage colony stimulating factor (MCSF) through an unknown mechanism 
was observed. MCSF has previously been reported to be important in brain 
development (Michaelson et al. 1996) and therefore it is hypothesised that this is an 
important effect of 24(5),25-epoxycholesterol on murine embryonic development.
use of small molecule inhibitors or RNAi in combination with oxysterol treatment. 
This approach would allow dissection of the mechanism by which oxysterols increase 
MCSF expression.
The use of SILAC in phosphoproteomic studies was also, albeit to a lesser extent, 
successful. A large number of phosphopeptides were identified with a Mascot score 
>25 and quantified (fig. 5.8). A number of these phosphopeptides confirmed predicted 
phosphorylation sites that had no previous experimental validation. In addition, a 
number of phosphorylation sites previously unreported on the canonical protein 
database Uniprot were identified (table 5.4; 5.5). The absence of a commercially 
available antibody for these previously unidentified phosphorylation sites means that 
validation is impossible. However, there is confidence in the mass spectrometry data 
and therefore it is probable that the sequence and phosphorylation site identifications 
are correct. The analysis of the function of these novel phosphorylation sites was 
beyond the scope of this work, however, a foundation is laid for future work. The 
identified phosphopeptides, novel and previously reported, can now be predicted as to 
where they will elute from both the strong cation exchange and C l8 HPLC column. 
This allows, if required, a focused approach for a given phosphopeptide.
The identification of reproducible changes in the phosphoproteome proved difficult. 
A number of issues identified in these studies would be able to improve subsequent 
studies. The low abundance of phosphopeptides makes their analysis difficult. In 
addition, a large number of non-phosphorylated peptides were also identified in the 
phosphoenriched samples (table 5.3). Therefore, improvements in phosphoenrichment 
would be beneficial to improve the number of phosphopeptides identified. This would 
also improve the probability of identifying the same phosphopeptide in different 
biological replicates giving a greater overlap of phosphopeptides between different 
samples. This would be beneficial to identify reproducible changes in the 
phosphoproteome. The use of SILAC as a technique might not be ideal for 
phosphoproteomic work due to the characteristic 3 precursor ions in a SILAC peptide 
spectrum splitting the signal from low abundance phosphopeptides. In addition, as 
phosphopeptides are poorly ionisable there is a risk of not detecting phosphopeptides 
present in the sample. The use of an alternate labelling strategy, such as iTraq, could 
help to limit this due to peptides in different groups having the same mass and, thus, 
only distinguishable in the MS/MS spectra. One problem of the phosphoproteomic
methodology is the lack of an internal positive control in a similar vein to the 
SREBP2 regulated genes in the protein expression studies. ERK 1/2, the only 
previously reported protein whose phosphorylation is induced by oxysterols, was not 
identified in any dataset. Therefore, due to the unknown effects of the oxysterols on 
phosphorylation beyond that reported for ERK 1/2 there is a lack of known changes in 
the phosphoproteomic data set to look for as a validation. This makes it difficult to 
analyse quantifiable changes in the data set with confidence. In addition, the observed 
variation between different biological replicates meant that there is doubt in the few 
reproducibly observed changes in SILAC phosphopeptide quantification data without 
further experimental validation.
As a cautionary note it is important to recognise that as the experiments presented 
here were performed in serum free media the observed changes might be increased, 
reduced or absent, in the presence of serum. Serum is a complex mixture that contains 
a large number of components including cholesterol and oxysterols. Serum free media 
for in vitro studies allows the removal of the variability of batch to batch serum 
composition but might not necessarily portray the in vivo situation. However, these 
proteomic and phosphoproteomic studies provide a wealth of data regarding the effect 
of oxysterols on SN4741 neuronal cells and provide a large dataset to inspire further 
work. The role of oxysterols in membrane homeostasis, in subcellular protein 
localisation, and in immunity can be further elucidated and all stem from these data 
presented here. The most exciting discovery is that of a role of oxysterols in MCSF 
expression. This observation ties in with observed relationship between MCSF 
expression and neuronal development, neurodegenerative disease, and immunity. All 
of these are areas with which oxysterols have been associated and therefore their 
relationship with MCSF is an ideal subject for future work.
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Appendix 3. All phosphopeptides identified as down-regulated after treatment with
24(5),25-epoxycholesterol (24(5),25-EC) in ^1 biological replicate. Un-normalised
SILAC phosphopeptide ratios are displayed
Mascot Score Ratio
25-OHChol
:Control
Ratio
24(5),25-EC
:Control
Replicate 1 2 1 2 1 2
Phosphopeptide Gene I PI
Number
EEVAS(ph)EPEEAASPTTPK Nop56 IPI00318048 48.39 / 0.358 / 0.413 /
RVS(ph)QEANLLTLAQK
Cl 3003 
9016Ri 
k IPI00225777 36.98 65.16 0.628 0.889 0.412 0.796
SETAPAAPAAPAPAEKT(ph)PVK
Histlhl
e IPI00223714 53.69 25.47 0.388 0.688 0.409 0.790
HG APAAPS( ph)PPPR
Tbcldl
Ob IPI00469012 43.89 50.35 0.521 0.574 0.408 0.770
SOET(ph)PEKPR Msll IPI00110256 30.08 / 0.650 / 0.408 /
GEGERS(ph)DEENEEK Polr3g IPI00463147 60.57 / 0.671 / 0.408 /
HS( ph) VTG YGDC( me) A AGAR Jub IPI00453693 35.36 / 0.440 / 0.404 /
GDVS(ph)EDEPSLGR Rnmt IPI00453849 32.67 / 0.598 / 0.400 /
RPMEEDGEEKSPS(ph)K n o IPIOO130591 34.61 / 0.410 / 0.400 /
RIS(ph)GLIYEETR
Histlh4
a IPI00623776 35.15 / 0.267 / 0.400 /
SRLTPT(ph)TPESSSTGTEDK Sqstml IPIOO133374 69.05 / 0.392 / 0.398 /
ADS(ph)DSEDKGEESKPK Cbxl IPIOO129466 40.05 / 0.347 / 0.393 /
PMSVAGS(ph)PLSPGPVR Irs2 IPI00379844 61.73 45.92 0.494 0.606 0.392 0.684
NNVMT(ph)SPNVHLK Cenpcl IPI00114808 34.17 / 0.284 / 0.390 /
LPTSEEERS(ph)PAK
Trp53bp
1 IPI0022980I 25.34 25.63 0.217 3.061 0.387 2.082
HLSTPSS V S( ph)PEPODPAK
Arhgefl
2 IPI00754880 46.3 36.63 0.450 0.545 0.387 0.820
GVOAGNSDT(ph)EGGQPGR Acini IPIOO121136 32.19 / 0.811 / 0.387 /
SETLVNAOOTPLGT(ph)PK Palm IPIOO129298 43.67 37.09 0.267 1.074 0.386 1.079
NGLSOPS(ph)EEEVDIPKPK Ddx21 IPIOO120691 42.24 / 0.323 / 0.384 /
LPSGSGPASPTT(ph)GSAVDIR Ahnak IPI00553798 65.09 / 0.339 / 0.378 /
GSGEASSDSIDHS(ph)PAK
Suv39h
2 IPI00111417 26.96 / 0.174 / 0.377 /
KTS(ph)LSDSTTSAYPGDAGK
Rab3ga
Pi IPI00749720 39.8 / 0.593 / 0.377 /
S( ph)NSLPHS A VSNAASK Wdr20a IPIOO153206 26.16 36.48 0.462 0.909 0.376 0.825
GHYEVTGS(ph)DDEAGK Ahnak IPI00553798 58.36 / 0.168 / 0.371 /
S(ph)ESSGNLPSVADTR Akapl IPI00230591 29.82 / 0.390 / 0.371 /
SNS(ph)FSDER Ahnak IPI00553798 29.85 / 0.154 / 0.366 /
RLS(ph)QSDEDVIR Wdr26 1PI00226275 83.2 29.45 0.399 0.357 0.365 0.414
GGVTGSPEASISGS(ph)KGDLK Ahnak IPI00553798 43.68 / 0.119 / 0.363 /
LGSSPTS(ph)SC(me)NPTPTK Speed IPI00798550 31.81 27.02 0.422 0.667 0.363 0.800
ETNVSKEDT(ph)DQEEK Psipl IPIOO115257 37.57 44.98 0.386 0.996 0.362 0.871
LPSDSSASPPLSQT(ph)TPNKDADD
OAR Eya3 IPI00411085 40.03 / 0.518 / 0.348 /
SC ph)PSRPLPE VTDEYK Ssb IPIOO134300 26.42 / 0.551 / 0.346 /
GGVTGSPEAS(ph)ISGSKGDLK Ahnak IPI00553798 43.68 / 0.135 / 0.346 /
GVTASSSS(ph)PASAPK Ncaml IPIOO122971 43.46 34.3 0.244 1.437 0.346 1.195
AS(ph)AVSPEKAPM(ox)TSK Tcofl IPI00115660 34.02 / 0.345 / 0.346 /
SLS(ph)PSHLTEDR Zc3hl3 IPI00515528 44.78 33.98 0.317 0.922 0.344 0.904
DSVPAS(ph)PGVPAADFPAETEQS
KPSK Top2a IPIOO122223 25.31 / 0.116 / 0.342 /
PASVDGSPVS(ph)PSTNR Irsl IPIOO119627 27.92 42.29 0.724 0.494 0.335 0.797
VDS(ph)SSEDGVDAKPDR Casp7 IPIOO 130131 50.6 39.73 0.535 0.540 0.325 0.690
SPAPSNPTLS(ph)PSTPAK
Mybbpl
a IPI00331361 34.8 33.16 0.159 1.852 0.323 1.256
281
KGDDS(ph)DEEDLC(me)ISNK Stardl3 IPI00857002 57.82 / 0.027 / 0.317 /
S(ph)SPPVEHPAGTSTTDNDVIIR Rail 4 IPI00453820 35.31 / 0.170 / 0.308 /
APQS(ph)PTLAPAK Cxadr IPI00270376 25.52 30.84 0.219 1.618 0.291 1.103
GDOVSONGLPAEQGS(ph)PR Sptbnl IPI00319830 58.12 / 0.654 / 0.208 /
SHS(ph)LDDLOGDADVGK Sashl 1PI00338954 / 58.75 / 0.525 / 0.538
LESHGSS(ph)EESLQVQEK Vcan IPI00875672 / 42.02 / 0.497 / 0.535
ANTSS( ph)DLEKDDDAYK Ranbp2 IPI00337844 / 40.08 / 0.436 / 0.533
SLPASGTPOS(ph)PPAVK IPI00851031 49.32 62.59 0.747 0.487 0.582 0.533
MSPNETLFLES(ph)TNK Rragc IPI00468702 / 32.32 / 0.407 / 0.530
TSS(ph)PNK.EESPK Papola 1PI00266738 26.95 31.16 0.825 0.503 0.879 0.530
AES(ph)PETSAVESTQSTPQK Pds5b IPI00845638 41.44 63.25 0.594 0.288 0.437 0.520
LEPAPLDSS(ph)PAVSTHEGSK Renbp IPIOO124826 / 31.06 / 0.584 / 0.515
(ac)S( ph)ET APV AQ AASTATEKPA A 
AK
Histlhl
a IPI00228616 / 53.02 / 0.439 / 0.514
POSPVIOATAGS(ph)PK ArfgeO IPIOO137087 / 41.94 / 0.350 / 0.511
APS(ph)PSQPPK Pds5b IPI00845638 27.46 25.3 0.582 0.410 0.547 0.501
RIS(ph)DPLTSSPGR Mcm2 IPI00323820 80.09 70.35 0.722 0.529 0.584 0.495
VS(ph)PVPSPSOPAR Micall IPIOO116371 / 25.71 / 0.435 / 0.486
IDQGS(ph)HTAGESSTR Tdpl IPI00222253 / 34.56 / 0.416 / 0.476
KPDQT(ph)LDEDDPGAAPLK Bsg IPI00408495 45.13 34.22 0.548 0.543 0.647 0.474
S(ph)PASTSSVNGTPGSQLSTPR Dclkl IPI00468380 / 43.36 / 0.459 / 0.472
KTS(ph)PASLDFPEPOK Znf828 IPI00453800 36.79 46.94 0.541 0.805 0.638 0.471
AOGHS(ph)PVNGLLK Ccnl2 IPI00310772 / 25.94 / 0.493 / 0.464
HNS(ph)TTSSTSSGGYR Abil IPI00798483 / 57.32 / 0.536 / 0.443
TASRPEDTPDSPSGPSS(ph)PK Lrrcl6a IPI00474873 / 46.92 / 0.216 / 0.439
RPDPDS( ph)DEDEDYER Rbml7 IPIOO 170394 64.68 49.04 0.649 0.562 0.562 0.428
AGYTT(ph)DESSSSSLHTTR Fxr2 IPIOO126389 / 38.76 / 0.551 / 0.358
LYNSEESRPYT(ph)NK Crkrs IPI00648022 / 49.1 / 0.205 / 0.338
PQSAS(ph)PAKEEQK Palm IPIOO129298 / 30.2 / 0.390 / 0.196
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Appendix 4. All phosphopeptides identified as up-regulated after treatment with
24(5),25-epoxycholesterol (24(5),25-EC) in ^1 biological replicate. Un-normalised
SILAC phosphopeptide ratios are displayed
Mascot Score Ratio
25-OHChoI
:Control
Ratio
24(5),25-EC
:ControI
Replicate 1 2 1 2 1 2
Phosphopeptide Gene IPI
Number
KDS(ph)ISEDEMVLR Wdtcl IPIOO108450 43.30 / 0.82 / 1.66 /
GGIDNPAIT(ph)SDQEVDDKK
Arhgap
5 IPIOO124298 40.63 / 0.92 / 1.13 /
KQIT(ph)VEELVR Plecl IPI00400215 38.61 / 0.62 / 1.07 /
PTGGLRDS(ph)EAEK Hirip3 IPI00222813 29.49 / 1.03 / 1.06 /
DELADEIANSS(ph)GK Myh9 IPI00123181 29.65 / 1.17 / 0.97 /
GPEVEGS(ph)PVSEALR Brwdl IPI00654074 37.76 / 0.55 / 0.95 /
LLODSSS(ph)PVDLAK Ncoa2 IPIOO116968 29.72 / 1.12 / 0.92 /
IKPDEDLPS(ph)PGSR Gli3 IPIOO123429 42.62 / 0.78 / 0.91 /
TSS(ph)PNKEESPK Papola IPI00266738 26.95 31.16 0.82 0.50 0.88 0.53
IKDPDLT(ph)TPDSK Ckap2 IPI00470092 44.82 / 0.79 / 0.85 /
SEVOAHS(ph)PSR Mtap2 IPI00895965 31.21 / 0.91 / 0.85 /
ADS( ph)PAGLEA AR
Kiaa028
4 IPI00380953 35.46 / 0.78 / 0.84 /
LPS(ph)PAOTOR Micall2 IPI00280103 30.76 33.11 0.87 0.51 0.82 0.88
PATS(ph)TPDLASHR PtpnH IPIOO122168 51.69 67.48 0.57 0.67 0.81 0.73
GGSS(ph)EELHDSPR Hdgfrp2 IPIOO 116442 34.55 / 0.74 / 0.81 /
ASS(ph)EDTLNKPGSASSGVAR Speed IPI00798550 33.64 / 0.89 / 0.80 /
AYT(ph)HQVVTR Cdk7 IPIOO129222 26.40 28.51 0.98 0.31 0.80 0.63
KGS(ph)LDYLK Luzpl IPI00322204 30.67 / 0.71 / 0.80 /
HGPAQ A VTGTS VTS( ph )PIK Ccnt2 IPI00654257 47.80 / 0.74 / 0.79 /
NS(ph )PNNISGISNPPGTPR Ssbp3 1PI00341944 51.85 / 0.82 / 0.79 /
KLS(ph)SGDLR Phldbl IPI00330246 30.55 / 0.68 / 0.79 /
ASSHSSQSQGGGS(ph)VTK Lmna IPI00620256 47.84 58.67 0.54 1.58 0.79 0.90
RAS(ph)LSDIGFGK Pctk3 IPIOO 11U 68 49.16 / 0.60 / 0.78 /
IKDPDLTT(ph)PDSK Ckap2 IPI00470092 44.82 / 0.95 / 0.78 /
S( ph) ASSDTSEELNSODSPK
Slc9a3r
1 IPIOO 109311 78.91 100.99 0.71 0.70 0.78 0.84
KGT(ph)GDC(me)SDEEVDGK Myh9 IPIOO 123181 49.18 / 0.84 / 0.78 /
HVSS(ph)PDVTTAQK Tdpl IPI00222253 32.78 32.90 0.72 0.81 0.78 0.93
SODATVS(ph)PGSEQSEK Zc3hcl IPI00465879 50.16 / 0.53 / 0.78 /
GQGTI ph)PPSGPGVGR Wbp7 IPI00857289 27.74 / 0.61 / 0.77 /
SGALAS(ph)PTDPFOSR Trim47 IPI00480235 32.36 36.30 0.59 0.77 0.77 0.80
OESLKS(ph)PEEEDQOAFR Nes IPI00453692 36.61 / 0.67 / 0.76 /
TQSSS(ph)C(me)EDLPSTTQPK Cask IPI00776341 25.68 / 0.46 / 0.76 /
RAS(ph)LEIGESFPEGTK Myo9b IPI00229766 60.85 42.49 0.99 0.58 0.76 0.71
RFS(ph)M(ox)EDLNK Pctk3 IPIOO 111 168 47.88 / 0.69 / 0.76 /
DDISElQSLASDHS(ph)GR Tjpl IPI00135971 31.83 / 0.57 / 0.76 /
C(me)IFMSETOSS(ph)PTK Pias2 IPI00453655 30.79 / 0.47 / 0.75 /
ODVDNAS(ph)LAR Vim IPI00227299 31.40 / 0.72 / 0.75 /
POSPVIQAT AGS(ph)PK Arfgef2 IPIOO137087 30.88 41.94 0.83 0.35 0.74 0.51
QEFSS(ph)EEMTK VcamI IPI00126834 25.88 / 0.83 / 0.74 /
SLS(ph)TSGESLYHVLGLDK Dnajc5 IPIOO 132206 50.50 47.88 0.51 1.70 0.74 1.20
(ac)SDQEAKPST(ph)EDLGDKK Sumol IPIOO124593 33.58 / 0.78 / 0.73 /
DCf me)AKS( ph)DDEESLTLPEK Nikbl IPI00719890 52.31 / 0.80 / 0.73 /
PAW  S( ph)PLSLSTE AR Crtcl 1PI00469761 43.71 / 0.80 / 0.73 /
YVSGSS(ph)PDLVTR PtpnH IPIOO122168 49.84 / 0.73 / 0.73 /
ASPDQNASTHT(ph)POSSAK Clintl IPI00648186 34.63 / 0.78 / 0.73 /
SSGSLS(ph)PGLETEDPLEAR
Tnkslb
pl IPI00459443 36.91 / 0.68 / 0.73 /
283
TASESISNLSEAGSl ph) VK Clip] IPI00857273 31.00 / 0.98 / 0.72 /
AQTPESC(me)GSVT(ph)PER Filipll IP100755058 30.92 / 0.94 / 0.72 /
T(ph)SPTVATOTGASVTSTR
Faml 17 
b 1PI00461475 68.26 64.54 0.73 0.73 0.72 0.89
S(ph)FEDLTDHPVTR Adam 17 IP100314443 44.01 46.28 0.71 0.66 0.72 0.94
SAT(ph)LETKPESK Ifhgrl IP100323231 25.38 / 0.64 / 0.72 /
VMTVTAVTTTATS(ph)DR Hdgfrp2 IPIOO116442 76.11 51.20 0.60 0.72 0.72 0.89
SDEEDRAS(ph)EPK Zc3hl8 IPI00673693 27.94 / 0.79 / 0.72 /
VEESSEIS(ph)PEPK Uspl IPI00330276 40.56 / 0.57 / 0.72 /
S(ph)LEGENHDPLSSWK Nes IPI00453692 45.85 / 0.68 / 0.72 /
MHASSTGSS(ph)C(me)DLSK Cdgap IPIOO125505 27.19 / 0.54 / 0.72 /
KIS(ph)GTTALQEALK Clipl IPI00857273 33.36 67.72 0.88 0.77 0.72 0.74
AKT(ph)PVTLK Tmpo IPI00828976 41.32 / 0.58 / 0.72 /
SSS(ph)FGSVSTSSTSSK Snxl6 IPI00331029 / 54.62 / 1.42 / 5.00
TAS(ph)GSSVTSLEGTR Ndrgl IPIOO125960 45.97 41.37 0.50 1.04 0.57 3.57
GGVTGS(ph)PEASISGSK Ahnak IPI00553798 43.68 27.58 0.21 3.27 0.47 2.79
SGFGGMS(ph)SPVIR Nup107 IPI00221767 28.39 40.37 0.37 2.64 0.63 2.32
LPTSEEERS(ph)PAK
Trp53bp
1 IPI00229801 25.34 25.63 0.22 3.06 0.39 2.08
SGFGGMSS(ph)PVIR Nupl07 IPI00221767 / 40.37 / 2.57 / 2.07
AS(ph)PALGSGHHDGSGDSLEMSS
LDR
Tomm7
Oa IPI00751137 64.86 47.86 0.29 2.31 0.46 2.05
ASS(ph)HSSOSOGGGSVTK Lmna IPI00620256 47.84 58.67 0.19 3.86 0.52 1.95
TEEDRENTQIDDTEPLS(ph)PVSNS
K
Trp53bp
1 IPI00229801 / 28.80 / 2.58 / 1.90
KOOOEPTC(me)EPS(ph)PK Hmga2 IPI00331612 26.67 30.20 0.29 2.23 0.43 1.72
SEDRPS(ph )SPQVS VAA VETK
Trp53bp
1 IPI00229801 / 48.56 / 2.07 / 1.70
AEAKPGT(ph)PAK Nolcl IPI00720058 36.93 39.65 0.31 2.25 0.47 1.67
PASfph)PLSGPR
D2Wsu
8le IPI00224127 / 29.84 / 1.80 / 1.65
GEVAPKET(ph)PKK
Marcksl
1 IPI00281011 / 26.82 / 2.27 / 1.65
TVGNVSfph)PTAOMVQR Rbm7 IPIOO133061 / 28.20 / 1.41 / 1.65
LHSAOLS(ph)PVDETPATOSOLK Ml flip IPI00459115 / 36.63 / 1.95 / 1.62
OEGAOENVKNSfph)PVPR Gmnn IPI00I31716 / 30.64 / 2.56 / 1.60
GISQTNLITTVT(ph)PEK Epb4113 1PI00229299 50.15 40.47 0.46 1.55 0.52 1.55
TTS(ph)PDLFESOSLTSASSK Epn2 IPI00336844 / 27.33 / 1.25 / 1.55
ATWGDGGDNS(ph)PSNVVSK Snap23 IPIOO113798 64.07 49.53 0.49 1.69 0.46 1.54
LEOHSCX>POLS(ph)PATSGR
Torlaip
1 IPI00762273 25.81 47.94 0.58 1.33 0.58 1.53
AGS(ph)SPTQGAQNEAPR Tc£20 IPI00407458 / 30.95 / 1.46 / 1.51
AS(ph)SHSSOSOGGGSVTK Lmna IPI00620256 / 58.67 / 2.60 / 1.51
C(me)QETESNEEQSIS(ph)PElCR Akapl2 IPIOO123709 / 85.89 / 1.19 / 1.49
AGGS(ph)PASYHGSTSPR Epn2 IPI00336844 49.92 47.77 0.50 1.47 0.50 1.47
SLYSSS(ph)PGGAYVTR Vim IPI00227299 34.83 53.18 0.67 0.97 0.67 1.47
FGEYNSNIS(ph)PEEK Nopl4 IPI00353010 36.25 30.49 0.43 1.68 0.54 1.45
GE AT AERPGEAAVASS( ph)PSK Marcks IPI00229534 53.11 53.46 0.60 1.36 0.58 1.45
LATSS(ph)PEQSWPSTFK Pml IPI00229072 / 29.49 / 1.18 / 1.43
KONETADEAT(ph)TPOAK Nolcl IPI00720058 / 43.74 / 1.50 / 1.42
AAKES1 ph)EEEEEEEETEEK Nolcl IPI00720058 93.93 73.89 0.42 1.80 0.46 1.41
EIITEEPS(ph)EEEADMPKPK Ddx21 IPIOO 120691 / 31.38 / 1.69 / 1.38
LLKPGEEPSEYTfph)DEEDTK Pgrmc2 IPI00351206 39.74 35.31 0.39 1.61 0.48 1.36
AEEDEILNRS(ph)PR Canx IPIOO119618 / 25.35 / 1.51 / 1.35
SSGS(ph)PYGGGYGSGGGSGGYGS
R
Hnmpa
3 IPI00269661 113.25 92.56 0.42 1.50 0.58 1.35
SSSSLLAS(ph)PSHIAAK Fam62b IPI00266942 26.75 30.80 0.59 1.46 0.57 1.34
NVAEALGHS(ph)PK Irf2bpl IPI00453578 37.33 27.45 0.75 0.81 0.67 1.34
QKS(ph)DAEEDGVTGSQDEEDSKP
K Canx IPIOO 119618 88.22 64.73 0.48 1.53 0.54 1.34
SKTS(ph)PVASGSTSK Cep170 IPI00667973 51.13 43.40 0.68 1.18 0.68 1.34
AFGPGLQGGNAGS(ph)PAR Flna IPI00875567 36.73 27.19 0.68 0.82 0.60 1.33
GPEVTSQGVQTSS(ph)PAC(me)K Atxn2 IPIOO117229 / 25.10 / 1.07 / 1.30
ASGOAFELILS(ph)PR Stmnl IP100551236 / 30.07 / 0.87 / 1.30
AVGEEQRS(ph)EEPK Akapl2 IP100123709 / 31.72 / 1.15 / 1.30
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Appendix 5. A ll phosphopeptides identified as down-regulated after treatment with 25-
hydroxy cholesterol (25-OHChol) in s i  biological replicate. Un-normalised SILAC
phosphopeptide ratios are displayed
Mascot Score Ratio Ratio
25-OHChol
:Control
24(5),25-EC
:ControI
Replicate 1 2 1 2 1 2
Phosphopeptide Gene IPI
Number
NEKS(ph)EEEQSSASVK Hnmpc IPI00874321 51.11 45.64 0.350 1.095 0.433 0.832
SPDEAT A ADQES(ph)EDDLS ASR Farpl IPI00356904 26.44 / 0.349 / 0.465 /
TEE VLSPDGSPSKS( ph)PSK Add3 IPI00387580 38.11 / 0.349 / 0.439 /
ADS(ph)DSEDKGEESKPK Cbxl IPIOO 129466 40.05 / 0.347 / 0.393 /
EELEQQT(ph)DGDC(me)DEEDDDK
DGEVPK Sec62 IPIOO134398 57.28 / 0.346 / 0.532 /
EDAPPEDK£S(ph)ESEAK Cds2 IPI00468999 26.03 / 0.346 / 0.594 /
GE V APKET ( ph)PK
Marcksl
1 IPI00281011 33.28 26.82 0.345 2.274 0.556 1.651
EROES(ph)ESEOELVNK Pdcdl1 IPI00551454 39.77 / 0.345 / 0.560 /
AS(ph)AVSPEKAPM(ox)TSK Tcofl IPIOO115660 34.02 / 0.345 / 0.346 /
ADS(ph)DSEDKGEESKPK Cbxl IPI00129466 40.05 / 0.344 / 0.451 /
LPSGSGPASPTT(ph)GSAVDIR Ahnak IPI00553798 65.09 / 0.339 / 0.378 /
SPFNSPS(ph)PQDSPR Nfic IPIOO 137501 40.52 35.42 0.334 1.146 0.464 1.050
IGPLGLS(ph)PK Rpll2 IPI00463634 45.65 / 0.333 / 0.426 /
E1ITEEPS( ph)EEE ADM(ox)PKPK Ddx21 IPIOO120691 56.99 / 0.330 / 0.443 /
NGLSOPS(ph)EEEADlPKPK Ddx21 IPIOO120691 36.77 / 0.325 / 0.431 /
NGLSOPS( ph )EEE VDIPK.PK Ddx21 IPIOO 120691 42.24 / 0.323 / 0.384 /
NISEES(ph)PLTHR Pask IPI00400044 32.53 / 0.322 / 0.610 /
S(ph)PAKEPVEOPR Spen IPI00828562 25.27 / 0.321 / 0.464 /
SLS(ph)PSHLTEDR Zc3hl3 IPI00515528 44.78 33.98 0.317 0.922 0.344 0.904
T(ph)GSESSOTGASATSGR Eif4b IPI00221581 79.96 77.19 0.314 1.215 0.474 0.757
AEAKPGT(ph)PAK Nolcl IPI00720058 36.93 39.65 0.308 2.251 0.470 1.673
RVSGS(ph)ATPNSEAPR Ddx51 IPI00396728 58.55 / 0.306 / 0.460 /
AS(ph)PALGSGHHDGSGDSLEMSS
LDR
Tomm7
Oa IPI00751137 64.86 47.86 0.293 2.308 0.464 2.047
S(ph)QEMVHLVNK Cd44 IPI00410802 52.66 33.35 0.292 1.021 0.420 0.827
S( ph)HTGE A AA VR Bcl2113 IPI00321499 35.83 / 0.288 / 0.467 /
KQQQEPTC(me)EPS(ph)PK Hmga2 IPI00331612 26.67 30.2 0.287 2.231 0.428 1.718
NNVMT(ph)SPNVHLK Cenpcl IPIOO114808 34.17 / 0.284 / 0.390 /
RVS(ph)GSATPNSEAPR Ddx51 IPI00396728 58.55 / 0.278 / 0.427 /
YLEIDS( ph)DEES R Sdadl IPI00387439 33.64 / 0.276 / 0.529 /
DDS(ph)GAEDN VDTHQQQAEN ST 
VPTADSR Rspryl IPI00223590 27.35 / 0.275 / 0.445 /
LSQ VNGATPV S( ph)PIEPESK
Mybbpl
a IPI00331361 33.48 / 0.272 / 0.461 /
SETLVNAOOTPLGT(ph)PK Palm IPIOO129298 43.67 37.09 0.267 1.074 0.386 1.079
RI S( ph)GLI YEETR
Hist 1 h4 
a IPI00623776 35.15 / 0.267 / 0.400 /
GS(ph)HC(me)SGSGDPAEYNLR Lmna IPI00620256 32.11 / 0.257 / 0.488 /
LSOVNGAT(ph)PVSPIEPESK
Mybbpl
a IPI00331361 33.48 / 0.254 / 0.436 /
SST(ph)PLPTVSSSAENTR Tmpo IPI00896574 55.29 / 0.246 / 0.516 /
GVTASSSS(ph)PASAPK Ncaml IPIOO122971 43.46 34.3 0.244 1.437 0.346 1.195
ASSHS(ph)SOSOGGGSVTK Lmna IPI00620256 47.84 58.67 0.224 2.410 0.536 1.175
APQS(ph)PTLAPAK Cxadr IPI00270376 25.52 30.84 0.219 1.618 0.291 1.103
LPTSEEERS(ph)PAK
Trp53bp
1 IPI00229801 25.34 25.63 0.217 3.061 0.387 2.082
GGVTGS(ph)PEASISGSK Ahnak IPI00553798 43.68 27.58 0.215 3.272 0.474 2.790
SPFNSPSPODS(ph)PR Nfic IPIOO137501 40.52 / 0.213 / 0.435 /
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ASS(Dh)HSSOSOGGGSVTK Lmna IPI00620256 47.84 58.67 0.194 3.858 0.523 1.945
LRS(ph)EDGVEGDLGETQSR Ahnak IPI00553798 33.49 32.86 0.178 1.087 0.415 0.795
GSGEASSDSIDHS(ph)PAK
Suv39h
2 IPI00111417 26.96 / 0.174 / 0.377 /
S(ph)SPPVEHPAGTSTTDNDVIIR Rail 4 IPI00453820 35.31 / 0.170 / 0.308 /
GH YE VTGS( ph )DDE AGK Ahnak IP100553798 58.36 / 0.168 / 0.371 /
SPAPSNPTLS(ph)PSTPAK
Mybbpl
a IPI00331361 34.8 33.16 0.159 1.852 0.323 1.256
SNS(ph)FSDER Ahnak IPI00553798 29.85 / 0.154 / 0.366 /
GGVTGSPEAS(ph)ISGSKGDLK Ahnak IPI00553798 43.68 / 0.135 / 0.346 /
GGVTGSPEASISGS(ph)KGDLK Ahnak 1PI00553798 43.68 / 0.119 / 0.363 /
DSVPAS(ph)PGVPAADFPAETEQS
KPSK Top2a IPIOO122223 25.31 / 0.116 / 0.342 /
SGAAEEDDS(ph)GVEVYYR Pdcdll IPI00551454 41.08 / 0.104 / 0.592 /
KGDDS(ph)DEEDLC(me)ISNK Stard13 IPI00857002 57.82 / 0.027 / 0.317 /
FIOELSGSS(ph)PK Tcfap4 IPIOO121217 27.49 35.23 0.018 1.013 0.430 0.581
MSPNETLFLES(ph)TNK Rragc IPI00468702 / 32.32 / 0.407 / 0.530
SPSPSPTS(ph)PGSLR Dclkl IPI00468380 / 51.87 / 0.398 / 0.582
POSAS(ph)PAKEEQK Palm IPIOO129298 / 30.2 / 0.390 / 0.196
LS(ph)PAYSLGSLTGASPR Phldbl IPI00330246 / 34.03 / 0.369 / 0.573
SGTSTP1TPGSTAITPGT(ph)PPSYS
SR Mtap2 IPI00895463 / 69.16 / 0.360 / 0.661
POSPVIOATAGS(ph)PK Arfgef2 IPIOO137087 30.88 41.94 0.827 0.350 0.742 0.511
AYT(ph)HOWTR Cdk7 IPIOO 129222 26.4 28.51 0.981 0.313 0.801 0.632
AES(ph)PETSAVESTOSTPQK Pds5b IPI00845638 41.44 63.25 0.594 0.288 0.437 0.520
TASRPEDTPDSPSGPSS(ph)PK Lrrc 16a IPI00474873 / 46.92 / 0.216 / 0.439
LYNSEESRPYT(ph)NK Crkrs IPI00648022 / 49.1 / 0.205 / 0.338
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Appendix 6. All phosphopeptides identified as up-regulated after treatment with 25-
hydroxycholesterol (25-OHChol) in ^1 biological replicate. Un-normalised SILAC
phosphopeptide ratios are displayed
Mascot Score Ratio
25-OHChol
:Control
Ratio
24(5),25-EC
:Control
Replicate 1 2 1 2 1 2
Phosphopeptide Gene IPI
Number
HGS(ph)DPAFGPSPR Fam83h IPI00227516 28.43 / 1.795 / 0.658 /
DELADEIAN SS(ph)GK Myh9 IPIOO123181 29.65 / 1.166 / 0.970 /
S(ph)STSGSASSLESGVYR Gtsel IPI00268247 63.04 / 1.152 / 0.614 /
AQT(ph)PESC(me)GSVTPER Filip] 1 IPI00755058 30.92 / 1.120 / 0.637 /
LLODSSS(ph)PVDLAK Ncoa2 IPI00116968 29.72 / 1.118 / 0.919 /
ROS(ph)LTSPDSOSTR Herd IPI00676574 33.46 38.87 1.064 0.991 0.698 0.776
VDHGAEIITQS(ph)PSR Mtap2 IPI00895965 61.57 80.97 1.062 0.717 0.679 0.989
GS(ph)PEDGSHEASPLEGK Rbm20 IPI00849187 51.26 / 1.055 / 0.586 /
PTGGLRDS(ph)EAEK Hirip3 IPI00222813 29.49 / 1.035 / 1.064 /
RAS( ph)LEIGES FPEGTK Myo9b IPI00229766 60.85 42.49 0.989 0.578 0.758 0.713
KLEVS(ph)PGDEQSNVETR Gnl3 IPI00222461 73.45 / 0.988 / 0.431 /
AYT(ph)HOVVTR Cdk7 IPIOO129222 26.4 28.51 0.981 0.313 0.801 0.632
TASESISNLSEAGS(ph)VK Clipl IPI00857273 31 / 0.975 / 0.725 /
IKDPDLTT(ph)PDSK Ckap2 IPI00470092 44.82 / 0.954 / 0.782 /
AOTPESC(meKJSVT(ph)PER Filipll IPI00755058 30.92 / 0.944 / 0.724 /
GGIDNPAIT(ph)SDQEVDDKK
Arhgap
5 IPIOO124298 40.63 / 0.924 / 1.125 /
SNS(ph)NSSSVlTTEDNK Filipll 1PI00755058 77.83 / 0.922 / 0.623 /
C(me)QS(ph)PILHSSSSASSNIPSAK IP100875090 39.2 48.16 0.918 0.573 0.700 0.668
SEVOAHS(ph)PSR Mtap2 IPI00895965 31.21 / 0.907 / 0.849 /
KS(ph)PEQESVSTAPQR Spg20 IPIOO153501 39.11 51.42 0.900 0.689 0.708 1.084
TTSTSNPSS(ph)PAPDWYK Atrx IPI00857253 38.08 / 0.892 / 0.604 /
ASS(ph)EDTLNKPGSASSGVAR Speed IPI00798550 33.64 / 0.887 / 0.805 /
YMSSDTT(ph)SPELR Sin3a IPIOO117932 27.09 / 0.883 / 0.580 /
KIS(ph)GTTALQEALK Clipl IPI00857273 33.36 67.72 0.882 0.770 0.720 0.745
NSGATADAGSIS(ph)PR Ercc5 IPI00875692 46.69 47.1 0.881 0.485 0.627 0.883
HNSAS(ph)VENVSLR Irs2 IPI00379844 53.04 55.86 0.877 0.752 0.615 0.720
YIASVQGSAPS(ph)PR Ranbp2 IPI00337844 36.79 / 0.875 / 0.596 /
EKEEEETS1 ph)PDTSIPR ArhgefS IPI00855144 48.09 / 0.868 / 0.565 /
LPS(ph)PAQT0R Micall2 IPI00280103 30.76 33.11 0.865 0.509 0.816 0.876
ASS(ph)HSSQSOGGGSVTK Lmna IP100620256 47.84 58.67 0.194 3.858 0.523 1.945
GGVTGS( ph)PEASISGSK Ahnak IPI00553798 43.68 27.58 0.215 3.272 0.474 2.790
LPTSEEERS(ph)PAK
Trp53bp
1 IPI00229801 25.34 25.63 0.217 3.061 0.387 2.082
SGFGGMS(ph)SPVIR Nupl07 IPI00221767 28.39 40.37 0.372 2.643 0.626 2.319
AS( ph )S HSSQSOGGGS VTK Lmna IPI00620256 / 58.67 / 2.595 / 1.511
TEEDRENTQ1 DDTEPLS(ph)PV SNS 
K
Trp53bp
1 IPI00229801 / 28.8 / 2.576 / 1.904
SGFGGMSS(ph)PVIR Nupl07 IPI00221767 / 40.37 / 2.574 / 2.074
QEGAQEN VKNS( ph)PVPR Gmnn IPIOO131716 / 30.64 / 2.565 / 1.603
ASSHS(ph)SOSOGGGSVTK Lmna IPI00620256 47.84 58.67 0.224 2.410 0.536 1.175
AS(ph)PALGSGHHDGSGDSLEMSS
LDR
Tomm7
Oa IPI00751137 64.86 47.86 0.293 2.308 0.464 2.047
GEVAPKET(ph)PKK
Marcksl
1 IPI00281011 / 26.82 / 2.274 / 1.651
AEAKPGT(ph)PAK Nolcl IPI00720058 36.93 39.65 0.308 2.251 0.470 1.673
KOOOEPTC(me)EPS(ph)PK Hmga2 IPI00331612 26.67 30.2 0.287 2.231 0.428 1.718
S EDRPS( ph )S PQ V S V A A VETK
Trp53bp
1 IPI0022980I / 48.56 / 2.071 / 1.704
LHSAQLS(ph)PVDETPATQSQLK Mlflip IPI00459115 / 36.63 / 1.947 / 1.619
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SP APSNPTLS( ph )PSTP AK
Mybbpl
a IPI00331361 34.8 33.16 0.159 1.852 0.323 1.256
PAS(ph)PLSGPR
D2Wsu 
81 e IPI00224127 / 29.84 / 1.802 / 1.652
AAKES(ph)EEEEEEEETEEK Nolcl IPI00720058 93.93 73.89 0.420 1.796 0.464 1.406
T(ph)SMGGTOOOFVEGVR Ctnnbl IPIOO125899 / 48.59 / 1.721 / 1.130
SLS(ph)TSGESLYHVLGLDK Dnajc5 IPIOO132206 50.5 47.88 0.508 1.703 0.739 1.197
EIITEEPS(ph)EEEADMPKPK Ddx21 IPIOO120691 / 31.38 / 1.693 / 1.383
ATWGDGGDNS(ph)PSNVVSK Snap23 IPIOO113798 64.07 49.53 0.493 1.687 0.455 1.545
FGEYNSNIS(ph)PEEK Nop 14 IPI00353010 36.25 30.49 0.434 1.684 0.539 1.451
HLFSS(ph)TENLAAR
Rabllfi
Pi IPIOO169485 / 39.84 / 1.665 / 1.264
NWTEDIEGGIS S( ph)P VK Nfic IPI00137501 / 32.95 / 1.656 / 1.073
APQS(ph)PTLAPAK Cxadr IPI00270376 25.52 30.84 0.219 1.618 0.291 1.103
LLKPGEEPSEYT(ph)DEEDTK Pgrmc2 IPI00351206 39.74 35.31 0.393 1.606 0.475 1.357
KFS(ph)EEPEVAANFTK Nop56 IPI00318048 35.3 31.73 0.442 1.595 0.504 0.850
ASSHSSQSQGGGS(ph)VTK Lmna IPI00620256 47.84 58.67 0.553 1.582 0.701 0.899
GISQTNLITTVT(ph)PEK Epb41l3 IPI00229299 50.15 40.47 0.458 1.549 0.521 1.551
QKS(ph)DAEEDGVTGSQDEEDSKP
K Canx IPI00119618 88.22 64.73 0.476 1.533 0.545 1.340
TTV YY 0S( ph)PLESKPR Atad2 IPIOO135252 / 41.56 / 1.532 / 1.139
T(ph)GSLOLSSTSIGTSSLK Coblll IPI00762331 / 31.52 / 1.526 / 0.746
VQTT(ph)PSKPGGDR Cdc20 IPI00320406 30.44 31.01 0.417 1.516 0.586 0.870
AEEDEILNRS(ph)PR Canx IPI00119618 / 25.35 / 1.506 / 1.350
S SGS(ph)P Y GGG Y GSGGGSGG Y GS 
R
Hnmpa
3 IPI00269661 113.25 92.56 0.420 1.501 0.581 1.346
KQNETADEAT(ph)TPQAK Nolcl IPI00720058 / 43.74 / 1.498 / 1.422
SRLTPTTPES(ph)SSTGTEDK Sqstml IPIOO133374 / 74.88 / 1.485 / 0.733
AAAT(ph)PESQEPQAK
Marcksl
1 IPI00281011 38.45 26.81 0.438 1.477 0.531 0.964
AGGS(ph)PASYHGSTSPR Epn2 IPI00336844 49.92 47.77 0.503 1.473 0.498 1.475
IALESVGQPEEQMESGNC(me)S(ph)
GGDDDWTHLSSK Sqstml IPIOO133374 / 27.33 / 1.471 / 0.787
SSSSLLAS(ph)PSHIAAK Fam62b IPI00266942 26.75 30.8 0.594 1.465 0.568 1.344
AGS(ph)SPTQGAQNEAPR Tcf20 IPI00407458 / 30.95 / 1.457 / 1.514
KAPLTLAGS(ph)PTPK Wiz IPI00263016 / 39.77 / 1.455 / 1.147
KLDTFQSTS(ph)PK Ddx24 IPIOO 113576 / 27.61 / 1.453 / 1.063
GVTASSSS(ph)PASAPK Ncaml IPIOO122971 43.46 34.3 0.244 1.437 0.346 1.195
SRLT(ph)PTTPESSSTGTEDK Sqstml IPIOO133374 / 74.88 / 1.435 / 0.821
SDAEEDGVTGS(ph)QDEEDSKPK Canx IPI00119618 88.22 64.73 0.467 1.430 0.557 1.215
SSS(ph)FGSVSTSSTSSK Snxl6 IPI00331029 / 54.62 / 1.416 / 4.998
S(ph)RPLNAVSQDGK Csda IPI00330591 47.17 44.25 0.563 1.416 0.553 1.041
TVGNVS(ph)PTAOMVQR Rbm7 IPIOO133061 / 28.2 / 1.414 / 1.646
S(ph)SGSPYGGGYGSGGGSGGYGS
R
Hnmpa
3 IPI00269661 113.25 92.56 0.461 1.414 0.578 1.245
SRLTPTT(ph)PESSSTGTEDK Sqstm 1 IPIOO133374 / 74.88 / 1.408 / 0.841
IAQEIASLS(ph)KEDVSK Ralbpl IPI00421132 48.23 52.17 0.463 1.392 0.539 1.266
KPAQETEETS(ph)SQESAEED Hmga2 IPI00331612 40.72 28.37 0.482 1.384 0.484 0.886
TEMDKS(ph)PFNSPSPQDSPR Nfic IPIOO137501 / 35.42 / 1.371 / 1.118
GDKS(ph)SEPTEDVETK Tgoln2 IPI00408895 46.27 33.26 0.585 1.370 0.553 1.109
GEATAERPGEAAVASS(ph)PSK Marcks IPI00229534 53.11 53.46 0.600 1.362 0.576 1.450
